Intellect Neurosciences, Inc. (ILNS) - Holy grail of Alzheimer's treatment - (David Blech Stock (>6 - 500 Beiträge pro Seite

[montamero]

http://www.intellectns.com
http://content.stockpr.com/intellectns/media/18bdef256a41338…
http://finance.yahoo.com/q?s=ILNS.PK&ql=0

[montamero]

Intellect Neurosciences Receives Notice of Allowance from United States Patent and Trademark Office for its ANTISENILIN® Alzheimer's Disease Immunotherapy Technology Platform

USPTO allows claims directed to methods of treating Alzheimer's disease using therapeutic antibodies that recognize the free C-terminus of Beta Amyloid 1-40

NEW YORK, March 6, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS.PK - News), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN® monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.


A Notice of Allowance is a written communication from the USPTO stating its intention to grant a U.S. patent, after payment of the Government Issue fee. Upon grant of the patent, Intellect Neurosciences will request a $2 million milestone payment from a top tier global pharmaceutical company based on its licensing agreement with the company.

"The fact that Intellect overcame an exceptionally high threshold for allowance set by the USPTO illustrates the strength of our patent, the significance of the underlying invention, and rewards our relentless efforts to obtain a patent of meaningful commercial value on behalf of the company and our shareholders," said Daniel G. Chain, PhD, Intellect Neurosciences chairman & CEO and inventor of the ANTISENILIN technology. "The decision by the USPTO to grant this patent is long overdue. We remain confident that we will obtain allowance of additional claims in the future for the other components of the ANTISENILIN platform."

The allowed patent application discloses therapeutic antibodies to treat Alzheimer's disease. The antibodies specifically bind to the ends of the beta amyloid protein without binding to the amyloid precursor protein (APP), which has important safety advantages compared to antibodies that do not have this feature. Based on recent submissions by Intellect, the USPTO allowed patent claims directed to treatment methods that use antibodies that recognize the free C-terminus of beta amyloid 1-40. Intellect has additional patent applications pending in the United States and in other countries relating to its antibody technology.

The best-known example of a therapeutic antibody that binds to the free C-terminus of beta amyloid 1-40 is ponezumab (aka PF-04360365). A phase 1 study to determine effect of PF-04360365 on clearance of beta amyloid from cerebrospinal fluid in patients with Alzheimer's disease and healthy volunteers is currently recruiting patients according to www.ClinicalTrials.gov and verified by Pfizer in February 2012. This trial, which is scheduled to complete in August 2012, follows other completed Phase 1 and 2 trials.

"It is important that the USPTO has finally acknowledged Dr. Chain's seminal discovery in 1997 that laid the foundations for Alzheimer's passive immunotherapy treatments targeting soluble beta amyloid which accumulates in the brain of Alzheimer's patients, leading to neurodegeneration," said Professor Kelvin Davies, Chairman of the Company's Scientific Advisory Board and the James E. Birren Chair in Gerontology at the University of Southern California. "Dr. Chain's approach has already been adopted by several major pharmaceutical companies with promising clinical data."

About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease, and other neurodegenerative diseases, focusing especially on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.

The company is currently developing products based on three platform technologies: ANTISENILIN® is Intellect's Alzheimer's beta amyloid monoclonal antibody platform technology which underlies a product in Phase 3 clinical trials licensed to major pharmaceutical companies. ANTISENILIN also underlies IN-N01, a humanized monoclonal antibody being developed by the company. RECALL-VAX™ is a therapeutic vaccine technology that underlies three preclinical drug candidates, RV01, RV02, which target beta amyloid and delta tau protein, respectively, and RV03, which is a combination of the two. IN-N01-OX2 is the first candidate to emerge from the company's CONJUMAB-A™ platform technology, based on a completely novel application of antibody drug conjugates (ADCs) in which the antibody is chemically conjugated to a small molecule (OX2) that has potent neuroprotective properties both as an antioxidant and inhibitor of protein aggregation.

Intellect is seeking to partner/license its platform technologies on a product- by-product basis to develop antibody-drug conjugates and therapeutic vaccines. RECALL-VAX and CONJUMAB-A have potential applications for treatment of several serious diseases such as Alzheimer's, Parkinson's, Huntington's, Cerebral Amyloid Angiopathy, Frontotemporal Dementia, Progressive Supranuclear Palsy, Pick's disease, Cortical Basal Degeneration, Age-Related Macular Degeneration, Glaucoma, and Peripheral Amyloidosis.

The company recently licensed OX1 a small molecule multimodal antioxidant to ViroPharma, Inc. for Friedreich's Ataxia and other neurodegenerative diseases. For more information, please visit www.intellectns.com.

http://finance.yahoo.com/news/intellect-neurosciences-receiv…

[montamero]

http://stockcharts.com/c-sc/sc?s=ilns&p=W&yr=2&mn=0&dy=0&i=p…

[montamero]

Name and Address Amount and Nature
of Beneficial Holder (1) of Beneficial Ownership Percent of Class (2)

Margery Chassman 83,734,211 (3) 65.8 %
465 W 23rd Street
Suite 12J
New York, New York 10011

Daniel G. Chain 232,905 (4) 0.2 %

Elliot Maza 60,838 (5) 0.05 %

Isaac Onn 10,000 0.008 %

Directors and executive officers as a group (3 persons) 311,743 0.2 %


(1) Except as otherwise noted, the address of record of each of the following individuals is: c/o Intellect Neurosciences, Inc., 45 West 36th St. 3rd Fl., New York, New York 10018.

(2) Percentages based on 66,751,143 shares of common stock issued and outstanding as of June 30, 2011, including as applicable, those shares that may be acquired within 60 days upon the exercise of stock options, warrants and/or the conversion of convertible securities by the relevant stockholder.

(3) Includes 60,600 shares of common stock which may be acquired within 60 days upon the exercise of warrants and/or the conversion of convertible securities by the relevant stockholder .

(4) Includes 139,905 shares of common stock which may be acquired within 60 days upon the exercise of stock options.

(5) Includes 60,838 shares of common stock which may be acquired within 60 days upon the exercise of stock options.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

We describe below any transactions, arrangements or relationships of which we are aware, as of the date of filing of this current report, which occurred since the beginning of the last fiscal year or are currently proposed to which we are or will be a participant (as defined in Item 404 of Regulation S-K); in which the amount involved exceeded or will exceed $120,000; and in which any related person (as defined in Item 404 of Regulation S-K) has or will have a direct or indirect material interest. We include in the description below transactions involving certain of our founders and control persons.

Certain Relationships Involving Margie Chassman and David Blech

Ms. Margie Chassman is one of our founding principal stockholders and is the spouse of Mr. David Blech. Ms. Chassman beneficially owns 65.8% of our common stock, including shares by a trust, for which Ms. Chassman serves as Trustee and of which one of Mr. Blech’s sons is a beneficiary. Ms. Chassman has expressly disclaimed beneficial ownership of certain of the shares that applicable SEC rules deem her to beneficially own. See “Item 12 - Security ownership of certain beneficial owners and management and related stockholder matters.”

http://freerealtime.brand.edgar-online.com/DisplayFilingInfo…

[montamero]

He helped create the biotech boom and when it went bust, so did he

David Blech exercised in the swimming pool at his Chelsea apartment as therapy for his depression.

NEW YORK - The father of Seattle's biotechnology industry has a probation officer.

He lives in a modest, cluttered apartment in Manhattan's Chelsea neighborhood, 3,000 miles from the glass-and-steel temples of the companies he helped create. A continent away from the houses of doctors who, with his help, turned their positions with the Fred Hutchinson Cancer Research Center into personal fortunes.

And only two miles but a world away from the $3 million penthouse where he lived in 1992, when he was on Forbes magazine's list of the 400 richest Americans.

Meeting with a Seattle newspaper reporter, David Blech wears sweat pants, a sleeveless T-shirt and beat-up white tennis shoes with loose laces. He looks like a disheveled Billy Crystal, curly hair cut close, jaw unshaven.

He takes lithium for manic depression and has spent time in a mental hospital.

But things could be worse: At least the federal judge who sentenced him for securities fraud in 1999 allowed him to stay out of prison.

Blech's precipitous fall from grace is no more fascinating than his ascension as a brash 24-year-old who turned a family dream into reality. He helped build an industry whose products have saved lives and made lots of money.

And, as a Seattle Times investigation being published this week has revealed, Blech helped create a situation at the Hutchinson Center in which the care of cancer patients might be compromised by business relationships.

The get-rich-quick dream of 1980 - after plastics, before the Internet - was biotechnology. With talk of the potential of a cure for cancer, the industry's economic possibilities seemed unlimited.

Blech, a songwriter and fledgling stockbroker, watched Genentech, a company with no profits and no products, sell shares for $35 apiece and double the price to $70 by the end of its first day on the market.

"I can do that," Blech told his father, a rabbi and stockbroker, and his brother, a public-relations man.

The three started with a name: Genetic Systems.

"The ideal catch-all but say-nothing name for our new biotechnology company," Blech recalls.

Next, they needed to find a scientist brash and respected enough to head the company.

Among their candidates: Dr. Robert Nowinski, a young, rising star at the Fred Hutchinson Cancer Research Center in Seattle. They had just read about him in an article entitled "Immunizing Immortality."

They called him, and for some reason - perhaps because he, like the Blechs, was from New York - Nowinski listened.

In fact, he told them, he had already been talking about setting up a company. He'd been in discussions with Bob Johnston, chief executive of Cytogen, and investor Charlie Allen of Allen & Co.

Blech says Nowinski told him, "I'm going into the monoclonal antibody business."

"So am I!" Blech responded. He persuaded Nowinski to fly to New York for a meeting.

Blech's father picked up the Seattle scientist at JFK International Airport and took such a roundabout way from Queens to Manhattan that, Blech recalls, Nowinski was sorry he'd ever come.

Blech concedes that Nowinski thought he'd been taken in by "a bunch of amateurs."

Blech didn't even have a credit card. He was a kid - wiry, fast-talking, high-strung, super-ambitious. In some ways, a lot like the 35-year-old Nowinski.

Blech won Nowinski from Johnston and Allen with the promise the scientist could do good work, get rich and stay close to "The Hutch" in Seattle.

Allen had wanted Nowinski and 11 other Seattle scientists to move to New Brunswick, N.J. Blech told Nowinski that was crazy.

"That was the best observation of my career," Blech said. "It's unusual that two kids from Brooklyn and their rabbi-stockbroker father could get a company away from Bob Johnston and Allen & Co., but we did. We used to call the company `Genetic Balls.' "

The Blechs had $10,000 apiece. Blech says they told Nowinski they'd borrow to put $200,000 in escrow for him to keep if they didn't raise $3 million within a year.

They raised $40 million.

Nowinski was given 1.2 million shares of stock at a penny a share. Under Blech's tutelage, Nowinski sprinkled shares around The Hutch like manna from heaven.

His brilliance and the penny stocks helped Nowinski recruit his boss, Dr. John Hansen, as medical adviser for Genetic Systems and his boss' boss, Dr. E. Donnall Thomas, as a key member of the company's scientific advisory board.

Then Genetic Systems struck a deal with Hutch officials for commercial rights to 37 drugs.

Three of those drugs were antibodies that were to be used in a Hutch experiment called Protocol 126, an experiment in which Hansen and Thomas were involved. As described in The Times earlier this week, that experiment was controversial within The Hutch, with some doctors complaining that the welfare of patients was compromised by the researchers' ties with Genetic Systems.

In 1982, when Genetic Systems went public at $1.25 a share, the Blechs, Nowinski, Hansen and Thomas all made lots of money. Three years later, the company was bought by Bristol-Myers for $10.50 a share.

Bristol-Myers hurried in to buy Genetic Systems for $294 million in stock two weeks after Eli Lilly, its rival, had bought Hybritech, another monoclonal-antibody company, for $350 million. Blech liked to brag that Genetic Systems sold for 15 times its original public-stock value, while Hybritech merely doubled its value.

Blech made $30 million on the Genetic Systems deal. Nowinski's stock at that point was worth more than $10 million and Hansen's $1.8 million. Assuming Thomas had kept his original stake, which is unknown, his share - in Bristol-Myers stock - was worth $1 million.

"I always took great comfort how the scientists made a million dollars each," Blech said.

As Rose Beer, then a company official, recalled, "We had a very high profile at Genetic Systems. Without any due diligence, Bristol Myers came in and bought us for about $300 million. And then did their due diligence. And what Bob (Nowinski) sold was his dream of what this company would be.

"Oh, man, if they only knew!"

They found out soon enough that the dream was brighter than the financial reality. In 1991, Bristol-Myers resold part of the former Genetic Systems for $20 million and closed the other part, taking a $274 million bath.

Despite that, Bristol-Myers has gone up six fold since then, increasing even further the value of the doctors' stock.

Selling vision and credentials

Blech became known as the nation's most aggressive biotech financier. He took high fees and a lot of stock for seed money, and he took the companies public fast.

While most biotechs had one or more products in Food and Drug Administration-sanctioned trials before they took their stock public, most of Blech's did not. That made the scientific studies and credibility of medical doctors on board all the more important.

The Hutch's Thomas, who won a share of the 1990 Nobel Prize for his work on bone-marrow transplants, was recruited by Blech for the advisory boards of three other companies.



Dr. James Bianco, founder of Cell Therapeutics, a company now worth $485 million.

And Blech helped two other Hutch scientists, Drs. James Bianco and Jack Singer, start Cell Therapeutics Inc.

"Bianco came to us," Blech recalls. "He told us this story about these amazing clinical results he was seeing."

Some scientists doubted the research, which touted unbelievably good results with a little-known drug shielding vital organs from harm during cancer chemotherapy. Blech says he knew the research was thin but he sold the vision and the credentials of the company's supporters, especially Thomas.

"Ultimately, the drug failed," Blech said. "I don't know why." But Cell Therapeutics tried another drug, then another. Recently the company rose from near-death to huge gains with an arsenic drug to fight blood cancers.

"They were constantly reinventing themselves," Blech said. "That's the wonderful part of dealing with (stock in) life and its frailties."

Major deal-maker in biotech

In 1989, the Blechs helped create Icos Corp., joining Nowinski and Dr. Chris Henney, who had left The Hutch to co-found Immunex.

The Blechs put up $1 million of borrowed money. They wanted PaineWebber to sell the stock; PaineWebber wanted the Blechs to recruit George Rathmann, founder and chairman of the largest biotech company in the nation, Amgen, of Thousand Oaks, Calif.

Rathmann had taken Amgen from $4 a share to $60 and sold $190 million in products in 1989.

Ken Lee of Ernst & Young said Rathmann, 65, was "one of the most important guys in biotech in the country." Landing him was a coup for Blech and Nowinski.


"George had a fantastic career at Amgen, you know; he was the king of biotech," Blech said. "Luckily, he had one more deal in him."

The board of Icos was amazing for a start-up company. It included the former chairmen of Citibank (Walter Wriston), IBM (Frank Cary) and General Foods (James Ferguson), a former secretary of commerce (Alexander Trowbridge), and David Blech and his brother, Isaac.

Icos had the largest start-up financing in biotech history, $33 million. The Bothell-based company went public at $8 a share in 1991. David Blech owned 7 percent, and made a quick $10 million.

Rathmann described Blech as a "pure-greed" venture capitalist, and one who was very important to Seattle biotech. "It's because of his very venturesome personality. You have that kind of mindset," he said.

In the next few years, Blech helped set up about 20 other companies, mostly outside the Seattle area, including Celgene of Warren, N.J., with Nowinski, and Incyte Pharmaceuticals of Palo Alto, Calif.

He was a master salesman, whipping out lists of investors and trust funds, spinning academic cachet into cash. He sold hope: You could find a cure and make a mint.

Picking up `fallen angels'
Research doctors from the Fred Hutchinson Cancer Research Center started at least 10 major companies, many with help from The Hutch and New York financiers David and Isaac Blech.


At the height of his power, Blech estimated his personal fortune in 1992 at $310 million.

But Genetic Systems never did make a product to help cure cancer. Neither did Cell Therapeutics.

"I made a lot of money in the companies in Seattle but the products didn't quite get there," Blech said. "So I guess I entered the '90s feeling a little guilty about all that. So I started putting money into `fallen angels.' "

That's how he referred to young biotech companies that had spent at least $100 million on research but didn't have a product ready by the time they were out of money.

Blech picked them up when nobody else would.

"People get tired, you know," he said. "A lot of bright stars become fallen angels before they shine again."

He saved NeoRx of Bothell with $10 million cash, helping it raise $31 million in licensing deals.

He saved Microprobe (now Epoch Pharmaceuticals) of Bothell, personally financing operations for 16 months. He wrote monthly checks and guaranteed the salaries for six executive officers.

He bailed out another dozen companies across the nation. He was sure his name would mean gold.

"I'm not telling you there wasn't an element of greed in it for myself," Blech said. "I'm sure that played a role in it. But my doors were open to everybody - whether it was an Icos with golden management or a NeoRx that was on its ass and needed $10 million to keep the company open. I tried to save both sectors."

When Blech himself fell, though, many looked away.

Things fall apart

The biotech market soured in 1993. Blech, obsessed with buying undervalued biotech stocks, bought more and more on credit. He shifted funds to hide his mounting losses.

Blech stopped taking lithium. "As a manic-depressive, I'd get real high and low, so I'd buy when prices were high and sell when prices were low, the exact opposite what you should," he said.

The Securities and Exchange Commission investigated whether Blech broke the law by giving cheap stock to money managers and others prior to public offerings. That would inflate the price. Blech denied any impropriety.

For a time, Blech-backed companies held up under the collapse. Then he ran out of cash and the short-sellers pounced.

The first sign of deep trouble was in April 1994, when Blech had to sell his 24 percent stake in NeoRx to avoid a margin call by Citibank on $40 million in loans.

Afterwards, Blech bragged about the money he'd made on NeoRx anyway and the $150 million he claimed was held in trusts nobody could touch no matter what happened to the market, the financial newspaper Barron's reported.

Falling deeper and deeper in debt, Blech admits, he executed sham and unauthorized stock sales. It was outright criminal activity and he knew it, but he said he couldn't stop.

D. Blech and Co. failed to open its doors on Sept. 22, 1994 - referred to on Wall Street as "Blech Thursday." At least 13 stocks for which Blech was the underwriter declined by 23 percent or more that day. One fell 64 percent. The whole biotech sector sagged.

More than 300 brokers lost their jobs when the firm collapsed, and Blech stood sobbing in his trading room at the end of the day.

"A few days after D. Blech & Co. closed its doors on September 22, 1994, Blech entered the hospital due to an emotional breakdown. He never returned to the firm's offices. Within days of the firm's collapse, Blech's wife filed for divorce," according to a National Association of Securities Dealers report. Blech hadn't told his wife he was forging her signature on documents.

The SEC said investors and broker-dealers took $22.5 million in losses because of Blech's stock manipulations.

As the SEC developed criminal charges against Blech, he turned informant. Lloyd Schwed, a Florida attorney for four brokers who sued Blech, was arrested in August 1996 and charged with shaking down Blech by offering to withhold tapes subpoenaed in the SEC investigation. Schwed told Blech he would destroy two especially damaging tapes if Blech settled the suit with a big payment. Blech had worn a wire for the feds.

In April 1998, Blech was charged with the illegal security actions that led to "Blech Thursday." He pleaded guilty to two counts of criminal fraud. He faced up to 97 months in prison.

He refused to seek an insanity plea, though, even after a court-appointed psychiatrist said manic depression had contributed to his crimes.

Federal prosecutors suggested leniency because Blech had helped them. In October 1999, U.S. District Judge Kevin Duffy sentenced Blech to five years' probation and community service.

The National Association of Securities Dealers fined Blech $20,000, censured him and barred him from associating with NASD members in the future. In addition, the SEC, four former brokers and a class of investors all filed lawsuits against Blech.

Blech had never been well-known in Seattle, and none of this was even reported in the daily newspapers in the city where he'd set up several biotechs and manipulated stocks in others. Blech has not been mentioned in The Seattle Times since 1996, and in the Seattle Post-Intelligencer since 1994.

Hoping for a comeback

Today, Blech is supported by his second wife, Margie, a graphic designer and aspiring actress.

He is trying to sell a manuscript of his life story - "Million Dollar Dreamer" - but publishers aren't buying.

Sally Richardson, president of St. Martin's Press, wrote to him recently: "People don't like David Blech, they don't root for him, and we don't think they would buy his book."

Blech says he thinks about his rise and fall every day. His early times with Nowinski were the best, he says: so young, so easy.

But it's been a long time since Blech has heard from Nowinski, who lives north of Seattle and recently left Vax Gen, a company trying to develop an AIDS vaccine.

Rathmann is about the only one who calls Blech from Seattle anymore. Rathmann and Bianco wrote letters of support to the judge in Blech's federal trial.

Blech hopes to make a comeback someday. Not now, but soon. He's restless. He has a part-time secretary in his home office, a desk in the corner off the living room. He promises to never borrow money again, but watches the market closely.

"I believe I have learned from my mistakes," Blech wrote recently. "I feel good about my legacy. I have helped create over $15 billion in biotech market value, and have been associated with several products which are currently being used in the treatment of AIDS and cancer.

"But, at 44, I am still too young to retire. I may have one more go at it in me. This time, I would try to do it in a more measured way, with only one or two biotech companies. I would not try to save the world."

http://seattletimes.nwsource.com/uninformed_consent/financie…

[Ahorne]

vielen dank für den Tipp

[montamero]

Antwort auf Beitrag Nr.: 43.088.832 von Ahorne am 25.04.12 22:04:49

Bitte!
Ein weiterer Tip von mir ist Chromadex (CDXC).
Habe dazu auch einen Thread eröffnet.
CDXC: Dr. Philip Frost hält ca. 20% und David Blech (Chassman) über 10%. Chromadex neue Produktlinie Bluscience wird gerade vermarktet und u.a. auf Walgreens angeboten, weiteres ist aus dem Thread zu entnehmen:

http://www.wallstreet-online.de/diskussion/1173896-1-10/chro…

[montamero]

Antwort auf Beitrag Nr.: 43.088.832 von Ahorne am 25.04.12 22:04:49

Video zu Intellect Neuroscience:
http://ir.stockpr.com/intellectns/videos/view/3/finding-the-…

[montamero]

News: http://finance.yahoo.com/news/intellect-neurosciences-adds-t…

[montamero]

NY man admits illegally trading stock for 2nd time
Despite ban, NY man admits trading biotechnology stocks illegally for 2nd time in 20 years

NEW YORK (AP) -- A onetime powerful biotechnology financier who was among America's wealthiest before a 1990s criminal fraud conviction pleaded guilty to fresh securities fraud charges Wednesday, admitting that his ban from acting as a securities broker or dealer didn't stop him from plunging illegally back into the world of biotech companies.

David Blech, 56, his head cast downward, pleaded guilty to two counts of securities fraud in U.S. District Court in Manhattan, agreeing not to challenge any sentence he may receive that isn't longer than four years and three months in prison.

The plea came 14 years after he was sentenced to probation for actions he took in response to a large decline in the value of biotechnology stocks in the spring of 1994. His footprint on the universe of biotechnology securities at the time was so large that at least a dozen stocks that his defunct company, D. Blech and Co., had underwritten lost nearly a quarter of their value when his company abruptly closed its doors on Sept. 22, 1994, a day known on Wall Street as "Blech Thursday."

On Wednesday, the Manhattan resident told a magistrate judge that he saw his investments sour again after he invested more than $1 million in late 2006 in a biotech company, Pluristem Therapeutics Inc.

"I was so fascinated with Pluristem and was so convinced that it would be a success that I actually borrowed much of the money I used to help my friends and family to buy Pluristem stock," he said. "By May of 2007, I was heavily in debt, and my financial obligations to my family and to others who had loaned me funds were overwhelming."

He said he began selling much of his stock to pay debts but also bought shares through accounts in the names of family and friends so that he wouldn't damage the value of the company's stock.

"The court should know, however, that I did not make any money on my investment in Pluristem. In fact, I lost several million dollars on my investment in Pluristem over time," he said.

He said he had a similar experience with his investment from 2005 to early 2008 in Intellect Neurosciences Inc. He said he "was desperate for money" in early 2008 and began selling Intellect stock to raise money while he was purchasing the company's shares through accounts in friends' and relatives' names.

"I knew what I was doing was wrong and violated the securities laws," he said.

William Prather, a spokesman for Pluristem, said the company had no immediate comment.

Daniel G. Chain, CEO and chairman of Intellect, said he was disappointed to hear about Blech's plea. "We had no inkling of what was going on as far as manipulating the stock at the time," he said.

Chain called Blech a "true supporter of the company" and said Blech's wife owns more than half of the company's shares, though neither she nor he has any decision-making role and doesn't sit on the board of the New York-based biopharmaceutical company, which works to discover and develop therapeutic drugs to slow, stop or prevent Alzheimer's disease and other serious neurological disorders.

Sentencing was set for Aug. 31, though his attorney, Roland Riopelle, said it was unlikely to occur until later in the year for the father of six children. Blech was freed on $500,000 bail.

Riopelle said Blech on Wednesday was "heavily medicated and has struggled with manic depression his whole life." He called him a "sympathetic figure in a way" who can't seem to overcome his belief that he can have a positive impact on the biotechnology industry.

"Some guys use the stock market like a casino," Riopelle said. "His behavior in the stock market is like a gambler in a casino."

The Securities and Exchange Commission on Wednesday also brought civil charges against Blech and his wife, saying they flouted federal securities laws when they repeatedly made unregistered sales of securities.

"Blech tried to rig the market in favor of his own investments and create a mirage of activity in the stocks of biopharmaceutical companies for which he was soliciting investors," said George S. Canellos, Director of the SEC's New York Regional Office.

The SEC said Blech established more than 50 brokerage accounts in the names of family members, friends, and even a private religious institution.

In 1992, Blech was listed on Forbes magazine's list of the 400 richest Americans with a net worth of more than $300 million. His lawyer said Wednesday that he still has shares left in some companies, but he no longer is worth tens of millions of dollars.

By 2001, Blech told The Seattle Times that he was already planning a comeback.

"I may have one more go at it in me," he said. "This time, I would try to do it in a more measured way, with only one or two biotech companies. I would not try to save the world."

[montamero]

http://www.sec.gov/litigation/complaints/2012/comp-pr2012-89…

[montamero]

Intellect Neurosciences Statement Regarding David Blech’s Indictment for Securities Fraud
Intellect Neurosciences and another biotechnology company were referenced in two lawsuits related to the manipulation of our stocks. It is exceedingly unfortunate, as the accused has been and remains a long-time supporter of Intellect and a friend to the company. We want to assure our shareholders that we have been interviewed extensively by the authorities, and they have acknowledged we were unaware of the actions taken. In the meantime, our focus remains on building Intellect Neurosciences into the pre-eminent developer of new drugs to treat Alzheimer’s and neurodegenerative diseases.

http://content.stockpr.com/intellectns/files/docs/Intellect+…

[Danny767]

Wieso läßt sich die Aktie derzeit nicht ordern?
Bei Consors zeigt es an das der Handelsplatz wegen eines Splits gesperrt ist- Hat jemand dazu infos?

[Danny767]

Es gibt einen Split 50:1
Die neue WKN ist A1H9NF
ISIN: US45822W2098

[montamero]

Up gehts!
Am 11.9. Bapineuzumap Präsentation (neue Versuchsreihe) von Pfizer. Ev. FDA approval.
Falls alles gut geht bekommt ILNS 5% vom Verkauf...
Alzheimer Markt 5-8 B$

[montamero]

Bapineuzumap wird weiter getestet... ILNS Aufwärtstrend

[montamero]

Post#6630 Wednesday, August 08, 2012 7:23:40 AM

thanks for the welcome mr WEaRElEGion or whatever or however u spell it, in my most humble opinion you are incorrect sir. can you document your math as far as ilns owes out more than they potentially have coming in? do u not agree that the failure of bapi strengthens and adds a lot more value to intellects portfolio of int. property, mainly its TAU application? are you not aware of intellects next milestone payment of 10 MILLION(gotta do some dd)for orphan drug status of ox1 from viropharma which will happen in 30-45 days(gotta do more dd)? anyway, my opinion or your opinion does not really matter however i'm betting on mine as per my current position of approx.23 million shares of which i plan to add as much as i can at these absurdly ridiculous levels(both in the open market and from any shareholder,affiliate or not who has an itch to unload,the more the merrier)and if the company itself needs operating capital in the future i will be glad to participate in that as well and ofcourse on friendly non toxic terms for the simple reason of a.protecting my equity stake and b. any deal down under a fully diluted share count market cap of imo 50 mill is a damn good deal. oh and by the way at the current pps on a FULLY DILUTED (not os)scenario(800 mil) would make the current market cap around 8 mill which is a joke(in my most humble/brilliant opinion). .... oh and one more thing the downside at these levels is 0 for the simple fact that i will and more importantly I CAN take in (with open arms) as much sell side inventory that can possibly hit the open market. be well

[montamero]

http://stockcharts.com/h-sc/ui?s=ilns

[montamero]

NEW YORK, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases today issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO.

Dear Shareholder,
The disappointing news yesterday from the bapineuzumab Alzheimer's Phase 3 Study 301 underscores the enormous challenges inherent in developing a successful disease-modifying treatment, particularly for this complex disease, despite the scientific community's confidence regarding the therapeutic target. The disappointment will be felt most acutely by the millions of Alzheimer's patients and their families who were hoping for an end to their suffering. Nevertheless, we should all take heart in the tremendous body of critically important information that has accumulated from these pioneering programs, and we salute the pharmaceutical companies for their leadership in pursuing them. As a result, we now are better positioned to improve clinical trial designs and to select candidates that are likely to yield viable disease-modifying treatments. We are pleased bapineuzumab development will continue; Johnson & Johnson spokeswoman Ellen Rose said, "A mid-stage brain imaging trial of a subcutaneous version of bapineuzumab will continue." It is our hope that the companies may eventually test this version of bapineuzumab in pre-Alzheimer's patients if the results of the study are favorable.
Intellect remains at the forefront of identifying viable treatments for this terrible condition. The company's competitive approach is two-pronged. The first is steering away from monotherapy against a single target, which may be ineffective in Alzheimer's disease. The second is focusing on pre-fibrillar tau protein. Pre-fibrillar tau protein is understood increasingly to be responsible for the irreversible damage to nerve cells after accumulation of beta amyloid, which brings about pathogenic changes to tau. In addition, we intend to put significant emphasis on translational biomarkers in the planned preclinical testing phase of our compounds to assist future clinical trial design. The sophisticated high-resolution brain and cell imaging tools the industry has at its disposal were not available until recently, so their inclusion in our planned preclinical studies will be a huge clinical and competitive advantage over compounds in later-stages of development today. Further, our relationships with key experts in the field have led to important new collaborations. As we generate and publish data from these collaborations, the interest in our programs currently being shown by several pharmaceutical companies will increase and could result in partnerships long before some of these programs reach clinical trials.
With our hand on the pulse of the latest scientific developments and our ability as a small innovation-driven company to act swiftly, we added six new patent families in less than two years. These patents cover new therapeutic products and an extremely promising new platform technology that could generate multiple partnering opportunities. Just hours before yesterday's bapineuzumab news broke, I presented at the IBC Antibody Drug Conjugates, Bispecifics & Empowered Antibodies Conference. My talk focused on N01-OX2, the lead compound of our CONJUMAB-A platform, which has promise for the treatment of dry and wet age related macular degeneration (AMD). AMD therapies generate $4 billion annually, even though the few approved treatments don't cure the disease and offer only modest improvements in vision for most patients. Our program already has attracted interest from global pharmaceutical companies, even at this early stage.
Intellect Neurosciences has carefully planned a survival strategy to ensure its continued viability. In doing so, we have remained ahead of the curve with respect to next-generation therapies by creating multiple distinctive platform technologies that generate drug candidates for a wide variety of diseases. We also have protected our work through an extensive global patent portfolio. Consequently, Intellect has a significant value proposition in our preclinical programs and in our OX1 product, which was licensed to ViroPharma and is anticipated to enter Phase 2 clinical trials in patients with Friedreich's Ataxia. With the anticipated completion of Phase 2 trials by 2015, Intellect could receive in excess of $100 million in milestone payments from ViroPharma and, upon regulatory approval, royalties from sales in this orphan indication over many years. Prior to 2015, new licensing deals for our pipeline programs could yield substantial non-dilutive capital.
Thank you for your continued support of Intellect Neurosciences and our important mission to create a world without Alzheimer's disease and other debilitating neurodegenerative diseases.
Sincerely,
Daniel Chain, Ph.D.
Chairman & CEO

[montamero]

+38,46%, Market Cap 1,72M ....alleine die Laborausrüstung kostete über 14M...und ILNS hat die vielversprechensten Patente gegen Alzheimer,Parkinson etc. Weltweit!

[montamero]

61100 Stk. ask zu 0,018 danach grüßen die 0,019....

[montamero]

52wk high 0,185

[montamero]

Intellect Neurosciences Inc. (OTCBB: ILNS) is a biopharmaceutical company engaged in the discovery and development of a new breed of innovative “disease-modifying” therapeutic drugs that are designed to slow, arrest and ultimately prevent Alzheimer's disease and other serious neurodegenerative disorders.

Intellect is focused on neurodegenerative conditions collectively known as proteinopathies such as Alzheimer’s, Parkinson’s and Huntington disease. Proteinopathies are caused by amyloidogenic proteins, such as amyloid beta, tau, alpha synuclein and Huntingtin. Intellect is the first company to develop antibody drug conjugates (ADCs) in which amyloid clearing antibodies are empowered by chemically linking them to molecules that offer neuroprotection, creating a single drug. The use of ADCs is one way in which Intellect is developing more effective drugs with the recognition that monotherapy may not be effective enough in treating the complex nature of proteinopathies.

A second approach being pioneered by Intellect, also based on this idea and specifically focused on Alzheimer’s disease, is a bi-specific vaccine that targets both beta amyloid and a pathogenic form of tau protein. In contrast to antibodies that only target beta amyloid and have not yet proven their ability to treat mild to moderate Alzheimer’s disease, the dual target vaccine being developed by Intellect has the potential to be used both prophylactically in presymptomatic patients and therapeutically in patients that are symptomatic.

Intellect Neurosciences has its origins in some of the earliest pioneering work that stimulated the development of the potential disease-modifying monoclonal antibodies that several global pharmaceutical companies have been testing as treatments for Alzheimer’s disease. The intellectual property resulting from the discovery of how such antibodies could be used as treatments predates competitive strategies such that the pharmaceutical companies developing those drugs, purchased licenses to the technology from Intellect. The company remains ahead of the curve with respect to next-generation therapies, as it has developed multiple distinctive platform technologies that are generating drug candidates for a wide variety of diseases.

The company developed OX1, a multimodal antioxidant molecule, through preclinical and human safety trials before licensing the program to ViroPharma. ViroPharma has said it plans to enter Phase 2 clinical trials in patients with Friedreich's Ataxia, an orphan indication, in 2013. Intellect could receive in excess of $100 million in milestone payments from ViroPharma and, if approved, royalties from sales over many years.

Intellect’s preclinical R&D pipeline is based on two proprietary platform technologies, CONJUMAB-A and RECALL-VAX and includes the following drug candidates:

CONJUMAB-A: Empowered Antibodies for the Treatment of Proteinopathies

N01-OX2 is a first-in-class ADC. It is a humanized monoclonal antibody specific for beta amyloid protein that is empowered to deliver on-site neuroprotection by its conjugation to melatonin. The goal of N01-OX2 is to reduce the oxidative stress that leads to cellular inflammation and damage. N01-OX2 is being developed for the treatment of age-related macular degeneration (AMD), the leading cause of blindness in people over the age of 55. AMD therapies generate $4 billion annually, even though the few approved treatments don't cure the disease and offer only modest improvements in vision for most patients. N01-OX2 also has potential applications for diabetic retinopathy, glaucoma, traumatic brain injury and Alzheimer’s disease.

T01-OX2 is an ADC comprised of a monoclonal antibody selective for oligomeric toxic forms of tau protein and is empowered with neuroprotection by its conjugation to melatonin. T01-OX2 is expected to reduce tau pathology and has potential for the treatment of Alzheimer’s disease, Frontotemporal dementia and also has potential applications to treat ophthalmology indications.

RECALL VAX: A chimeric peptide vaccine comprised of a human B cell epitope linked to a bacterial T cell epitope to produce highly specific vaccines against one or more amyloidogenic proteins.

RV03 is a first-in-class bi-specific vaccine targeting both beta amyloid and delta tau. Delta tau is a shorter form of the tau protein. It is especially toxic to nerve cells and precedes the formation of neurofibrillary tangles. RV03 has potential for the treatment of Alzheimer’s disease and Frontotemporal dementia.

http://www.intellectns.com

[montamero]

http://finance.yahoo.com/mb/ILNS/" target="_blank" rel="nofollow ugc noopener"> http://finance.yahoo.com/mb/ILNS/
http://www.otcmarkets.com/stock/Ilns/quote
http://www.barchart.com/opinions/stocks/ILNS
http://www.barchart.com/cheatsheet.php?sym=ILNS
http://www.otcmarkets.com/stock/ILNS/chart

[montamero]

http://finance.yahoo.com/mb/ILNS/
http://www.otcmarkets.com/stock/Ilns/quote
http://www.barchart.com/opinions/stocks/ILNS
http://www.barchart.com/cheatsheet.php?sym=ILNS
http://www.otcmarkets.com/stock/ILNS/chart

[montamero]

http://stockcharts.com/h-sc/ui?s=ILNS

[montamero]

[montamero]

BioMed Reports has ILNS highlighted in their updates:Here is the link....buy in now as this looks as though it will move quickly upwards on positive news.

http://www.biomedreports.com/20120917105149/healthcare-revie…

[montamero]

InsideBulls.com Profiles The Best Penny Stock Picks: (OTCQX: BRIZF), (OTCQB: CONX), (PINKSHEETS: UNDR), (OTCBB: ILNS)

InsideBulls.com MacReport Media

Your online resource for microcap stock news and information, Insidebulls.com offers a free newsletter featuring some of the best penny stock picks available. Our sole purpose is to find the best penny stock picks and keep you informed with fast moving penny stocks. To receive our amazing penny stock newsletter and alerts go to http://insidebulls.com/
***The following Penny Stocks are active this week:***
Brazil Resources Inc. (OTCQX: BRIZF) is a mineral exploration company with a focus on the acquisition and development of projects in emerging producing gold districts in Brazil and other parts of South America. Currently, the Company is advancing its Montes Aureos property located in the State of Maranhao, Brazil, within the Gurupi gold belt. For the Best Penny Stock Picks Subscribe to http://www.insidebulls.com/
HPIL Holding (OTCQB: HPIL) is a worldwide diversified holding company. HPIL Holding is focused on investing in both private and public companies in differing business sectors. HPIL Holding does not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, acquires various types of business. Also HPIL Holding evaluates the acquisition of intellectual properties and technologies, with a particular interest in the healthcare and environmental quality sectors. For the Best Penny Stock Picks Subscribe to http://www.insidebulls.com/
UnderSea Recovery Corporation (PINKSHEETS: UNDR) engaged in the business of locating and recovering historical shipwrecks,primarily those from the 15th through 19th centuries, andother cultural resources (artifacts and other objects of historical andarchaeological interest) from the world's oceans and large lakes by applyingadvanced technologies in an environmentally and ecologically responsiblemanner. For the Best Penny Stock Picks Subscribe to http://www.insidebulls.com/
Intellect Neurosciences, Inc. (OTCBB: ILNS) is a biopharmaceutical company engaged in the discovery and development of a new breed of innovative disease-modifying therapeutic drugs that are designed to slow, arrest and ultimately prevent Alzheimer's disease and other serious neurodegenerative disorders. For the Best Penny Stock Picks Subscribe to http://www.insidebulls.com/
Subscribe Here - http://www.insidebulls.com/
Disclosure: http://insidebulls.com/ is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit http://insidebulls.com/ for complete risks and disclosures.
CONTACT: INSIDEBULLS.COM [e-mail]
SOURCE: InsideBulls.com

http://www.equities.com/news/headline-story?dt=2012-09-18&va…

[montamero]

Bid 0,023 Ask 0,0265

[montamero]

NEWS!!

Intellect Neurosciences and Medical Research Council Technology Announce Humanization of Next-Generation Monoclonal Antibody to Amyloid Beta With Reduced Potential for Inflammation in the Brain of Alzheimer's Patients
MRCT Amends Agreement Increasing Its Shared Risk in Development of Humanized Antibody


NEW YORK and LONDON, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies, and MRC Technology (MRCT), leading specialists in the humanization of antibodies, announced today they have completed humanization of 82E1, a mouse monoclonal antibody to create a high-affinity stabilized IgG4 therapeutic antibody that binds the amino terminus of amyloid beta without binding to the amyloid precursor protein (APP).
Antibodies exist in several isoforms; IgG1 antibodies have the strongest potential to induce inflammation while IgG4 has the lowest potential. The Intellect antibody, called IN-N01, is anticipated to promote the clearance of monomeric, oligomeric and plaque forms of amyloid beta, which accumulate in the brains of Alzheimer's patients or following traumatic brain injury and in the retina of the eye in patients with age-related macular degeneration, diabetic neuropathy and glaucoma.
Intellect Neurosciences and MRCT also have amended their Service Agreement to reduce Intellect's cash outlay in exchange for equity. This reflects MRCT's new strategy of risk sharing on exciting antibody projects.
"IN-N01 is an important addition to Intellect's diversified preclinical pipeline," commented Daniel G. Chain, PhD, Intellect's Chairman and CEO. "The recent Phase 3 data for bapineuzumab, an IgG1 antibody, despite failing to show improvement in clinical endpoints, demonstrated through the use of biomarkers the drug engaged the amyloid beta target and reduced neurodegeneration indicating both the need for earlier intervention and improved antibody-based therapies. We anticipate IN-N01 will have improved safety, which means that it can be used at higher, more frequent doses that likely will result in clinical efficacy, especially if administered to presymptomatic patients."
IN-N01 could be developed without further modification or empowered by chemically combining the antibody with a small molecule, such as an antioxidant, using Intellect's CONJUMAB(TM) platform technology. The company plans to evaluate IN-N01 in both contexts. Additionally, Intellect plans to test IN-N01 in combination with its tau monoclonal antibodies, TOC1- and TauC3.
"MRCT's collaboration with the team at Intellect Neurosciences applying our unparalleled expertise to this important and timely project will be critical to the development of IN-N01 as a therapeutic antibody and we are confident in its potential success," said Dr. Dave Tapolczay, MRCT's CEO. "We believe Intellect Neurosciences is on track with a promising drug candidate and therefore were pleased to offset their cost of development by sharing in the risk."
About Intellect Neurosciences
Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.
For more information, please visit www.intellectns.com.
The Intellect Neurosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14741
About Medical Research Council Technology
MRC Technology (www.mrctechnology.org) is a technology transfer company and charity responsible for adding commercial value to cutting edge scientific discoveries through strategic patent protection, creative licensing of intellectual property (IP), partnered research or further scientific development.
MRC Technology also has small molecule drug discovery and therapeutic antibody facilities, providing lead-stage therapeutic assets to pharmaceutical and biotechnology companies.
MRC Technology's scientists have a proven track record of success in antibody humanization, having humanized more than 50 antibodies including Tysabri(R) and Actemra(R). A further six are in clinical trials (including Vedolizumab) with another two in preclinical studies. For additional information please visit http://www.antibodyengineering.co.uk
The MRC Technology logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14742
Safe Harbor Statement Regarding Forward--Looking Statements:
The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward--looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward--looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333--128226), filed on October 13, 2011, and in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012, which was filed on May 14, 2012.

Contact:
Contact for Intellect Neurosciences:
Jules Abraham
JQA Partners, LLC
917-885-7378
[e-mail]
Contact Information for MRC Technology
Suzy Hargreaves
Marketing & Communications Officer
E-mail: [e-mail]
Phone: [phone]
Media contact
Zyme Communications
Katie Odgaard
E-mail: [e-mail]
Phone: [phone]


http://finance.yahoo.com/news/intellect-neurosciences-medica…

[montamero]

Intellect kann nächstes Jahr bereits mehr als 100M$ wert sein, d. h. ILNS könnte dann im Bereich von 1-5$ gehandelt werden. Das Potential wäre vorhanden..... nur meine Meinung und Einschätzung.

[montamero]

bid 0,024 ask 0,027

[montamero]

0,026/0,027

[montamero]

Some useful facts about MRC Technology
The numbers
MRC Technology protects and translates scientific discoveries from the UK Medical Research Council-funded Units and Institutes. The MRC’s budget for this in 2009/2010 was £375 million.

At the start of 2010, total licensing income generated by MRC Technology stood at over £500 million.

The Centre for Therapeutic Discovery has capacity for 8 small molecue and 5 antibody projects per year. This is set to increase to 16 small molecule and 8 antibody projects per year over the next 18 months.

Up to July 2009, DGF has invested over GBP£7 million in 67 early stage research projects with commercial potential.
Over 20 companies are licensed to sell our research reagents.


http://www.mrctechnology.org/about/facts-and-figures

[montamero]

HUGE NEWS!!!
http://finance.yahoo.com/news/lonza-intellect-neurosciences-…

[montamero]

HUGE NEWS!!!
http://finance.yahoo.com/news/lonza-intellect-neurosciences-…

[montamero]

Lonza and Intellect Neurosciences Announce Intellect’s Intention to Award Production of its Antibody Drug Conjugate, CONJUMAB-A


New York (USA) and Basel (Switzerland), 27 September 2012 – Lonza announced today that Intellect Neurosciences, Inc. (OTCBB:ILNS) awarded the future development and manufacture of the antibody drug conjugate CONJUMAB-A to Lonza, subject to completion of a definitive development and manufacturing agreement. Lonza will supply the preclinical study material for the drug optimization and drug selection for Intellect’s CONJUMAB-A, initially focusing on age-related macular degeneration (AMD) with potential applications for Alzheimer’s disease. Intellect Neurosciences is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies.

The new program is expected to include in vitro and in vivo studies to evaluate both therapeutic and prophylactic potential in AMD testing different chemical variants manufactured by Lonza. Intellect also plans to work with a number of independent specialized contract research organizations to evaluate the compounds produced by Lonza Chemical Manufacturing in Visp, Switzerland. Intellect‘s program is led by Dan Shochat, Ph.D., Intellect Neurosciences’ Consulting Vice President of Development and a pioneer in the development of antibody drug conjugates for cancer treatments.

"CONJUMAB-A is a first-in-class drug compound intended to address an important unmet need in AMD, which is the leading cause of blindness in people over the age of 55. We anticipate improved efficacy compared to naked amyloid beta antibodies currently in clinical development for AMD. The selection of Lonza as our manufacturer, just under a year since we introduced the platform, represents an important next step in the evolution of Intellect Neurosciences, and we are very proud to be working with such a high caliber team at Lonza," said Dr. Daniel Chain, Chairman and CEO. "Based on recent discussions with global pharmaceutical companies that have expressed interest in the program, we see this program as a near-term opportunity for potential partnering for Intellect."

"Lonza looks forward to collaborating with Intellect Neurosciences on its CONJUMAB-A program," said Stefan Stoffel, Head of Lonza Chemical Manufacturing. "We have already generated a detailed road map for the optimization and manufacture of CONJUMAB-A, and are excited to be associated with this entirely novel and promising application for antibody-drug conjugates."

http://www.lonza.com/about-lonza/media-center/news/2012/1209…" target="_blank" rel="nofollow ugc noopener">http://www.lonza.com/about-lonza/media-center/news/2012/1209…

[montamero]

Lonza to develop antibody drug conjugate

PBR Staff Writer

Published 28 September 2012

Lonza has received a contract from Intellect Neurosciences to develop and manufacture the antibody drug conjugate, Conjumab-A.

Under the contract, Lonza will supply the preclinical study material for the drug optimization and drug selection for Intellect's Conjumab-A, aiming on age-related macular degeneration (AMD) with potential applications for Alzheimer's disease.

The program is also expected to have in vitro and in vivo studies to evaluate both therapeutic and prophylactic potential in AMD testing different chemical variants manufactured by Lonza.

Intellect Neurosciences chairman and CEO Daniel Chain said Conjumab-A is a first-in-class drug compound intended to address an important unmet need in AMD, which is the cause of blindness in people over the age of 55.

''The selection of Lonza as our manufacturer, just under a year since we introduced the platform, represents an important next step in the evolution of Intellect Neurosciences, and we are very proud to be working with such a high caliber team at Lonza," Chain added.

Lonza chemical manufacturing head Stefan Stoffel said, "We have already generated a detailed road map for the optimization and manufacture of CONJUMAB-A, and are excited to be associated with this entirely novel and promising application for antibody-drug conjugates."

http://www.pharmaceutical-business-review.com/news/lonza-to-…

[montamero]

Schweizer Börse auf Erholungskurs


Am Donnerstag sind die Kurse an der SIX höher in den Handel gestartet.
Bild: Keystone
27.09.2012 09:08
Nach den kräftigen Einbussen vom Vortag hat die Schweizer Börse am Donnerstag höher eröffnet.

Händler hatten im Vorfeld mit einer technischen Erholung gerechnet, nachdem sich die Aktienkurse in den USA trotz der Turbulenzen in der Euro-Zone weniger schlecht als zunächst erwartet entwickelt hatten. Und in Teilen Fernosts tendierten die Märkte freundlich.

Der Swiss Market Index steigt am Donnerstag nach Handelseröffnung um 0,3 Prozent. Dabei legt die Aktie von UBS mit 1 Prozent von den Titeln im SMI am meisten zu.

Ein ehemals ranghoher Wertpapierhändler der Credit Suisse ist in London festgenommen worden. Ihm droht die Überstellung in die USA, wo ihm Betrug im Zusammenhang mit Milliarden-Verlusten der Bank bei Ramsch-Anleihen 2007/2008 vorgeworfen wird. Der heute 39-Jährige war zu der Zeit der globale Chef der Credit Suisse für den Handel mit strukturierten Krediten. Die Aktie steigt 0,8 Prozent.

Wegen der Kündigung eines langfristigen Liefervertrags eines Grosskunden im Bereich Photovoltaik rechnet Phoenix Mecano mit einem Abwertungsverlust in dem Sektor von sechs bis acht Millionen Euro. Der Komponentenhersteller revidiert daher die Ebit-Prognose für das laufende Jahr nach unten auf 32 bis 37 von bisher 43 bis 53 Millionen Euro.

Sonova hat anlässlich eines Investorentages den Ausblick bestätigt und erwartet für das laufende Geschäftsjahr ein Umsatzwachstum von sieben bis neun Prozent in Lokalwährungen und eine EBITA-Steigerung von 15 bis 20 Prozent. Die Aktie legt 0,2 Prozent zu.

Intellect Neurosciences vergibt die Entwicklung und Produktion des Antikörper-Wirkstoff-Konjugates CONJUMAB-A an Lonza. Die Aktie steigt 0,5 Prozent.

(cash/Reuters)

[montamero]

http://www.cash.ch/news/boersenkommentar/schweizer_boerse_au…

[montamero]

Lonza and Intellect Neurosciences Announces Intellect's Intention to Award Production of Its Antibody Drug Conjugate, CONJUMAB-A to Lonza

28 Sep 2012

NEW YORK, NY, USA and BASEL, Switzerland I September 27, 2012 I Lonza announced today that Intellect Neurosciences, Inc. (ILNS) awarded the future development and manufacture of the antibody drug conjugate CONJUMAB-A to Lonza, subject to completion of a definitive development and manufacturing agreement. Lonza will supply the preclinical study material for the drug optimization and drug selection for Intellect's CONJUMAB-A, initially focusing on age-related macular degeneration (AMD) with potential applications for Alzheimer's disease. Intellect Neurosciences is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies.

The new program is expected to include in vitro and in vivo studies to evaluate both therapeutic and prophylactic potential in AMD testing different chemical variants manufactured by Lonza. Intellect also plans to work with a number of independent specialized contract research organizations to evaluate the compounds produced by Lonza Chemical Manufacturing in Visp, Switzerland. Intellect's program is led by Dan Shochat, Ph.D., Intellect Neurosciences' Consulting Vice President of Development and a pioneer in the development of antibody drug conjugates for cancer treatments.

"CONJUMAB-A is a first-in-class drug compound intended to address an important unmet need in AMD, which is the leading cause of blindness in people over the age of 55. We anticipate improved efficacy compared to naked amyloid beta antibodies currently in clinical development for AMD. The selection of Lonza as our manufacturer, just under a year since we introduced the platform, represents an important next step in the evolution of Intellect Neurosciences, and we are very proud to be working with such a high caliber team at Lonza," said Dr. Daniel Chain, Chairman and CEO. "Based on recent discussions with global pharmaceutical companies that have expressed interest in the program, we see this program as a near-term opportunity for potential partnering for Intellect."

"Lonza looks forward to collaborating with Intellect Neurosciences on its CONJUMAB-A program," said Stefan Stoffel, Head of Lonza Chemical Manufacturing. "We have already generated a detailed road map for the optimization and manufacture of CONJUMAB-A, and are excited to be associated with this entirely novel and promising application for antibody-drug conjugates."

About CONJUMAB-A

CONJUMAB-A (also known as IN-NO1-OX2), is an antibody drug conjugate, targeting age- related macular degeneration and Alzheimer's disease. The CONJUMAB platform empowers monoclonal antibodies targeting amyloidogenic proteins with additional neuroprotective properties by combining them chemically with a small molecule such as an antioxidant. CONJUMAB-A, the first compound from this platform, is a monoclonal antibody specific for beta amyloid conjugated to melatonin which is a recognized as a potent antioxidant. Beta amyloid, when it accumulates in the retina of the eye, causes damage by oxidative stress. The conjugate is anticipated to increase the therapeutic window for melatonin to protect retinal epithelial cells, promote clearance of beta-amyloid away from sites of damage and limit potential off-target side-effects. CONJUMAB-A may also have potential applications for diabetic retinopathy, glaucoma, traumatic brain injury, and Alzheimer's disease.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.

For more information please visit www.intellectns.com

The Intellect Neurosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14741

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of chemical and biological active pharmaceutical ingredients. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts, which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza is not subject to the SGX-ST's continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting.

SOURCE: Intellect Neurosciences

http://www.pipelinereview.com/index.php/2012092849021/Antibo…

[montamero]

Über Lonza

Company History

1897 Foundation of Lonza AG Electricity Works in Gampel, Valais (Switzerland), on the banks of river Lonza. The electricity was used to manufacture calcium carbide and acetylene.
1909 Lonza moves to Visp and manufactures synthetic fertilizers out of nitrogen, ammonia and calcium carbide.
1920 Production of nitric acid, ketene, and diketene starts.
1956 Start of Production of Niacin, a vitamin of the B-group.
1965 Change of the raw material base from carbide to naphtha and further development of backwards integration: intermediates and additives for pharmaceuticals, agrochemicals, dyestuffs, colours, adhesives, etc.
1969 Lonza expands to the USA and starts its business with chemical specialties.
1974 Merger with Alusuisse and development into an internationally operating enterprise.
1980 Lonza starts its biotechnological business.
1982 Start of exclusive manufacturing of substances for pharmaceutical and agrochemical companies.
1992 Lonza acquires a biotechnological production facility (fermentation) in the Czech Republic.
1996 In Guangzhou, China, a joint venture is signed to build up a niacinamide plant primarily to satisfy the regional market needs.
1996 Lonza acquires Celltech Biologics (GB and USA) and expands into the business with mammalian cell cultures and monoclonal antibodies.
1999 Lonza is de-merged from the Alusuisse-Lonza Group and listed as an independent company at the Swiss stock exchange.
2004 Lonza starts-up three 20’000-liter mammalian cell culture fermentation reactors in Portsmouth, NH (USA), the biggest single investment in its history.
2005 Lonza announces a significant investment program in the expansion of its peptides manufacturing capacities in its production site in Visp, Switzerland.
2006 Lonza carries out a series of strategic transactions aimed at transforming the company into one of the world’s leading suppliers of active pharmaceutical ingredients, biopharmaceuticals and research products to the pharmaceutical, healthcare and life-science industries.
Acquisition of Bioproducts manufacturing division of UCB (Braine-L’Alleud, Belgium) positions Lonza as a leading global provider of peptides to the biopharmaceutical market.
The fourth 20’000-liter bioreactor in Portsmouth, NH (USA) came on stream.
IPO of Polynt S.p.A., Lonza’s Polymer Intermediates business. Lonza retains a minority stake in Polynt.
Lonza announces the acquisition of the complementary Bioproducts and Biopharma businesses from Cambrex to further enhance Lonza’s capability to service the needs of the highgrowth life sciences R&D and pharmaceutical development industries. The acquisition also expands Lonza’s geographical footprint, particularly in the USA.
Agreement with Genentech, one of the world’s largest biotechnology companies, to acquire mid-scale biopharmaceutical manufacturing operation in Porriño, Spain, providing significant manufacturing capacity two years earlier than planned. In addition, Lonza will build and start up a large-scale mammalian biopharmaceutical facility in Singapore which Genentech will have an exclusive option to buy upon US FDA licensure. In parallel, Lonza will build its own planned large-scale (4 x 20’000-liter) biopharmaceutical manufacturing facility in Singapore.
2007 Lonza announced that it has completed the acquisition of the Research Bioproducts business and the Microbial Biopharmaceutical business of the US company Cambrex, published in October 2006.
Lonza announced the acquisition of the assets of S.A.M. Electron Technologies based in Shawinigan (Canada). The acquisition of these assets is concurrent with an exclusive worldwide license for a cerium mediator electrochemical technology (CeTECH™) from Hydro-Québec and lease agreement with the City of Shawinigan. CeTECH™ is an electrochemical cerium based oxidation technology which can be used to produce a variety of high value added compounds. It has been demonstrated on a commercial scale for the production of vitamin K-3.
Lonza finalizes the divestiture of its purified isophthalic acid plant in Singapore.
2008 Lonza finalizes the selling of the majority of its shares in Polynt S.p.A.
Lonza completes the acquisition of amaxa. The acquisition of amaxa is in line with Lonza’s strategy of growing its life-science platform. amaxa is a premium supplier to the cell discovery market with leading edge, proprietary technologies in well-defined market niches of transfection systems. The deal further strengthens Lonza’s position as a worldwide leader in cell discovery by integrating this unique, proprietary technology into its portfolio and by continuing to develop the company’s activities.
2009 Teva and Lonza announced their agreement to establish a joint venture to develop, manufacture and market a portfolio of biosimilars.
Lonza strengthens its protein design technology offering for biopharmaceutical development by acquiring Algonomics NV (Gent, Belgium).
Lonza expands its cell-biology platform by acquiring Simbiosys Biowares’ preclinical cell and molecular biology group.
2010 Lonza expands its capacities for Carnipure™ and Carniking™ by investing in a new manufacturing facility for L-carnitine products in Nansha.
Lonza invests in new plant for vitamin B3 (nicotinates) in Nansha.
Lonza Group Ltd acquires MODA Technology Partners ("MODA"), a software company that provides paperless quality control solutions. The acquisition will strengthen the Rapid Testing Solutions platform of Lonza’s Bioscience division by adding a complementary product offering for quality assurance (QA) and quality control (QC) organizations in the life-science industry.
Lonza acquires viral vaccine and vector manufacturer Vivante GMP Solutions. The acquisition advances Lonza’s strategy to broaden its biologics custom service offering for the growing viral vaccine and gene therapy markets.
Lonza signs agreement with GlaxoSmithKline (GSK) to secure capacity and expertise in biological manufacturing to support ongoing development of GSK’s biopharmaceuticals portfolio. Thereby Lonza will supply manufacturing capacity for five early stage monoclonal antibodies.
Lonza acquires biotech service provider Algonomics, a contract research organization providing integrated immunogenicity prediction services to support companies in the development of biotherapeutics.
2011 Lonza invests £16 million to further develop the flexibility and capability of its Slough, UK biopharmaceutical manufacturing facility to respond to a broader range of customer projects and strengthen its global network of biologics development and manufacturing. The project is scheduled for completion by the end of 2012.
Lonza plans to invest CHF 24 million to expand cytotoxic manufacturing capabilities in Visp, Switzerland to serve growing oncology API market. Cytotoxic APIs are commonly used in oncology therapeutics, which represent one of the fastest growing segments of the pharma and biotech industry.
Lonza expands its viral-based therapeutics business with the construction of a new, state-of-the-art cGMP clean room located adjacent to its existing Houston, Texas operations.
Lonza is investing CHF 10 million to expand its biopharmaceutical development services platform in Singapore to meet increasing demand for biopharma development services from preclinical to commercial.
Lonza invests CHF 5.8 million in a formulation plant for Meta™ metaldehyde. This will enable Lonza to supply its own formulations, allowing the company in the future to serve the market not only with metaldehyde as an active substance, but also with ready-made slug pellets. It is expected to become operational in the second half of 2012.
Lonza celebrates 40 years as leading producer of vitamin B3. Since 1971, Lonza has supplied more than half the world’s demand for vitamin B3 in the human and animal health nutrition industries.
Lonza Group Ltd and global regenerative medicine company Mesoblast Limited enter into a strategic alliance for clinical and long-term commercial production of Mesoblast’s off-the-shelf (allogeneic) adult stem cell products.
Lonza acquires Arch Chemicals, Inc., a global biocides company providing innovative solutions to destroy or to selectively inhibit the growth of harmful microorganisms, to create the world’s leading Microbial Control business. The combined businesses will be able to develop innovative microbial control formulations based on a broad portfolio of registered and approved active ingredients. Jeanne Thoma is appointed to Chief Operating Officer for Lonza’s Microbial Control sector (LMC) which will be created following the acquisition.
Lonza Group Ltd (SIX stock code: LONN VX; SGX-ST stock code: O6Z) makes its trading debut on the Main Board of the Singapore Exchange Securities Trading Limited (“SGX-ST”) on 21 October 2011 and consequently is the first SIX Swiss-listed company to dual list in Singapore.
Lonza to expand early phase manufacturing capacity at its site in Nansha, China, to serve small molecules market.

[montamero]

IHub Post 6467

I have a few points of interest.Made contact many times with the CEO.Never said a word regarding the content.I will post a few coments from emails I received.

Here is a link that is about a month old regarding what this company imo is seeking.


http://www.fiercebiotech.com/story/jj-grabs-promising-genmab…

Fortunately we have several other programs focused on next generation therapeutics that are generating interest from potential corporate partners. We do plan to collect the unpaid milestone payment one way or the other.


We are in discussions with various parties that may ultimately yield something positive for the company and its shareholders.

Apart from contributing all the intellectual capital, I have dedicated 15 years of my life and personally invested in the IP and programs to the tune of about $3 million prior to the inception of the company. After inception, I loaned Intellect funds on several occasions without being compensated for the loans. I have never sold any Intellect shares. I think you will be hard-pressed to find other founder CEOs who have given as much as I have.

Sincerely,



Daniel G. Chain, Ph.D.

Chairman & CEO

Intellect Neurosciences, Inc.,

45 West 36th Street

3rd Floor

New York, NY 10018

Tel. [phone]

Fax. [phone]

Cell. 718 406 1331

www.intellectns.com


Now look at the most recent pr.




"IN-N01 is an important addition to Intellect's diversified preclinical pipeline," commented Daniel G. Chain, PhD, Intellect's Chairman and CEO. "The recent Phase 3 data for bapineuzumab, an IgG1 antibody, despite failing to show improvement in clinical endpoints, demonstrated through the use of biomarkers the drug engaged the amyloid beta target and reduced neurodegeneration indicating both the need for earlier intervention and improved antibody-based therapies. We anticipate IN-N01 will have improved safety, which means that it can be used at higher, more frequent doses that likely will result in clinical efficacy, especially if administered to presymptomatic patients."

Big Pharma just spent 1.5 billion.Alot of free knowledge was gained imo.Now it appears Intellect will seek what worked.

demonstrated through the use of biomarkers the drug engaged the amyloid beta target and reduced neurodegeneration indicating both the need for earlier intervention and improved antibody-based therapies.

I own shares.

Have no clue what may happen.I think the risk may very well turn into a large reward.

[montamero]

Der Deal mit Lonza kann Ilns zu einigen hundert Millionen verhelfen. Bin gespannt auf die Zahlen!

[montamero]

Lonza und Intellect Neurosciences kündigen die Intention von Intellect an, die Produktion für ihr Antikörper-Wirkstoff-Konjugat CONJUMAB-A an Lonza zu vergeben

September 27,2012

New York und Basel, Schweiz, 27. September 2012 – Lonza gibt heute bekannt, dass Neurosciences, Inc. (OTCBB:ILNS), vorbehaltlich einer endgültigen Entwicklungs- und Produktionsvereinbarung vor hat, die zukünftige Entwicklung und Produktion des Antikörper-Wirkstoff-Konjugates CONJUMAB-A an Lonza zu vergeben. Lonza wird das präklinische Studienmaterial, zunächst fokussiert auf die altersbedingte Makuladegeneration (AMD) mit Anwendungspotenzial für Alzheimer Erkrankungen, für die Optimierung und Auswahl von Intellect‘s Antikörper-Wirkstoff-Konjugates CONJUMAB-A liefern. Intellect Neurosciences ist ein in der Forschung und Entwicklung von krankheitsmodifizierenden Therapeutika zur Behandlung von Proteinopathien tätiges biopharmazeutisches Unternehmen.

Das neue Programm wird voraussichtlich In-vitro- und In-vivo-Studien beinhalten, um sowohl das therapeutische als auch das prophylaktische Potential verschiedener chemischer Varianten für AMD zu evaluieren, welche von Lonza hergestellt werden. Intellect plant ebenfalls mit einer Reihe von unabhängigen, spezialisierten Auftragsforschungs-Organisationen zusammenzuarbeiten, um die von Lonza Chemical Manufacturing in Visp, Schweiz, hergestellten Stoffe zu bewerten. Geleitet wird Intellect’s Programm von Dr. Dan Shochat, Intellect Neurosciences‘ Consulting Vice President Entwicklung, und ein Pionier in der Entwicklung von Antikörper-Wirkstoff-Konjugaten zur Krebsbehandlung.

„CONJUMAB-A ist als eine first-in-class Wirkstoffverbindung darauf ausgerichtet, einen wichtigen, bisher medizinisch nicht abgedeckten Bedarf bei AMD, der häufigsten Ursache für Sehbehinderung und Erblindung bei über 55-Jährigen, zu adressieren. Wir erwarten eine verbesserte Wirksamkeit verglichen zu den reinen amyloiden Beta-Antikörpern, die sich derzeit für AMD in der klinischen Entwicklung befinden. Das Abkommen mit Lonza nach nur knapp einem Jahr, seitdem wir die Plattform eingeführt haben, ist ein wichtiger nächster Schritt in der Evolution von Intellect Neurosciences. Wir sind sehr stolz darauf, mit einem so hochkarätigen Team von Lonza zusammenzuarbeiten", sagte Dr. Daniel Chain, Chairman und CEO. „Basierend auf den jüngsten Diskussionen mit globalen pharmazeutischen Unternehmen, die Interesse an dem Programm bekundet haben, sehen wir dieses Programm als zukünftige Möglichkeit für potentielle Partnerschaften für Intellect."

„Lonza sieht der Zusammenarbeit mit Intellect Neurosciences an dem CONJUMAB-A-Programm mit Spannung entgegen", sagte Stefan Stoffel, Leiter Chemical Custom Manufacturing bei Lonza. „Wir haben bereits eine detaillierte Planung für die Optimierung und Produktion von CONJUMAB-A erarbeitet, und freuen uns, mit dieser vollkommen neuen und vielversprechenden Anwendung der Antikörper-Wirkstoff-Konjugate assoziiert zu werden."

[montamero]

NEW ILNS LONZA Article

http://www.in-pharmatechnologist.com/Processing/Lonza-to-mak…" target="_blank" rel="nofollow ugc noopener">http://www.in-pharmatechnologist.com/Processing/Lonza-to-mak…


"While it is hard to say how significant the Intellect contract is for Lonza - no financial terms were disclosed - the deal does underline the growing interest top tier contract manufactoring organisations (CMOs) have in ADC development and manufacture."

[montamero]

Da muss man schon am ask zugreifen um noch welche zu bekommen bevor die Zahlen kommen

[montamero]

Zugreifen solange es noch möglich ist!

[montamero]

Ach ja, News out, siehe Yahoo

[montamero]

Intellect Neurosciences and iNovacia Enter Research Service Agreement to Evaluate Lead Compounds for CONJUMAB-A Program

NEW YORK and STOCKHOLM, Oct. 3, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies, and iNovacia, leading experts in compound screening, announced today they have entered into a Research Service Agreement to evaluate preclinical compounds for the drug optimization and selection program for Intellect's antibody drug conjugate, CONJUMAB-A, which is being developed for age related macular degeneration (AMD).

CONJUMAB-A is anticipated to counter the neurotoxic effects of amyloid beta accumulation and to promote its clearance away from tissues where it causes damage. iNovacia will perform a series of in vitro tests to evaluate compounds, which are designed to allow Intellect to select the optimal drug candidate for further development.

"CONJUMAB-A will be a first-in-class drug compound intended to address an important unmet need in AMD, which is the leading cause of blindness in people over the age of 55. We believe the antibody drug conjugate will show improved efficacy compared to the naked amyloid beta antibodies currently in clinical development for AMD. iNovacia has significant expertise in compound screening, including assay development, and we are confident in their ability to conduct these important studies and deliver data in a timely manner," said Daniel Chain, Ph.D., chairman and CEO of Intellect. "Based on recent discussions with global pharmaceutical companies that have expressed interest in the CONJUMAB-A program, we foresee near-term opportunities for potential partnership."

"We look forward to our inaugural collaboration with the team at Intellect Neurosciences, with the hope that we might continue to work together on future compounds," said Dr. Thomas Olin, CEO of iNovacia. "We have established a successful track record with several pharmaceutical and biotechnology customers in the United States and in Europe and are anxious to provide value to Intellect as well."

About CONJUMAB-A

The CONJUMAB platform empowers monoclonal antibodies targeting amyloidogenic proteins with additional neuroprotective properties by combining them chemically with a small molecule, such as an antioxidant. CONJUMAB-A, the first compound from this platform, is a monoclonal antibody specific for beta amyloid conjugated to melatonin, which is recognized as a potent antioxidant. Beta amyloid, when it accumulates in the retina of the eye, causes damage by oxidative stress. The conjugate is anticipated to increase the therapeutic window for melatonin to protect retinal epithelial cells, promote clearance of beta-amyloid away from sites of damage, and avoid potential off-target side effects. CONJUMAB-A also may have potential applications for diabetic retinopathy, glaucoma, traumatic brain injury, and Alzheimer's disease.

About Intellect Neurosciences

Intellect Neurosciences, Inc., develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.

For more information, please visit www.intellectns.com.

The Intellect Neurosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14741

About iNovacia

iNovacia provides high-throughput screening (HTS), fragment-based screening (FBS) and other drug discovery services to translate targets into validated leads for pharmaceutical and biotech companies. Enabled by a proprietary 300,000 compound library of highest international standard, unique biophysical tools for characterization of mode-of-action and structure-activity relationships, iNovacia mitigates technical risk, minimizes lead-time and optimizes quality of drug discovery projects. iNovacia is a wholly owned subsidiary of Kancera AB (Nasdaq OMX Stockholm First North, KAN).

Safe Harbor Statement Regarding Forward-‐Looking Statements:

The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-‐looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-‐looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-‐128226), filed on October 13, 2011, and in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012, which was filed on May 14, 2012.

Contact for Intellect Neurosciences:
Jules Abraham
Principal
JQA Partners, LLC
917-885-7378
[e-mail]


http://www.nasdaq.com/article/intellect-neurosciences-and-in…

[montamero]

Nächster sprung nach oben steht bevor.... 0,06 - 0,08 , bei guten News mehr.

[montamero]

http://www.barchart.com/opinions/stocks/ILNS

[montamero]

http://www.intellectns.com/blog

[montamero]

http://biz.yahoo.com/e/121012/ilns8-k.html

[montamero]

Form 10-K for INTELLECT NEUROSCIENCES, INC.

15-Oct-2012

Annual Report


ITEM 7. MANAGEMENTS'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements included elsewhere in this report and the information described under the caption "Risk Factors" and "Special Note Regarding Forward Looking Statements" above.

General

We are a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of neurodegenerative conditions, collectively known as proteinopathies, which include Alzheimer's ("AD"), Parkinson's and Huntington disease. We have an internal diversified pipeline and have granted licenses related to our patent estate to major pharmaceutical companies.

Since our inception in 2005, we have devoted substantially all of our efforts and resources to advancing our intellectual property portfolio and research and development activities. We have entered into license and other agreements with large pharmaceutical companies related to our patent estate, however, neither we nor any of our licensees have obtained regulatory approval for sales of any product candidates covered by our patents. We operate under a single segment. Our fiscal year end is June 30.

Our core business strategy is to build a portfolio of compounds with the potential to treat or prevent neurodegenerative diseases, develop each to pre-determined milestones, and license them to pharmaceutical companies for advanced development and commercialization. To supplement our own work, we intend to license promising novel technologies and early stage compounds from academia and other biotechnology companies. We intend to obtain revenues from licensing fees, milestone payments, development fees, royalties and/or sales related to the use of our drug candidates or intellectual property for specific therapeutic indications or applications. As an example, we developed OX1, a small molecule multi-modal antioxidant, completed preclinical and human safety trials, and then licensed the program in 2011 to ViroPharma Inc. for development of a drug to treat Friedreich's Ataxia and other neurodegenerative diseases. We could receive up to $120 million in milestone payments from ViroPharma and significant royalties from sales if the resulting drug product is approved for sale by the US Food and Drug Administration ("FDA").

Our current business is focused on granting licenses to our patent estate to large pharmaceutical companies and on research and development of proprietary therapies for the treatment of proteinopathies through outsourcing and other arrangements with third parties. We expect research and development, including patent related costs, to continue to be the most significant expense of our business for the foreseeable future. Our research and development activity is subject to change as we develop a better understanding of our projects and their prospects. Total research and development costs from inception through June 30, 2012 were $14,432,789.

Results of Operations

Year Ended June 30, 2012 Compared to the Year Ended June 30, 2011:



Year Ended June 30,
(in thousands)
2012 2011 Change
Revenue 6,500,000 - 6,500,000
Research and Development Costs 996,225 105,793 (890,432 )
General and Administrative 5,219,993 3,426,094 (1,793,899 )

Income (loss) from operations $ 283,782 $ (3,531,887 ) $ 3,815,669




Year Ended June 30,
(in thousands)
2012 2011 Change
Income (loss) from operations 283,782 (3,531,887 ) 3,815,669
Other income 3,772,509 4,613,282 (840,773 )

Net income $ 4,056,291 $ 1,081,395 $ 2,974,896

Operating income increased $3,815,669 to income of $283,782 for the year ended June 30, 2012 from a loss of $3,531,887 for the year ended June 30, 2011. Revenue increased to $6,500,000 for the year ended June 30, 2012 as compared to $0 for the year ended June 30, 2011, due to our granting of an exclusive license to ViroPharma related to certain of our licensed patents and patent applications related to OX1 in exchange for payment of a $6.5 million up front licensing fee.

Research and Development costs increased by $890,432 from $105,793 for the year ended June 30, 2011 to $996,225 for the year ended June 30, 2012 primarily due to increased R&D activities with respect to our clinical drug candidate OX1.

Our General and Administrative Expenses for the year ended June 30, 2012 were $5,219,993 compared to $3,426,094 for the year ended June 30, 2011. The increase of $1,793,899 primarily is the result of $1.3 million in license fees paid relating to intellectual property that we have licensed relating to our OX1 product development program. The remainder of the increase in General and Administrative expenses relates to increased professional fees we incurred relating to the licensing of our clinical drug candidate OX1.

Other income decreased by $840,773 to $3,772,509 for the year ended June 30, 2012 from $4,613,282 for the year ended June 30, 2011. Interest expense decreased to $948,887, from $4,370,698 for the year ended June 30, 2011 to $3,421,811 for the year ended June 30, 2012. This is primarily due to the Company recording less of an interest charge relating to the fair value of the warrant liability associated with the issuance of our convertible debt. , The gain on the change in fair value of our derivative liabilities decreased $1,715,600 to $7,194,320 for the year ending June 30, 2012 as compared to a gain of $8,909,920 for the year ending June 30, 2011. The change in the fair market value of our derivative instruments and preferred stock liability results from the recording of the fair value of warrants issued in our financing, and the preferred stock liability which is stated at fair value relating to our Series B Preferred Stock.

As a result of these items our net income increased $2,974,896 to $4,056,291 for the year ended June 30, 2012 compared to a net income of $1,081,395 for the year ended June 30, 2011.

We have recorded a 100% valuation allowance against the deferred tax asset consisting of available net operating loss carry forwards and derivative liabilities and accordingly no income tax benefit was provided.

Impact of Inflation

The impact of inflation upon our revenue and income/(loss) from continuing operations during each of the past two fiscal years has not been material to our financial position or results of operations for those years because we have no products for sale and do not maintain any inventories whose costs are affected by inflation.

Liquidity and Capital Resources

Since our inception in 2005, we have mainly generated losses from operations and we anticipate that we will continue to generate significant losses from operations for the foreseeable future. As of June 30, 2012 and 2011, our deficit accumulated during the development stage was $71,036,333 and $75,092,624, respectively. Our income (loss) from operations for the years ended June 30, 2012 and 2011 was $283,782 and $(3,531,887), respectively. Our cash used in operations was $83,018 and $2,161,931 for the years ended June 30, 2012 and 2011, respectively. Our capital deficiency was $7,979,805 and $12,422,253 as of June 30, 2012 and 2011, respectively.

We have limited capital resources and operations since inception have been funded with the proceeds from equity and debt financings and license fee arrangements. As of June 30, 2012, we had cash and cash equivalents of $2,307. We anticipate that our existing capital resources will enable us to continue operations for the next month. If we fail to raise additional capital or obtain substantial cash inflows from existing or potential partners within the next few months, we may be forced to cease operations.

The audit report prepared by our independent registered public accounting firm relating to our consolidated financial statements for the year ended June 30, 2012 includes an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern.

April and May 2012 Financing

During April and May 2012, we sold investment units for an aggregate purchase price of $201,500. Each unit consisted of a Convertible Promissory Note (the "April and May 2012 Notes") and warrants (the "April and May 2012 Warrants"). Total proceeds from the sale of these investment units were $101,500.

The April and May 2012 Notes have an aggregate face amount of $201,500, are due in April and May 2015 and bear interest at 14%, payable at maturity. The April and May 2012 Notes are convertible into 4,030,000 shares of our Common stock and the May 2012 Warrants entitle the holders to purchase up to 25,150,000 shares of our Common Stock.

During July and August 2012, we sold an additional $300,000 of investment units with the same terms as the April and May 2012 Notes and Warrants.

June 2011 Financing

On June 30, 2011, we sold investment units for an aggregate purchase price of $100,000. Each unit consisted of a Convertible Promissory Note (the "June 2011 Notes") and warrants (the "June 2011 Warrants"). Total proceeds from the sale of these investment units were $100,000.

The June 2011 Notes have an aggregate face amount of $100,000, are due on June 30, 2014 and bear interest at 14%, payable at maturity. The June 2011 Notes are convertible into 2 million shares of our Common stock. The June 2011 Warrants entitle the holders to purchase up to 10 million shares of our Common Stock.

During July 2011, we sold an additional $150,000 of investment units with the same terms as the June 2011 Notes and Warrants.

March 2011 Financing Transaction

On March 14, 2011, we sold investment units for an aggregate purchase price of $500,000. Each unit consisted of a Convertible Promissory Note (the "March 2011 Notes"), shares of Series C Convertible Preferred Stock ("Series C Prefs") and warrants (the "March 2011 Warrants"). Total proceeds from the sale of these investment units were $500,000.

The March 2011 Notes have an aggregate face amount of $500,000, are due on March 14, 2014 and bear interest at 14%, payable at maturity. As a result of the ratchet provisions contained in the March 2011 Notes, the holders are entitled to convert the Notes into 10 million shares of our Common Stock. We issued to the purchasers of the March 2011 Notes an aggregate of 10,000 shares of Series C Prefs with an initial aggregate liquidation preference equal to $10 million. As a result of the ratchet provisions contained the Certificate of Designation of the Series C Preferred Stock; the Series C Prefs are convertible into 200 million shares of our common stock. As a result of the ratchet provisions contained in the terms of the March 2011 Warrants, the holders are entitled to purchase up to 10 million shares of our Common Stock.

December 2010 Financing Transactions

On December 15, 2010, we sold investment units for an aggregate purchase price of $500,000. Each unit consisted of a Convertible Promissory Note (the "December 2010 Notes"), Series C Prefs and warrants (the "December 2010 Warrants"). Total proceeds from the sale of these investment units were $500,000.

The December 2010 Notes have an aggregate face amount of $500,000, are due on December 15, 2013 and bear interest at 14%, payable at maturity. As a result of the ratchet provisions contained in the December 2010 Notes, the holders are entitled to convert the Notes into 10 million shares of our Common Stock. We issued to the purchasers of the December 2010 Notes an aggregate of 10,000 shares of Series C Prefs with an initial aggregate liquidation preference equal to $10 million. As a result of the ratchet provisions contained the Certificate of Designation of the Series C Preferred Stock, the Series C Prefs are convertible into 200 million shares of our common stock. As a result of the ratchet provisions contained in the terms of the December 2010 Warrants, the holders are entitled to purchase up to 10 million shares of our Common Stock.

As a result of the "ratchet" provisions contained in the April 2010 Notes described below and outstanding Warrants, the conversion price of the remaining outstanding April 2010 Notes and exercise price of our outstanding Warrants were adjusted to $0.05 per common share. The conversion price of previously issued and outstanding Series B Convertible Preferred Stock held by holders other than the purchasers of the April 2010 Notes is not subject to adjustment as a result of the issuance of the December 2010 Notes.

In January 2011, as a result of the "ratchet" provisions contained in the April 2010 Notes, we issued to purchasers of the April 2010 Notes remaining outstanding an additional 2,000 shares of our Series C Convertible Preferred Stock with an initial aggregate liquidation preference equal to $2 million, which are convertible into 40 million shares of our common stock.

Repayment of Outstanding Promissory Notes. Effective April 23, 2010, all the holders of the 2007 Notes accepted shares of our common stock in repayment of their 2007 Notes and agreed to the cancellation of their warrants (except for holders owning notes with an aggregate principal amount of $310,000 and 3,543 warrants). All such notes were past due and in default. Each holder received a number of shares of our common stock equal to the sum of the full principal amount of his or her notes, plus all accrued and unpaid interest, divided by
2.50. Holders of notes who purchased investment units in the April 2010 Financing for total consideration of at least $500,000 received a number of shares of our common stock equal to the sum of the full principal amount of the notes held by such purchasers prior to the April 2010 Financing, plus all accrued and unpaid interest on such notes, divided by 1.50. In connection with the repayment of the outstanding promissory notes, each holder agreed to the cancellation of his or her existing warrants that were issued in connection with the original issuance of the Notes. In addition, each holder agreed not to sell, transfer or pledge any shares of our common stock received upon repayment of his or her notes for a period of one year. In addition, all of the holders of the 2008 Notes accepted shares of our common stock in repayment of their 2008 Notes and agreed to the cancellation of their warrants and all of the holders of the Royalty Notes accepted shares of our common stock in repayment of their Royalty Notes and agreed to the cancellation of their warrants.

The holders of the November Notes exchanged an amount equal to the principal component of the November Notes for investment units and accepted shares of our common stock in payment of the accrued interest and the escrow agent released the Purchaser Shares to them. We subsequently issued 1,000 replacement shares to our CEO.

Conversion of Outstanding Series B Convertible Preferred Stock. Effective April 23, 2010, all of the holders of the Series B Preferred (except holders owning Series B Preferred with an aggregate liquidation preference of $1,870,380 and 8,497 warrants) exercised the conversion feature contained in the Series B Preferred and exchanged their securities for shares of our common stock and agreed to the cancellation of their Series B Warrants.

We issued 26,543 shares of our common stock and 14,000 warrants to purchase shares of our common stock to various consultants in connection with transactions referred to above.

Off -Balance Sheet Arrangements

As of June 30, 2012, we had no material off-balance sheet arrangements other than obligations under various agreements as follows:

Under a License Agreement with NYU and a similar License Agreement with University of South Alabama Medical Science Foundation ("SAMSF") related to our OX1 program, we are obligated to make future payments totaling approximately $1.5 million to each of NYU and SAMSF upon achievement of certain milestones based on phases of clinical development and approval of the FDA (or foreign equivalent) and also to pay each of NYU and SAMSF a royalty based on product sales by Intellect or royalty payments received by Intellect. In September 2011, we granted a sublicense of the License Agreements to ViroPharma pursuant to which we received a $6.5 million up-front licensing fee and are entitled to receive additional regulatory milestone payments based upon defined events in the United States and the European Union. Pursuant to the terms of the License Agreements, we paid SAMS and NYU $650,000 of the up-front licensing fee and are obligated to pay a portion of future payments we may receive from ViroPharma.

Mindset acquired from Mayo Foundation for Medical Education and Research ("Mayo") a non-exclusive license to use certain transgenic mice as models for AD and is obligated to pay Mayo a royalty of 2.5% of any net revenue that Mindset receives from the sale or licensing of a drug product for AD in which the Mayo transgenic mice were used for research purposes. The Mayo transgenic mice were used by the SAMSF to conduct research with respect to OX1. Pursuant to the Assignment that we executed with the SAMSF, we agreed to assume Mindset's obligations to pay royalties to Mayo. We have not received any net revenue that would trigger a payment obligation to Mayo.

Pursuant to a Letter Agreement with the Institute for the Study of Aging, we are obligated to pay a total of $225,500 of milestone payments contingent upon future clinical development of OX1.

Under a Research Agreement with MRC Technology ("MRCT"), we are obligated to make future research milestone payments totaling approximately $560,000 to MRCT related to the development of the 82E1 humanized antibody and to pay additional milestones related to the commercialization, and a royalty based on sales, of the resulting drug products. MRCT has achieved their research milestones and we have included the total $560,000 in accrued expenses. On September 16, 2012 the Company issued to MRCT 11,200,000 warrants with an exercise price of $0.0625 in full consideration for the money owed to MRCT.

Under the terms of a Beta-Amyloid Specific, Humanized Monoclonal Antibody Purchase and Sale Agreement with Immuno-Biological Laboratories Co., Ltd ("IBL"), we agreed to pay IBL a total of $2,125,000 upon the achievement of certain milestones plus a specified royalty based on sales of any pharmaceutical product derived from the 82E1or 1A10 antibodies. We have paid $40,000 to date.

Under the terms of a Royalty Participation Agreement effective as of July 31, 2008, certain of our lenders are entitled to an aggregate share of 25% of future royalties that we receive from the license of our ANTISENILIN patent estate.

Under a License Agreement with Northwestern University ("NWU") related to our TOC-01 program, we are obligated to make future payments totaling approximately $700,000 to NWU upon achievement of certain milestones based on phases of clinical development and also to pay NWU a royalty based on product sales.

Under the terms of a consulting agreement with a former member of our Board of Directors, we are obligated to pay $1,000,000 from revenue generated from product sales or licenses. We have paid $119,070 to date.

Under an Agreement with The Regents of The University of California, on behalf of its Irvine campus ("University") executed in April 2012, we are obligated to make future payments totaling approximately $176 thousand to the University as payment for research and development work to be conducted by the University related to our Anti-Amyloid RECALL-VAX vaccine, Anti-Tau RECALL-VAX vaccine and the combination of Anti-Beta Amyloid and Anti-Tau RECALL-VAX vaccine.

In the ordinary course of business, we enter into agreements with third parties that include indemnification provisions which, in our judgment, are normal and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to our product candidates, use of such product candidates, or other actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have no liabilities recorded for these provisions as of June 30, 2012 or 2011.

In the normal course of business, we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits, claims, environmental actions or the actions of various regulatory agencies. We consult with counsel and other appropriate experts to assess the claim. If, in our opinion, we have incurred a probable loss as set forth by accounting principles generally accepted in the United States, an estimate is made of the loss and the appropriate accounting entries are reflected in our consolidated financial statements. After consultation with legal counsel, we do not anticipate that liabilities arising out of currently pending or threatened lawsuits and claims will have a material adverse effect on our consolidated financial position, results of operations or cash flows.

Critical Accounting Estimates and New Accounting Pronouncements

Critical Accounting Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect reported amounts and related disclosures in the financial statements. Management considers an accounting estimate to be critical if it requires assumptions to be made that were uncertain at the time the estimate was made, and changes in the estimate or different estimates that could have been selected could have a material impact on our consolidated results of operations or financial condition.

Convertible Instruments We evaluate and account for conversion options embedded in convertible instruments in accordance with ASC 815 "Derivatives and Hedging Activities". Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

We account for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: We record when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. We also record when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.

Common Stock Purchase Warrants We classify as equity any contracts that require physical settlement or net-share settlement or provide us a choice of net-cash settlement or settlement in our own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 ("Contracts in Entity's Own Equity"). We classify as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). We assess classification of our common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

Preferred Stock. We apply the guidance enumerated in ASC 480 "Distinguishing Liabilities from Equity" when determining the classification and measurement of preferred stock. Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. We classify conditionally redeemable preferred shares (if any), which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control, as temporary equity. At all other times, we classified our preferred shares in stockholders' equity.

Derivative Instruments. Our derivative financial instruments consist of embedded derivatives related to the convertible debt, warrants and beneficial conversion features embedded within our convertible debt. The accounting treatment of derivative financial instruments requires that we record the derivatives and related warrants at their fair values as of the inception date of the debt agreements and at fair value as of each subsequent balance sheet date. Any change in fair value was recorded as non-operating, non-cash income or expense at each balance sheet date. If the fair value of the derivatives was higher at the subsequent balance sheet date, we recorded a non-operating, non-cash charge. If the fair value of the derivatives was lower at the subsequent balance sheet date, we recorded non-operating, non-cash income.

Research and Development Costs and Clinical Trial Expenses. Research and development costs include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, maintenance of research equipment, costs related to research collaboration and licensing agreements, the cost of services provided by outside contractors, including services related to our clinical trials, clinical trial expenses, the full cost of manufacturing drugs for use in research, preclinical development, and clinical trials. All costs associated with research and development are expensed as incurred.

Revenue Recognition. We recognize revenue in accordance with authoritative accounting guidance, which provides that non-refundable upfront and research and development milestone payments and payments for services are recognized as revenue as the related services are performed over the term of the collaboration.


http://biz.yahoo.com/e/121015/ilns10-k.html

[montamero]

Intellect Neurosciences Sues Pfizer Over $2 Million Milestone Payment

Intellect Neurosciences (OTCQB: ILNS), a junior biotech conducting research regarding proprietary drug candidates to treat Alzheimer’s disease (AD) and other diseases associated with oxidative stress, said this morning that it has filed a lawsuit in the New York State Supreme Court against a top tier global pharmaceutical company for breach of the licensing agreement between the parties.
The lawsuit has been in the making since the U.S. Patent and Trademark Office issued Intellect a patent in May covering the company’s ANTISENILIN® monoclonal antibody platform technology for the treatment and prevention of Alzheimer’s disease. The patent is a fundamental component of a licensing agreement between Intellect and an unnamed major pharma. Intellect believes that the allowance of the patent triggered a milestone payment of $2 to Intellect, but the big drug maker does not agree.

As with many licensing agreements, names are not disclosed as part of non-disclosure agreements, so gleaning the name of the global pharma from the news was impossible, but not too difficult to track-down. First, an article published through Accesswire on July 15 offered commentary in saying,

“A news story from Reuters reports that the findings offer a bit of evidence that the drug, bapineuzumab, which is being developed jointly by Pfizer Inc, Irish drugmaker Elan, and Johnson & Johnson is having a desired effect. The news comes on the heels of a report from BioMedReports, a news portal which revealed for the first time on Tuesday that several big pharmaceutical companies originally licensed the drug’s technology platform from Intellect Neurosciences (ILNS.OB) after the company’s founder and chairman, Dr. Daniel G. Chain discovered and protected the humanized monoclonal antibody.”




Further, a press release from Intellect issued via PR Newswire on June 24, 2008 stated,
“Intellect recently announced that it has granted a royalty-bearing license to Wyeth and Elan Pharma International Ltd. (Elan) regarding patents and patent applications related to antibodies and methods of treatment for Alzheimer’s disease including a co-exclusive license to Bapineuzumab under the ANTISENILIN(R) patents.”

Since Pfizer bought Wyeth for $68 billion, “connecting-the-dots” lead to a common thread of the lawsuit being against Pfizer (NYSE: PFE) as the defendant in the lawsuit is unnamed and Elan’s (NYSE: ELN) name doesn’t seem to be under and NDA.

A search with the New York State Supreme Court system confirmed that Pfizer is the defendant in the case that was filed on September 21, 2012.

The due diligence was not really necessary as the web search revealed Pfizer, but it did provoke the thought that Intellect probably has a licensing agreement with Johnson & Johnson (NYSE: JNJ) related to ANTISENILIN as well.

Commenting on the lawsuit, Daniel Chain, Ph.D., chairman and CEO of Intellect, said, “The idea that this global pharmaceutical company would attempt to withhold payment of a milestone payment stipulated in a license contract should be exceptionally distressing to every patent holder, especially small biopharmaceutical companies the size of Intellect Neurosciences, whose ability, in this case, to conduct critically important Alzheimer’s research is dependent on receiving such payments from its licensees. After exhausting all non-litigious options to secure our $2 million milestone payment, we realized we have no option save pursuing payment via the courts.”

The patent discloses therapeutic antibodies to treat or delay onset of Alzheimer’s disease and is based on discoveries that stimulated development of monoclonal antibodies that several global pharmaceutical companies have tested as treatments for Alzheimer’s disease. The antibodies specifically bind to the ends of the beta amyloid protein without binding to the amyloid precursor protein (APP), which has important advantages compared to antibodies that do not have this feature, according to Intellect’s press release today.


http://www.otcshowcase.com/intellect-neurosciences-sues-pfiz…

[montamero]

Intellect Neurosciences Issues Letter to Shareholders
Press Release: Intellect Neurosciences, Inc. – 20 hours ago


NEW YORK, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for proteinopathies, today issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO.

Dear Shareholder,
I am encouraged by several recent developments that reinforce my confidence in our corporate strategy. Intellect's origins are rooted in my pioneering work from the late 90's that stimulated development of the monoclonal antibodies, which several global pharmaceutical companies have tested as treatments for Alzheimer's disease. While the recently reported Phase 3 clinical trial results for bapineuzumab fell short of expectations, the Alzheimer's community is encouraged by the demonstration using biomarkers that the drug had engaged the target, reduced the amount of plaque and slowed neurodegeneration based upon the decrease in the amount of tau protein measured in the cerebral spinal fluid (CSF). Similarly, Phase 3 data from Lilly's solanezumab appeared to show some clinical benefit in a pooled analysis of early Alzheimer's patients. Lilly is anticipated to present biomarker data at a conference later this month.
As I wrote in my recent blog, the presenters and expert panelists at the American Neurological Association (ANA) annual meeting in Boston last week conveyed a strong sense that Intellect is correct in its belief beta amyloid (Aβ) plays a central and causative role in the pathogenesis of Alzheimer's disease and that immunotherapy represents a realistic path forward. The next-generation drugs will have an improved probability of success because of the lessons we have learned, especially the need for earlier intervention and careful criteria for the selection of patients to improve homogeneity in clinical trials.
Importantly, these data support our investment in IN-N01, a next-generation antibody drug candidate that recently completed the humanization process. As explained in our joint announcement with MRC Technology on September 19, we anticipate IN-N01 will have an improved safety profile, which means that it can be used at higher, more frequent doses than the other amyloid-beta antibodies in development. The enhanced dosing likely will result in stronger clinical efficacy, particularly if administered to early stage or presymptomatic patients. We believe IN-N01 could be developed rapidly by using biomarker signals during Phase 2 trials in patients with mild disease, similar to Lilly's approach for solanezumab. This approach should offset the increased costs associated with lengthy trials anticipated to be required in presymptomatic patients. IN-N01 is patent protected until at least the mid-2020s in the United States, Europe and Japan.
With several license agreements to date and products in clinical development for Alzheimer's disease and Friedreich's Ataxia, Intellect has established an impressive track record of being at the forefront of tomorrow's therapeutic candidates for neurodegeneration. Moreover, based upon conversations with several pharmaceutical companies, we anticipate further transactions for a number of our preclinical assets, which have the potential to generate significant revenues for Intellect, long before any of our products reach the market.

Pipeline activities:
Our antibody-drug conjugate platform, CONJUMAB, provides potential development of two independent antibody-based products from the same starting material, our compound, IN-N01. Our recent agreement with Lonza, with whom we signed a letter of intent, was an important step in the development of our first ADC, CONJUMAB-A. We are excited to have reached a point at which Lonza is now manufacturing the preclinical materials for the drug optimization and drug selection program, and look forward to testing these compounds in the near future. With sufficient financial resources, we could reasonably expect to file two INDs within two years, one for CONJUMAB-A initially focused on age-related macular degeneration and a second for IN-N01 for a second indication such as familial Alzheimer's disease or traumatic brain injury, both of which could qualify as orphan diseases.

Patent news:
We remain determined to secure our ANTISENILIN patents still under review by the USPTO and hopeful that this can be accomplished over the next few months. The demonstration using biomarkers that bapineuzumab reduces amyloid plaque and neurodegeneration in the brain of Alzheimer's patients provides compelling new evidence in support of the ANTISENILIN platform technology. Similarly, we plan to continue with the appeal process that we initiated in February to overcome the challenge to our patents in Europe.
We were disappointed by the failure of one of our global pharmaceutical licensees to pay the $2 million milestone payment triggered by the issuance of our patent by the USPTO on May 8, 2012 eventually leaving us no option except to pursue our claim in the courts. The action of our licensee in this regard is unconscionable and, in my opinion at least, an affront to the pharmaceutical industry that desperately needs to foster rather than thwart innovation at a time that global pharmaceutical companies are substantially reducing their internal R&D and relying more and more on companies such as Intellect Neurosciences to provide the next generations of high value therapeutics. The community at large should be aghast that a small company such as ours needs to divert attention and limited resources from its critically important mission of developing disease modifying therapies for Alzheimer's and other serious neurological diseases.

Business Development:
We are engaged in discussions regarding potential collaborations with several global pharmaceutical companies. Our recent acquisition of two monoclonal antibodies against neurotoxic forms of tau protein prompted inquiries from several pharmaceutical companies, two of which have signed confidentiality agreements, and indicated a high level of interest in seeing additional data. Additionally, we have obtained significant interest in our CONJUMAB-A program. Such statements should be useful to our fund raising efforts as we seek to advance candidate selection and preclinical development on an accelerated path and underscore the need to focus on our internal programs.

Increased Public Awareness:
We continue our efforts to increase public and investor awareness of Intellect through media outreach and other activities, including my participation as presenter at several international industry and investor conferences.

I was pleased to accept an invitation to participate as Distinguished Speaker at CBI's 6th Annual Alzheimer's Drug Development Summit, December 11-12, 2012, in Philadelphia, PA (http://www.cbinet.com/conference/pc12188). The title of my presentation is Recent Advancements in Vaccine Development for AD Prophylaxis and Management that will give me an excellent opportunity to discuss Intellect's dual target amyloid beta/tau vaccine in the context of other developments in the field.
We recently introduced a blog page to our website (www.intellectns.com/blog) in which I plan to share my thoughts and perspectives on industry-related developments and invite you to visit the site regularly for news and blog updates.

Conclusion:
We are pleased with the recent progress, which speaks volumes about a company the size of Intellect Neurosciences. Our ability to move forward is the result of a carefully planned strategy as we continue to develop distinctive platform technologies that are generating drug candidates for a variety of neurodegenerative diseases. These platforms and the resulting candidates continue to attract interest from pharmaceutical companies, which indicate their desire to engage in more substantive partnering discussions as our next milestones are met. Intellect remains ahead of the curve with respect to next-generation therapies, and the company is dedicated to retaining its position by capitalizing on its experience in biopharmaceutical development, network of world-renowned academic and clinical consultants, and specialized contract research organizations.
Thank you for your continued support of Intellect Neurosciences and our important mission to create a world without Alzheimer's disease and other debilitating neurodegenerative diseases.

Sincerely,
Daniel Chain, PhD
Chairman and Chief Executive Officer

Safe Harbor Statement Regarding Forward-Looking Statements:
The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward--looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward--looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333--128226), filed on October 15, 2012, and in our Quarterly Report for the quarterly period ended March 31, 2012, which was filed on May 14, 2012.

Contact:
Jules Abraham
JQA Partners, LLC
917-885-7378
[e-mail]

http://finance.yahoo.com/news/intellect-neurosciences-issues…

[montamero]

Daniel Chain Sues Pfizer for $2M

October 17, 2012 at 6:32 am

Intellect Neurosciences has filed a breach of contract suit against Pfizer Inc. for failing to make a $2 million milestone payment for rights to its Alzheimer’s disease technology.
Intellect Neurosciences was founded by CEO Daniel Chain, who laid the groundwork for the technology in dispute with Pfizer during his tenure at Mindset, a Jerusalem-based startup.
Intellect contends that the licensing fee was triggered when the U.S. Patent and Trademark Office issued the company a patent on May 8 that covers its Antisenilin monoclonal antibody platform technology for the treatment and prevention of Alzheimer’s disease.
“It’s a distressing situation for us, a small company, to go head-to-head with a major company,” Intellect Neurosciences Chairman and CEO Daniel Chain said in a report to The Pink Sheet. The milestone payment “was clear, black and white in the agreement.”
Intellect Neurosciences’ patent discloses therapeutic antibodies to treat or delay onset of Alzheimer’s disease. The antibodies bind to both ends of the beta amyloid protein without binding to the amyloid precursor protein.
Following the recent American Neurology Association annual meeting, Chain posted an Oct. 9 personal perspective on the conference on the company’s homepage. “As the dust settles after the initial disappointing results from four major Alzheimer’s Phase III trials,” he concludes, the ANA “offered glimmers of light that renewed hope. The presenters and expert panelists conveyed a strong sense that Intellect is correct in its belief beta amyloid (Aß) plays a central and causative role in the pathogenesis of Alzheimer’s disease and that immunotherapy represents a realistic path forward. The next-generation drugs will have an improved probability of success because of the lessons we have learned.”

http://www.bioisrael.com/daniel-chain-sues-pfizer-for-2m

[montamero]

http://www.fiercebiotech.com/story/after-phiii-flops-alzheim…

http://www.fiercebiotech.com/special-reports/top-20-biotech-…

[montamero]

ILNS wäre bereit, mehrere News sind ausständig:

Die zuletzt von einer Uni aquirierten Moleküle gegen Parkinson befinden sich nicht mehr in ILNS internal Pipeline, siehe ILNS website. Zwei Pharma Comp. unterschrieben einen Geheimhaltungsvertrag... Es gab auch keine Details zum Lonza Deal. Ev. könnte auch IN-NO1 bereits vergeben sein. Bin gespannt wann Zahlen veröffentlicht werden.

http://stockcharts.com/freecharts/gallery.html?ilns

[montamero]

Intellect Neuroscience ist kein Pinky mehr!!!

[montamero]

http://www3.imperial.ac.uk/newsandeventspggrp/imperialcolleg…

[montamero]

Intellect Neurosciences Announces New Findings Supporting Its Tau Oligomer Selective TOC-1 Monoclonal Antibody for the Treatment of Alzheimer's Disease
New Publication Proposes Mechanism for Inhibition of Fast Axonal Transport by Tau Oligomers



NEW YORK, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, announced today scientists at Northwestern University have published new findings on its tau oligomer selective TOC-1 monoclonal antibody. These new data explain a phenomenon concerning the role of aggregated oligomeric tau as an inhibitor of fast axonal transport (FAT). FAT is the mechanism by which newly synthesized membrane and other proteins made in the nerve cell body essential for neuronal membrane function and maintenance are provided to the synapse.
The paper, titled, "Tau oligomers and tau toxicity in neurodegenerative disease," was written by Lester Binder, Ph.D., the Abbott Laboratories, Duane and Susan Burnham Research Professor of Genetic and Molecular Medicine, at Northwestern University. It appeared in the recent edition of Biochemistry Society Transactions.
"The inhibition of FAT requires a small stretch of amino acids termed phosphatase-activation domain, or PAD. Using a PAD-specific antibody, TNT1 and Tau oligomer selective antibody TOC-1, Dr. Binder's research group was able to demonstrate the PAD is more exposed in oligomeric tau leading to dissociation of the microtubules in diseased neurons. This leads to an increase in FAT inhibition and represents an early event in AD pathogenesis. These findings support our belief, shared by several global pharmaceutical companies with whom we are in discussions, that TOC-1 has important therapeutic potential," stated Daniel Chain, PhD, chairman and CEO of Intellect.
Intellect previously obtained development and commercialization rights to TOC-1 under an exclusive license agreement with Northwestern University and plans to develop it for the treatment of Alzheimer's disease (AD) and other tauopathies.
Dr. Chain will speak about Intellect's TOC-1 program at the International Drug Discovery Science and Technology (IDDST) conference November 8-10 in Nanjing, China.
Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases especially focused on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please visit www.intellectns.com.
The Intellect Neurosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14741
Safe Harbor Statement Regarding Forward-Looking Statements:
The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333--128226), filed on October 15, 2012.

Contact:
Jules Abraham
JQA Partners, LLC
[e-mail]
917-885-7378



http://finance.yahoo.com/news/intellect-neurosciences-announ…

[montamero]

D. h. Intellect Neuroscience ist im Besitz eines ganz neuen Medikamententypes gegen Alzheimer und es wurde nachgewiesen

[montamero]

http://www.iddst.com/iddst2012/fullprogram_track16.asp
http://otcshortreport.com/ILNS

[montamero]

About CONJUMAB-A:


Antibody drug conjugates are a novel class of therapeutics with multiple applications to treat a broad spectrum of diseases. While current immunotherapy approaches attack the antibodies, they do not appropriately guard against the side effects, such as inflammation, that often comes with treatment. Most commonly seen in the treatment of certain types of cancer, Intellect Neurosciences’ newest treatment platform, CONJUMAB-A, applies the antibody drug conjugate approach to neurological disease. Intended to overcome the limitations of current passive immunotherapy approaches, the CONJUMAB-A platform increases clearance of amyloid proteins while delivering cytoprotective molecules to areas of the brain and other organs that may have been damaged as a result of these infirmities. One example of CONJUMAB-A’s cytoprotective mechanism is the reduction of inflammation caused by amyloidosis (the abnormal deposit of beta amyloid in the brain or other organs, which can result in plaque or lesions), while avoiding vasogenic edema, a common side effect of plaque dissolution that occurs in some patients. This approach has applications both in the therapeutic arena in diseases such as Alzheimer’s, Parkinson’s, Huntington’s, Age-Related Macular Degeneration, Glaucoma, Cerebral Angiopathy, Frontotemporal Dementia, Progressive Supranuclear Palsy, Pick’s disease, Cortical Basal Degeneration and Peripheral Amyloidosis. It also has tremendous potential for in vivo imaging of beta amyloid in the brain.

Intellect Neuroscience’s flagship CONJUMAB-A molecule, IN-N01-OX2, is a non-activating, stabilized IgG4 humanized antibody specific for beta amyloid protein (IN-N01, Intellect’s lead ANTISENILIN molecule) conjugated to as small molecule with neuroprotective properties. While lead testing and optimization is expected to be complete in 2012, IN-N01-OX2 is expected to enhance the clearing capacity of IN-N01, deliver on-site protection against beta amyloid neurotoxicity and prevent interaction with the melatonin receptor.

http://www.intellectns.com/platform-technologies/conjumab-a

Intellect Neurosciences and Medical Research Council Technology Announce Humanization of Next-Generation Monoclonal Antibody to Amyloid Beta With Reduced Potential for Inflammation in the Brain of Alzheimer's Patients
Sep 19, 2012, 9:35 AM EDT

Lonza and Intellect Neurosciences Announces Intellect's Intention to Award Production of Its Antibody Drug Conjugate, CONJUMAB-A to Lonza
Sep 27, 2012, 9:35 AM EDT

Intellect Neurosciences and iNovacia Enter Research Service Agreement to Evaluate Lead Compounds for CONJUMAB-A Program
Oct 3, 2012, 9:35 AM EDT

[montamero]

Intellect Neurosciences Announces New Findings Supporting its Patented ANTISENILIN Platform Technology for the Treatment of Alzheimer's Disease. New Publication Demonstrates Safety and Efficacy in Reducing Brain Amyloid in Preclinical Model


NEW YORK, Nov. 28, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, announced today new findings on ponezumab (PF-04360365), an investigational anti-amyloid beta monoclonal antibody that specifically targets the neoepitope at the C-terminus of the peptide, published in the October 2012 edition of Current Alzheimer Research.

These new data describe the properties of a version of ponezumab in which naturally occurring sugar bound to the surface of the murine antibody was removed to improve the safety of the drug. The aglycosylated murine surrogate of ponezumab was administered by intraperitoneal injection once weekly for up to 26 weeks at doses of 0, 10, 30, or 100 mg/kg. Drug exposure and plasma amyloid beta levels increased with increasing dose. After 26 weeks, the 100mg/kg group had significantly greater plasma levels of A1-x and Ax-40 than the vehicle group (p < 0.001). There was no evidence of vasogenic edema or other drug induced pathologies.
The paper, titled, "Chronic Administration of an aglycosylated Murine Antibody of Ponezumab Does Not Worsen Microhemorrhages in Aged Tg2576 Mice," was written by Gary B. Freeman and colleagues from Pfizer Worldwide Research & Development, Groton, CT, USA.
Intellect recently was awarded a patent from the United States Patent and Trademark Office (USPTO) that discloses therapeutic antibodies that recognize the free C-terminus of A beta 1-40 to treat Alzheimer's disease.
"We are encouraged by these data supporting our belief that antibodies targeting soluble forms of A beta can be beneficial in treating AD patients. This idea is consistent with results from the solanezumab Phase 3 clinical trials, which showed a modest but consistent clinical benefit from reducing A beta monomers in the brain. That data has positive implications for the important therapeutic potential of ponezumab, as well of Intellect's internal pipeline of A beta-specific antibodies, including 1A10 (targets the C terminus of A beta at position 40), IC3 (targets the C-terminus of A beta at position 42) and 82E1 (aka IN-N01, targets the N-terminus)," stated Daniel Chain, PhD, chairman and CEO of Intellect. "We have been granted several patents by the USPTO in relation to these antibodies any of which could be developed singly or empowered with additional neuroprotective function under our CONJUMAB platform."
Intellect Neurosciences, Inc., develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases especially focused on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please visit www.intellectns.com.
The Intellect Neurosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14741

Safe Harbor Statement Regarding Forward-Looking Statements:
The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward--looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward--looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Quarterly Report on Form 10-Q (file no. 333--128226), filed on November 20, 2012.

Contact:
Jules Abraham
JQA Partners, LLC
[e-mail]
917-885-7378

http://finance.yahoo.com/news/intellect-neurosciences-announ…

[dottore]

wenn man sich mal ansieht, was montamero alles zusammengetragen hat, muss ich ihm dafür erst einmal sehr ehrlich danken.

Als OTC-Geschädigter habe ich mir angewöhnt, die Kontaktadresse auf der homepage

in google maps und Streetview anzusehen. Ein Eindruck macht das schon. So habe ich bei Bio-Matrix Tech. gesehen, dass alle Subsidiarie die gleiche Anschrift hatten und auf dem Bild eine Mailbox-Anbieter-filiale war, die auch noch schlechte Ratings hatte.
Hier bei ILNS ist es eine schäbige Strasse in NY und das am schlechtesten erhaltene Gebäude, vielleicht mal 4 Meter länge eingezwängt mit 4 Stockwerken. ILNS befindet sich auf Floor 3. Man sieht da durch das Fenster unordentlich etwas an der Scheibe angelehnt.

Der Eindruck ist mit einem Labor, das Antikörper herstellt nicht vereinbar.

[dottore]

Zitat von montamero: +38,46%, Market Cap 1,72M ....alleine die Laborausrüstung kostete über 14M...und ILNS hat die vielversprechensten Patente gegen Alzheimer,Parkinson etc. Weltweit!

Wo ist das Labor? Adresse?

[montamero]

Gute Frage, mit Google ist es schwer ersichtlich.
Dazu würde ich an deiner Stelle einfach bei ILNS nachfragen:

http://www.intellectns.com/contact-us

Aus dem Jahre 2009:

DANIEL G. CHAIN, Ph.D., is a co-founder of Intellect Neurosciences, which he joined as Chairman and CEO in October 2005. Dr. Chain was previously President and CEO of Mindset Biopharmaceuticals, (USA) Inc., which he founded in 1998 and for which he continues to serve as President. Dr. Chain is the inventor of Intellect's ANTISENILIN� monoclonal antibody, which relates to the company's platform technology for the prevention and treatment of Alzheimer's disease. Dr. Chain obtained his B.Sc. in biochemistry from the Institute of Biology in London and obtained his Ph.D. in biochemistry from the Weizmann Institute of Science in Israel. He trained as a post-doctoral research fellow at the Center for Neurobiology and Behavior at Columbia University in New York, where his work focused on researching the molecular basis of long-term memory.


19. Okt. 2009

Dr. Chain: The company started in 2005 as a private company. It acquired its core assets from another company called Mindset Biopharmaceuticals, a company based in Israel and of which I was the founder, and it also licensed technology from various academic institutions in the U.S., notably New York University, and the University of South Alabama and various other academic organizations. That's how it started. To give you a few minutes on my background, I trained as a biochemist. I did my Ph.D in Israel, and then I spent several years at the Center for Neurobiology and Behavior at Columbia University, working on the fundamental mechanisms of learning and memory in simple organisms and got interested in Alzheimer's disease, which was then a very strong debate, a scientific debate as to what was the molecular basis for the disease, and especially what may be the valid target for therapy. I got interested from this general interest in thinking about memory, and then one day developed an idea for a potential therapy for Alzheimer's disease based on using monoclonal antibodies that would uniquely target the beta-amyloid toxin, which accumulates in the brain of Alzheimer's patients. With that idea I decided I would leave academia and start a biotech company. I spent the next several years assembling a technology portfolio for the new company, Mindset Biopharmaceuticals. My original idea was somewhat ahead of its time and very difficult to get investors interested in. Because it was very early in the field, we decided to license additional technologies into Mindset using various different therapeutic approaches for Alzheimer's disease. Given so, it was extremely difficult to raise capital and after several years the company was out of money. Fortunately we were able transfer the assets over to Intellect Neurosciences, which I co-founded in New York in 2005. My focus has not changed for 12 years now, and we are still developing therapeutics for Alzheimer's disease.

TWST: So the primary technology for your therapy grew out of an idea you had when you were doing research?

Dr. Chain: Yes, I was researching in a completely different area, completely unrelated but that stimulated my interest in Alzheimer's disease. And I really had no more than a lay understanding of Alzheimer's at that time. But I spent quite a long time thinking, and reading and talking to people in the field, and then literally woke up one Sunday morning with this idea as to how one could potentially use monoclonal antibodies that would uniquely recognize this toxin, and it followed many years of proof of concept. So that was really how I started. Intellect now has the benefit of what turned out to be an extremely important and pivotal patent position in the Alzheimer's field because, in fact, I went ahead and I filed a patent on that original idea. Today there are three products in clinical development by Big Pharma using our ANTISENILIN¨ platform technology. Two of them are licensed from Intellect and one is optional from Intellect. So it's been quite an interesting story over the last 12 years. The most advanced product that's licensed is Bapineuzumab, which is being co-developed by Wyeth and Elan Pharmaceuticals. Recently, Elan announced that they would joint venture on this program with Johnson & Johnson. So there has been a tremendous investment in this Phase III trial, which is ongoing, aiming to enroll thousands of patients in Europe and the U.S. The Phase III data is expected in 2011. If all goes well, the drug would be on the market in 2012, which would make it 15 years from idea to drug, which is I think not untypical in biotech and really spells out the challenge of the whole field: How do you get investors interested and maintain their interest over such a long period of time? Really, I think this story sums up the whole state of the industry in a way. We are in a very fortunate position because we've licensed this technology, and so we're entitled to some significant royalty interest in the sales of the products without needing to invest in them further. The investment is coming from major pharmaceutical companies. That's our most advanced product.

We did a similar license deal with another drug company, it's another top-tier global pharmaceutical company. We can't disclose the name of the company except under confidentiality, but we have a similar type of product in Phase II clinical trial. Then just a few months ago, we announced an option to GlaxoSmithKline to purchase a similar license, and they have a Phase I product. So those are the most advanced from that technology. In addition, we have an internal drug development pipeline that we're very excited about. We have a small molecule, which is in the clinic; we completed two Phase I studies in a total of 90 subjects. These would have been healthy, elderly volunteers. The drug, it's called OX01, has a very potent antioxidant activity and also inhibits the formation of the toxic oligomers, these assemblies of beta-amyloids that cause neurotoxicity in Alzheimer's disease. And the mechanism that seems to link these two things is binding to copper. It binds copper with a very high affinity, and copper is implicated strongly in the formation of these amyloid structures. This is a very interesting molecule, which has potential applications for treating Alzheimer's disease, Parkinson's, motor neuron diseases and other neurodegenerative diseases as well. There are a number of orphan indications as well that we may go after for that molecule. But our focus is primarily in Alzheimer's. We can't do too many things for a small company. We are now planning Phase II trials - there will probably be two trials for Phase II in Alzheimer's patients. We are very excited about the drug's potential. It's a completely different approach to the monoclonal antibody approach, obviously, but it's an approach that targets two primary steps in the amyloid pathway. We actually have four, I mean if you include the three products that are being developed independently based on our technology and our own, we have four products clinical. We have a Phase III, licensed product, which could be on the market, as I said, in 2012 if all goes well with it; a Phase II with another global pharma company; a Phase I, which is optional to GSK, and then our own molecule, OX01, which is almost ready to go into Phase II. Then we have a very interesting preclinical portfolio as well. We have a humanized monoclonal antibody also against the beta-amyloid toxin. So it's similar in concept to bapineuzumab, for example, but we are looking at it as a follow-on, second-generation type of product that we believe will have an improved safety profile compared to anything else that is currently in clinical development. That's still preclinical, but we obtained the antibody, we humanized it, and we're further optimizing it and intend to take it towards the clinic. The third program is - which is also preclinical - is an active vaccine for Alzheimer's disease, which is sort of the Holy Grail in Alzheimer's disease. It is a flu shot type of approach and there is quite a good proof of concept for such an approach. And we have a strong patent position around that, and we hope that product will also get into the clinic. So we run the whole gamut, from early-stage preclinical through late-stage clinical.

TWST: As our population ages, is there an increased interest in Alzheimer's research?

Dr. Chain: I think there is. In the last few years, there have been various celebrities who have been afflicted with Alzheimer's disease, and that helped to boost awareness among the public as to this disease really can affect anybody. And so Rita Hayworth, for example, suffered from Alzheimer's disease, and her daughter has done a tremendous amount through the Alzheimer's Association to promote the awareness of the disease. Rita Hayworth was very young - I think she was in her 50s when she got Alzheimer's disease. I think there is a general increased awareness. And it's a disease where there are a number of risk factors, but by far the most important is age.

If we live long enough, chances are we'll all develop Alzheimer's disease. And generally it starts around the age of around 65, and then it doubles in frequency every five to 10 years. So 40% of the population entering their ninth decade have Alzheimer's disease, which is a massive problem. There are a lot of people, such as Rita Hayworth and many others, who developed the disease much younger. People can develop Alzheimer's in their 40s even, and usually there is a genetic predisposition for early onset Alzheimer's disease, which is not so obvious in late onset, but it is a huge problem. Alzheimer's lasts an average of eight years but can be anything from eight years to 20 years, and it has such a devastating impact not just on the victims but on their families. It's one of the major health issues I think that we face in the developed world today.

TWST: You talked a little bit about the partnerships with some of the drug companies. What about academic associations?

Dr. Chain: Yes, as I said, we launched a part of our technology from universities that we have collaborated - I mean during the early stages of the licensing, we had active collaboration with academia. But as the products develop and mature, and become real drug products, we used the academic collaborations less. But we're always looking at new opportunities. And for biotechnology, most of those come out of academia one way or another. So we keep our eyes open, and we have contacts with a lot of the tech transfer offices of the universities, and we are always open to new opportunities.

TWST: You mentioned you are also looking at therapies for Parkinson's Disease. How do you select which therapies to explore?

Dr. Chain: We select therapies through the mode of action of the drug. We have this drug and the more we work on it, the more we learn about how it actually exerts its effect. That gives us insight as to the type of diseases that one might go after. So going back to the academic collaborations, that's certainly an area where we do have collaborations to help identify additional disease indications for drugs that we have in the portfolio. We've had a number of those types of collaborations; we start by having discussions with key experts in a field on a drug or therapeutic. Then we work with that expert to test the drug for a particular disease indications.

TWST: How do you see your company developing over the next several years?

Dr. Chain: If all goes well with bapineuzumab, that drug will be on the market in three years time, and we should be one of the very few cash-positive biotech companies. And we would hope that revenues from the royalties from bapineuzumab and from other drugs, such as the Phase II drugs and so on, will support an expansion of our R&D activities and allow us to bring additional products through to market. We also expect that we would partner the products that we are currently developing internally with major pharmaceutical companies. So we are in constant discussions both on the preclinical and clinical programs. We get approached by major pharma companies interested in what we are developing. I think there is a reasonably high anticipation that each of these programs will be licensed to major pharma a long time before they are ready for the market.

TWST: Are you considering creating your own sales force or producing the drugs yourself?

Dr. Chain: No, we're really not. We are strictly an R&D-focused company, and it's really not within our thinking to sell these drugs ourselves. That requires a major pharma partner, and that's going to get even tougher for companies over the next few years. I think only the very large companies will really effectively compete in the market. There is a huge cost coming from actually having developed the drug through, for example, Phase III trial, which in itself can cost easily in the hundreds of millions of dollars, to then having sufficient marketing force to get the drug out to the population. That requires massive resources.

TWST: Have changes in the health care industry impacted your operations?

Dr. Chain: It hasn't changed us directly, but I think it's a source of considerable concern among investors. I think one thing that changed is it's getting more and more difficult to get investments for early-stage products. Early stage used to be preclinical. Now early stage is also early-stage clinical. Venture capitalists and others are looking at product opportunities later and later in the pipeline. On the other hand, there is a huge lack of products in the pharma pipeline. That's one of the problems for pharma, that they don't have enough in their pipeline to assure them blockbuster drugs every year for the foreseeable future. So where are these new products going to come from? I think academia will continue to innovate and there will always be small biotech with innovative approaches. But I see a huge problem in getting those ideas to be developed as drugs. I think that's the biggest challenge for pharma, the lack of pipeline, and I don't see a real resolution to that. On top of it, you've got tremendous risks associated with development of drugs. So even if it looks promising at the beginning, with bapineuzumab as an example, it takes 15 years to have a drug on the market, which means you have five years left on your patent. So I think there are a lot of things to be concerned about. I think Big Pharma is very worried about the competition from generics when it takes into account that it has to spend $1 billion to produce a new drug for the market.

TWST: And as you said, there is risk at each stage along the way.

Dr. Chain: At every stage there is a risk, all the way through development until that last day when you get an NDA. So I think there are some real challenges out there in the long term for the pharmaceutical industry. And already there were changes - I mean unless there is a disease with a massive population, pharma is generally not that interested. And there are an awful lot of diseases that are not exactly orphan diseases, but they are sort of somewhere in the middle that; they are important diseases but are not necessarily affecting enough people to make it attractive for the risk on investment. There are a lot of challenges and concerns for the overall health industry in the future. But on the other hand, it's a huge opportunity for a company like Intellect where we have innovation. We've already invested many years. The current portfolio is based on 12 years R&D. So we've sort of taken a large part of the risk off the table.

TWST: What else makes Intellect a good investment?

Dr. Chain: I think it's the way that we've been able to mitigate the risk by having a diversified portfolio, and that's been my approach from the beginning. My idea was you never know which drug can actually make it. I think there is a very high chance when you're in Phase III, but still you're never absolutely sure until you have the drug. Having the spectrum that Intellect has - preclinical, early-stage clinical, late-stage clinical - is very, very unusual. With the diverse portfolio also come multiple different partnering opportunities with major pharmaceutical companies. Already, as I said, we have interest from large companies who are looking at technologies at each stage of development - a Big Pharma looking at preclinical programs and clinical programs that we have in the portfolio. I think it's having the diverse portfolio and all of these different opportunities that that generates, which really differentiates us from a lot of biotech companies. A lot of biotech companies basically start from one idea or with one molecule, and you're either successful or you are not. Whereas what we've managed to do is to build a strong technology portfolio around Alzheimer's disease and related neurodegenerative disorders.

TWST: Who are the other decision-makers in your company and would you give us just a little bit about their backgrounds?

Dr. Chain: Our President and Chief Financial Officer is Elliot Maza. Elliot was originally a lawyer at Sullivan and Cromwell. He was a Senior Partner at Ernst & Young. He was an investment banker at JP Morgan & Goldman Sachs for many years. Prior to joining Intellect, he was the CFO at another biotechnology company, Emisphere Technologies. So he really has a tremendous breadth and scope, and he is absolutely a key part of the team at Intellect. We have a very esteemed group of advisors, both scientific and medical, opinion leaders in the Alzheimer's field. It's sort of a who's who of the Alzheimer's field, and these are all folks who are actively involved with the company. We also have a fully independent board of directors, including Bill Keane, who chairs the Audit Committee, who has a lot of experience in finance. But he was also a CFO of Genta previously and has served in similar capacities for a number of companies in the field. Kathleen Mullinix, who was the CEO of Synaptic when it was sold to Lundbeck, has had many, many years in biotechnology. Harvey Kellman also started many biotech companies in his long career. So we have a very experienced professional, independent board of directors. Initially, we had research labs in Israel. We had a whole group in Israel; we had about 25 people there. But eventually it became too cumbersome for a small company to be separated by 6,000 miles. We decided to close down the operation in Israel and our plan is to regroup and start a new research activity here in New York. We are partly waiting for the process of financing, and we are waiting for the new East River Bioscience Park to open in New York next year. I think it will be a marvelous addition to New York City in terms of being the only dedicated campus for companies like us. The first phase of it is supposed to open early next year, and we are hoping that we will be one of the first tenants to move in there. We are in financing mode, trying to raise capital and to fund our internal development plans and hope it will all come into play at the right time.

TWST: Thank you. (LMR)
DANIEL G. CHAIN, Ph.D.

CEO

Intellect Neurosciences, Inc.

7 West 18th Street, 9th fl.

New York, NY 10011

[phone]

[phone] - FAX

www.intellectns.com

http://www.twst.com/interview/27117

[dottore]

7 West 18th Street, 9th fl.
New York, NY 10011

bei google.maps unter "7 West 18th Street, New York, NY 10011, USA"

naja, neunter Stock ist nicht einsehbar. Der letzte zählbare Stock ist 8. Im Dach wäre dann der neunte Stock.
Das Haus ist nicht ganz so schäbig

45 West 36th Street, 3rd Floor
New York, NY 10018

einfach schrecklich

All die "NEWS" sind in Verantwortung der Emittenten veröffentlicht. Eine Gegenprobe wäre da sehr sinnvoll. Im Fall Lonza gibt es die! Aber im Sinne von: Lonza stellt für ILNS die Antikörper her. Bei wem liegt da nun welches Patent?
Wer führt welche klinischen Untersuchungen und wo durch. Entweder ist mein Englisch zu schlecht (durchaus wahrscheinlich) oder es ist nichts dahinter.
Im Zweifelsfall gegen den Angeklagten! Investiere lieber, wo ich weiß, was ich habe(n könnte)

[dottore]

Nachtrag: Lonza bestätigt "Intention", aber nicht den Abschluss des Deals. Das gibt es nur bei ILNS

Das stinkt!

[montamero]

BID/ASK 0,02/0,019

[montamero]

Bid Price
Size
Date/Time
NITE 0.02 10000 08:45
VERT 0.01 10000 11/26
MERQ 0.009 10000 11/26
PUMA 0.003 10000 08:30
CANT 0.0024 10000 07:40
MAXM 0.0001 10000 12/06
PERT 0.0001 10000 12/13
CSTI 0.0001 10000 07:40
VFIN U 11/09
LAFC U 11/09
BMAK U 11/09
UBSS U 08:04
RAFF U 08:15
ATDF U 08:30
ETRF U 09:18
cCDEL U 06:25
MPID

Ask Price
Size
Date/Time
MERQ 0.021 10000 09:18
PUMA 0.04 10000 08:30
CANT 0.072 10000 07:40
PERT 0.087 10000 12/13
ETRF 0.09 10000 07:50
CSTI 0.10 5000 07:40
NITE 0.107 5000 12/13
VERT 2.00 100 11/26
MAXM 200000.00 1 04/11
VFIN U 11/09
LAFC U 11/09
BMAK U 11/09
UBSS U 08:04
RAFF U 08:15
ATDF U 08:30
cCDEL U 06:25

http://www.otcmarkets.com/stock/ILNS/quote

[montamero]

$$ILNS$$

[dottore]

10 Tausend Aktien entsprechen einem Wert von 100 $, wenn sie gekauft werden.
Wenn du sie verkaufen willst, weniger bis gar nichts

[montamero]

Alzheimer’s Disease Drug Development Deserves Special Government Incentives Including Market Exclusivity

Dec 13 2012
I was invited to speak about vaccines at the 6th Annual Alzheimer’s Drug Discovery Summit in Philadelphia. The meeting provided an excellent forum for a group of academic opinion leaders and industry specialists to hold in-depth discussions regarding recent developments and work being conducted internationally in the field. Unquestionably, 2012 has been an important year that generated critically important clinical data, including the results of the beta amyloid antibody Phase 3 trials and the studies conducted by the Dominantly Inherited Alzheimer’s Network (DIAN) that likely will have a significant impact on the design of future Alzheimer’s clinical trials. At the same time, the fact that the two major sets of Phase 3 clinical trials failed to meet their primary objectives underscored the enormous challenges that lie ahead, including the need to start treatments far earlier, likely when the first symptoms appear or perhaps several years before the onset of symptomatic disease.

The summit was organized by CBI in consultation with Marc Cantillon, MD, Wellness Managements LLC, and former Executive Director, Critical Path Institute Coalition Against Major Diseases (CAMD).

The first day of the conference was chaired by Johan Luthman, PhD, Senior Program Leader Neuroscience R&D, Franchise Integrator at Merck who also spoke about qualification of diagnostic and prognostic biomarkers for AD. Dr. Luthman emphasized the role of biomarkers as essential tools to support diagnosis of early stage AD, offering possibilities to detect prodromal, pre-dementia, stages of the disease and the potential to identify even presymptomatic patients at risk of developing the disease. In addition, Dr. Luthman described how in various natural progression studies, some biomarkers also have been shown to be good predictors of the clinical rate of disease progression (e.g. conversion to dementia), and explained how this link provides opportunities to allowing further stratification of trial populations, as well as evaluate novel therapeutics in populations that previously could not be entered into trials.

The opening address was by John C. Morris, MD, Friedman Distinguished Professor of Neurology, Director Knight Alzheimer’s Disease Research Center, Washington University School of Medicine. As Professor Morris explained, the initial publication of cross-sectional results from DIAN validate the use of Alzheimer’s biomarkers to identify preclinical AD as only mutant carriers demonstrated biomarker abnormalities. Although preliminary, the findings propose an instructive timeline for the pathophysiology of preclinical AD, beginning with elevated CSF Ab that presumably is present at birth but at perhaps 20-25 years prior to onset of symptomatic AD, begins to decline. The DIAN study will provide the infrastructure for randomized, placebo-controlled secondary prevention trials of mechanism-based therapies in dominantly inherited AD. Three drugs have been selected for an initial trial, including gantenerumab (Roche), a monoclonal antibody that binds to all forms of aggregated beta amyloid and currently in prodromal Phase 2/3 trials; solanezumab (Eli Lilly & Co), a monoclonal antibody that binds to soluble forms of beta amyloid, which is to be tested in additional Phase 3 trials; and a BACE inhibitor from Eli Lilly that targets beta amyloid, theoretically reducing the production of beta amyloid and slowing the accumulation of plaques in the brain. Although dominantly inherited AD occurs in only about 1 percent of the population, most experts believe the lessons learned from these trials will have widespread utility and may be applied to testing therapeutics in a much broader population.

J. Michael Ryan, MD, Vice President and Head Neurodegeneration Clinical Science Unit at Novartis moderated a Roundtable Discussion starting with his personal perspective of how recent results will reshape the design and conduct of future AD clinical trials, as well as the allocation of resources devoted to Alzheimer’s research. Dr. Ryan highlighted what had been a recurring theme throughout the conference regarding how the industry will address the major challenges ahead.

I had recommended the organizers of the conference invite John Repas MD, PhD, Director of Policy at the Neurotechnology Industry Organization (NIO), a global trade association representing companies involved in commercial neurosciences, brain research institutes and patient advocacy groups.

In his address, Dr. Repas outlined federal policy levers to foster innovation and address public health in AD, especially focused on the NIO-sponsored National Neurodegenerative Disease Incentive, which aims to address the widening gap between prevalence and treatment in neurodegenerative disease conditions, such as AD, Parkinson’s and others that are causing massive public health and economic burdens. Dr. Repas said the prospects for advancing new therapies to practice are imperiled by the unique length and expense of clinical trials needed to demonstrate safety and efficacy in these diseases. Because of the slowly progressing nature of neurodegenerative diseases, the additional development time consumes both patent protection and defers market entry. It also has led many investors and developers to abandon disease-modifying approaches entirely.

I fully concur with NIO’s belief that the solution to this problem lies in creating a new market exclusivity for sponsors of novel disease-modifying therapeutics that are targeted to neurodegenerative disease, especially AD. The rationale of the NIO initiative follows that of the 1983 Orphan Drug Act, which has since spurred development of new medicines for hundreds of orphan diseases that, otherwise, would not have been addressable given the small market size. A guaranteed market exclusivity period of ten years would be sufficient to tilt the cost-benefit consideration toward continuing drug development for neurodegenerative diseases.

Much has been made about the recent decision of the Obama Administration to push for a $156 million increase in funding for Alzheimer's research over the next two years. Its proponents, especially the Alzheimer’s Association, should be lauded for their commitment to the cause. However, the size of the award is just a drop in the bucket that, in my opinion, will do very little, if anything, to alleviate the situation. Sadly, it underscores a gross lack of understanding on Capitol Hill regarding the needs of the research community -- including industry -- to identify new drugs and advance them through clinical trials as the only way to prevent a catastrophic socio-economic disaster, as more and more Americans are affected by this disease. One wonders how those government officials involved in this decision would feel about the impact of allocating similar funds, barely sufficient to purchase a single stealth bomber, to the overall security of the nation.

I would urge all to support the NIO initiative.

--Daniel Chain, Chairman and CEO, Intellect Neurosciences, Inc.

http://www.intellectns.com/blog

[dottore]

da ich dieser Aktie sehr skeptisch gegenüber stehe, habe ich nachgesehen, ob Daniel Chain tatsächlich als Redner auf der Veranstaltung war.
Ja er war es und wird im Programm Namentlich und als CEO der Intellect Neurosciences aufgeführt.

Also, wie ist das mit all dem Negativen von mir bisher gefundenen in Einklang zu bringen?

Ich weiß es nicht! Aber man muss nicht immer überall dabei sein und auch nicht als "Mann edr ersten Stunde". Aber wenn man die Chance dafür hat ....


Nein, ich werde nicht einsteigen, aber genau beobachten

[dottore]

noch den link

http://www.cbinet.com/conference/speakers/pc12188#.UM8Fjqze_…

[dottore]

in 2008, an AD vaccine by Elan Pharmaceuticals was canceled after long-term follow up of Phase 1 studies showed that while the patients mounted a robust immune response and had a proportional decrease in amyloid plaques in the brain, there was no improvement in the symptoms.

http://www.dddmag.com/articles/2010/10/alzheimer%E2%80%99s-r…

Es ist unwahrscheinlich, dass die amyloide eine Rolle spielen beim Alzheimer. Es gibt auch noch andere Firmen, die trotzdem in diesem Bereich noch aktiv sind, aber es ist wahrscheinlich, dass in absehbarer Zeit auch die ihre Studien einstellen.

Wenn Intellect Neuroscienses wirklich so viel versprechend wäre, dann wären sie schon lange Übernahmekandidat. Die Marktkapitalisierung von knapp über 1 Mio $ wäre doch geschenkt.

[dottore]

Obwohl ich durchaus scheinbar zutreffendes gefunden habe, und Geschäfte mit Big-Pharma scheinbar tatsächlich gelaufen sind, bewegt sich hier gar nichts nach oben.
Wenn alles seine Richtigkeit hätte, dann müßte der Kurs schon längs bei 1 $ stehen und eine Kapitalmassnahme durchgeführt werden

NICHTS !
Nun schwanke ich zwischen der Sorge, die Chance meines Lebens zu verpassen, ewnn ich nicht dicke einsteige und dem Verdacht, dass da was nicht stimmen kann. Kann mir nicht vorstellen, der Einzige oder fast Einzige zu sein, der hier das Potential erkannt haben soll.

Was tun? Wie mehr erfahren und wissen, dass es dann auch stimmt?

@ montamero

Du hast den Wert doch als erster hervorgekramt. Was ist denn nun?

[montamero]

Egal was kurzfristig noch passiert, Ilns hat den 126,5 million usd deal mit viropharma (ox1). Diese gehen anfang 2013 in Phase 2 trial. D. h. Milestone (8 oder 10 millionen, soweit ich mich erinnere) wird ausgezahlt. Über conjumab-a, Recall-Vax, Toc-1 etc. sind noch viele Informationen ausständig. Ich werde weiterhin aufstocken.

[montamero]

Was sind antibody-drug conjugates Liznezdeals wert?

Celgene signs $500m antibody deal with Sutro

Joins list of companies with interest in antibody-drug conjugates

Celgene and Sutro Biopharma have agreed a deal worth up to $500m to develop novel antibody-drug conjugates bispecific antibodies for two undisclosed targets. The agreement will see antibody-focused Sutro use its cell-free protein synthesis technology for initial product design in the early research stages, with Celgene to support further development, regulatory and commercialisation efforts.

According to Sutro, it will receive a “substantial upfront payment” as part of the total $500m deal, which also includes an equity investment in the company and milestone payments. ”We are pleased to work with Celgene on multiple programmes that utilise a broad spectrum of Sutro’s cell free protein synthesis technology and capabilities,” said William Newell, chief executive officer of Sutro.

Dr Thomas Daniel, Celgene president, global research and early development, added, “We look forward to working with the team at Sutro and to exploring their platform’s potential to accelerate the discovery and development of superior multifunctional biologics.”
Antibody-drug conjugates are becoming an increasing area of interest for pharma companies who are interesting in exploiting their method of action, which involves a cancer cell-targeting antibody attached to a cytotoxic drug via a linking technology, allowing tumour cells to be targeted more directly over healthy cells.

This includes Abbott’s decision to expand its deal with Seattle Genetics to develop antibody-drug conjugates for several oncology targets.

Menarini also recently signed a €800m deal with Oxford BioTherapeutics to collaborate on the development of antibody-body based drugs for the treatment of several cancers.

In addition, Roche is involved in the advancement of antibody-drug conjugates with T-DM1, which has caused great excitement for its potential in the treatment of breast cancer.


http://www.pmlive.com/pharma_news/celgene_signs_$500m_antibo…

[montamero]

Artikel über Lonza Visp:

Produziert Lonza Visp bald für Roche?

Am Lonza-Standort in Visp könnte bald die Produktion eines hochmodernen Pharmawirkstoffes erfolgen, das Blockbuster-Potenzial hat.

Gute Nachrichten in turbulenten Zeiten für die Lonza-Werke in Visp: Am grössten Produktionsstandort des Chemiekonzerrns mit rund 50 Produktionsstätten weltweit könnte in absehbarer Zeit die Produktion eines innovativen Pharmawirkstoffes aufgenommen werden. «In Visp werden wir bald ein neues, hochinnovatives Produkt herstellen. Unser Kunde wartet nur noch auf das Okay der Zulassungsbehörden», sagt Lonza-Chef Richard Ridinger im Interview mit der «SonntagsZeitung».
Nach Informationen der «SonntagsZeitung» handelt es sich um das neue Brustkrebsmittel T-DM1 von Roche. Dieses hat Blockbuster-Potenzial, bringt also mindestens eine Milliarde Dollar im Jahr ein.

«Visp ist kein Klumpfuss, Visp ist spitze»

Erneut bekennt sich Ridinger im Interview zum Standort Visp, dem in jüngster Zeit Frankenstärke, Energie- und Transportkosten sowie hohe Lohnkosten zu schaffen machen. «Doch Visp ist kein Klumpfuss, sondern ein wichtiges Standbein. Überall, wo es schwierig wird, wo High-Tech und Qualität gefragt ist, ist Visp spitze, zum Beispiel bei der biotechnologischen Herstellung von Wirkstoffen für die Pharmaindustrie.»

Die Löhne der Angestellten in Visp geraten auch zunehmend unter Druck, weil im Oberwalliser Standort Massengüter wie etwa B3 produziert werden, die auf dem Weltmarkt unter massiven Druck stehen. «Wir haben in Visp hervorragende Chemiker und Ingenieure. Die hohen Lohnkosten müssen wir mit effizienteren Technologien, Automatisierung und Produktinnovationen in den Griff kriegen», sagt Ridinger.

Keine Verlagerung ins Ausland

Einer Verlagerung der Produktion von Massengütern an kostengünstigere Standorte im Ausland erteilt Ridinger eine Absage. «Visp ist eine komplexe petrochemische Anlage. Vorne kommen Öl und Gas hinein, hinten kommen ganz unterschiedliche Produkte raus. Man kann nicht einfach einzelne Punkte aus diesem Verbund herauslösen.»

«Deutlich weniger Werke»

Ende Oktober gab Lonza bekannt, allein am Standort Visp 400 Stellen der knapp 3000 Stellen abzubauen. Darüber hinaus stehen alle 50 Produktionsstandorte auf dem Prüfstand. Ridinger stellt eine signifikante Reduktion des Produktionsnetzes in Aussicht: «Am Schluss werden wir wohl mit deutlich weniger Werken auskommen und eine höhere Produktivität erreichen.»

Lonza will überdies sein Produktportfolio bereinigen und die Konzernstruktur anpassen. Nach vier grösseren Akquisitionen ist das Unternehmen Ridinger zufolge zu komplex.

http://www.1815.ch/wallis/aktuell/produziert-lonza-visp-bald…

[dottore]

der Artikel ist interessant und finde ich auch ok, dass du ihn hier reingestellt hast.
Trotzdem vermisse ich den Zusammenhang zu Intellect.

[dottore]

ist dieses T DM 1 das conjumab von Neuroscienses? Dann wäre der Zusammenhang klar

[montamero]

Frohe Weihnachten!
http://m.seekingalpha.com/article/1077121-star-scientific-an…

[montamero]

Author of SA article referencing ILNS in his report...kind of comical when you see a reference like this below. I do like his ILNS reference!

http://seekingalpha.com/article/1077121-star-scientific-and-…

Here is an interesting fact. Intellect Neurosciences (ILNS.PK) is currently trading at $0.01 with a market cap of $1M. Yet in March 2012, this company was granted a patent for Antisenilin, an Alzheimer's drug therapy that targets amyloid beta proteins, and is now in Phase III trials. On the other hand, overly hyped Star Scientific with a market cap of $464M, has no direct patent coverage, not even a Phase I clinical trial, and even worse, has not even the authorization from the FDA to begin clinical trials.


About the SA-Author:

Edward Schneider is a managing director of Quan Management LLC. Mr. Schneider has over 20 years of investment experience, including 15 years managing technology funds in both quoted equities and venture capital. Prior to founding Quan Management in 2000, Mr. Schneider was a Geneva-based fund manager for Lloyds TSB Bank from 1994 to 2000, where he managed funds in excess of US$100 million as well as an external venture capital portfolio. From 1986 – 1994, Mr. Schneider was a buy-side equity analyst for Connecticut-based Wright Investors’ Service. Mr. Schneider holds a CFA designation, an MBA from Thunderbird and a BA from Emory University.

Description: Hedge fund manager.
Interests: Stocks - long, Stocks - short, Tech stock

Hedge Fund Manager haben ILNS im Visier?!

[montamero]

http://propthink.com/viropharma-strengthening-financial-prof…

[dottore]

es gibt nur 1 Mio Aktien, da werden Fonds ganz bestimmt nicht zugreifen und weitere gzu genehmigende Aktien stehen unmittelbar bevor. Das muss so sein um endlich mal aus den Miesen zu kommen. Dann allerdings wäre ein Fond eine gute Sache und der Kleinanleger hätte wieder mal das Nachsehen.

[montamero]

The Only Economically Sustainable Approach to Treat Alzheimer’s Disease may be through Next-Generation Vaccines

Jan 1 2013

Disease-modification is becoming less attractive as an approach for treating Alzheimer’s disease for two main reasons. First, as evidenced by recent Phase 3 clinical trials results, patients who are symptomatic probably have disease that is too far advanced to benefit significantly from treatments that slow the degenerative process. Second, treating very early stage or presymptomatic patients will be extremely expensive and prove too costly a burden for healthcare systems. An article by scientists from the Karolinska Institute in Sweden, published in the October issue of Current Alzheimer’s Research, indicated the economic cost of treatment with a chronically and frequently administered disease-modifying drug would outweigh the cost of palliative care, including full-time nursing care of patients with advanced disease. This economic model leads one to conclude that a vaccination given on an annual or semi-annual basis may be the only economically feasible approach to prevent and manage Alzheimer’s disease.

This idea generated significant interest and discussion when I introduced the topic at the 6th Annual Alzheimer’s Drug Discovery Summit in Philadelphia last month. One of my goals was to raise awareness of recent developments, including our own, that I believe could ultimately result in a safe and effective vaccine, which when administered to tens of millions of people around the world, could delay or prevent the onset of symptomatic Alzheimer’s disease. I started by reminding the audience of how the vaccine field evolved, beginning with the remarkable demonstration that “inoculation” of an Alzheimer’s mouse model with aggregated human beta amyloid protein (Aß) resulted in dramatic reduction of amyloid plaque in the brain. These data, first reported by scientists from Elan Pharmaceuticals in 1999, were the first in vivo demonstrations that antibodies against Aß can reduce plaque, confirming my predictions for the ANTISENILIN antibodies two years prior.

Unfortunately, the initial excitement regarding active immunotherapy was short-lived because of several ill-conceived choices made with the first Alzheimer’s vaccine tested in humans, AN1792. The trial was terminated after just two inoculations of the vaccine because of acute brain inflammation in several patients enrolled in the Phase 2 clinical trial. For a while, it seemed that Alzheimer’s immunotherapy was dead in the water. However, this initial failure was gradually shown to be largely the result of an autoimmune response against Aß, which can be easily avoided by removing the harmful C-terminus portion of Aß containing T-cell epitopes. The impact of this change is reflected by several successful safety trials involving second-generation vaccine candidates.

The AN1792 trial has since influenced the development of immunotherapy approaches. I wonder if progress may have been accelerated were it not for the AN1792 debacle. For example, there has been a major shift in focus from active immunotherapy to passive immunotherapy. This shift was based on the rationale that administering externally-generated antibodies is probably safer than stimulating an immune response in patients. However, passive immunotherapy was found to have its own significant safety issues, especially with antibodies that bind plaque with high affinity. On the other hand, second-generation vaccines currently in clinical development appear to have overcome the problems encountered with AN1792 and show no evidence of vasogenic edema or microhemorrhages. The different safety profiles between passive and active immunization strategies are likely related to the slower build-up of antibodies from active immunization. This change in approach avoids the rapid dissolution of pre-existing plaque that results when a bolus injection of externally administered antibody causes toxic fragments to be released back into circulation. This may be less of an issue if treatment is initiated before plaques form or using subcutaneous instead of intravenous administration as is being tested with bapineuzumab.

Table 1 (Information from www.clinicaltrials.gov)



Table 1 above summarizes three ongoing Phase 2 clinical trials to evaluate second-generation vaccines: CAD016 sponsored by Novartis in collaboration with Cytos, ACC-001 sponsored by Janssen Alzheimer’s immunotherapy R&D in collaboration with Pfizer, and AD02 sponsored by Affiris in collaboration with Glaxo. The three vaccines each contain a short-fragment corresponding to a portion of Aß adjacent to the N-terminus. In the case of AD02, the peptide is comprised of an artificial sequence of amino acids that mimics the structure of the N-terminus to produce a “mimotope.” The advantages of using short peptides (whether natural or artificial) are first to avoid incorporating potentially harmful T-cell epitopes that could cause an autoimmune response and second, to guarantee the antibodies generated in response to the vaccine only bind Aß not the amyloid precursor protein (APP) thereby reducing the potential for adverse off-target side-effects. However, the use of small peptides also poses challenges, especially regarding the ability to mount a robust and sustained antibody response even in the presence of a strong adjuvant. In CAD106 and ACC-001, several copies of the short peptides are linked to a much larger immunostimulatory molecule, a viral like particle in the case of CAD106 and a mutant form of diphtheria toxin in the case of ACC-001.

In each case, the larger molecules provide the necessary T-cell response to obtain an immune response. However, the disadvantage is a reduced concentration of active peptide per vaccine dose. The Phase 1 results with CAD106 were encouraging because they showed most vaccinated patients mounted an immune response, however, these responses appeared fairly transient, suggesting patients failed to obtain a sustained immune response. This could result in CAD106 needing to be administered repeatedly thereby losing the cost advantage of vaccination.

Intellect Neurosciences’ RECALL-VAX technology platform aims to overcome this challenge. In our vaccine candidate, a similar fragment of Aß is joined with a small bacterial T-cell epitope comprised of tetanus toxoid, thus assuring a higher molar concentration of the Ab peptide per vaccine dose. A second advantage rests in the fact most people have been inoculated against tetanus toxoid, allowing this new vaccine to recall a memory imprint that exists in the immune system, thereby improving the patient’s immunity against Alzheimer’s. Consequently, we believe RECALL-VAX has the best chance of developing a robust and sustained immune response in elderly patients whose immune systems are generally weakened by age. Intellect Neurosciences has been granted numerous patents in relation to RECALL-VAX, including in 26 European countries, Japan and the United States.

There is a growing sentiment among Alzheimer’s researchers that Aβ monotherapy may be ineffective to treat the disease or stop it in its tracks for several reasons: First, the degree to which Aβ levels need to be reduced to delay onset or slow progression is unknown. Secondly, Aβ therapies are unlikely to improve function or plasticity of damaged but surviving nerve cells. Thirdly, other mechanisms are important, especially tau pathology, which acts synergistically with Aβ in Alzheimer’s, causing irreversible damage to nerve cells.

This notion led to our collaboration with Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders and his team, and our collaboration with Dr. Kim Green at the University of California, Irvine, to evaluate a number of vaccine candidates based on the RECALL-VAX approach including, RV03, a first-in class bispecific vaccine targeting both Aβ and ∆ tau, a particularly pathogenic form of the protein that precedes neurofibrillary tangle formation. Our combined research is focused on developing the first dual vaccine against these two important therapeutic targets to prevent the irreversible damage and death of nerve cells caused by these two proteins.

One hopes the improved safety profile of candidates currently in clinical development will stimulate interest in the vaccine approach and importantly lead to the type of investment needed to progress development of next-generation drugs, such as RV03, which has the potential to be a game-changer in the prophylaxis and management of Alzheimer’s disease.

I ended the talk with my favorite quote from the great 19th century French chemist and bacteriologist, Louis Pasteur (1822-1895), who first coined the word “vaccine”: “Through perseverance in one field of investigation, one succeeds in acquiring what I call the instinct of truth.” Pasteur’s determination to stay the course led to his creation of the first vaccines for rabies and anthrax and laid the foundations for the manufacture of many other vaccines saving millions of lives. We can learn from his example as we continue with our important mission to create a world without Alzheimer's disease.

In the meantime, I wish you a very happy, healthy and prosperous New Year.

-Daniel Chain, Ph.D., Chairman and CEO, Intellect Neurosciences, Inc.

http://www.intellectns.com/blog


Intellect Neurosciences CEO Daniel Chain Provides Conference Highlights of Alzheimer's Drug Development Summit in Neurotech Insights Magazine

NEW YORK, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, provided conference highlights from the December 11-12 Alzheimer's Drug Development Summit in Neurotech Insights magazine. Dr. Chain was a Distinguished Speaker at the conference.

In addition to Dr. Chain's presentation, titled "Recent Advancements in Vaccine Development for AD Prophylaxis and Management," which reviewed the challenges associated with the development of a safe and effective Alzheimer's vaccine and described the rationale in support of Intellect's ground-breaking approach, Dr. Chain provided overviews of the major talks of the conference. His overview concluded with an analysis of the way the federal government has failed to address the cost of development for new treatments for Alzheimer's disease.

In the article, Dr. Chain commented, "I fully concur with the Neurotechnology Industry Association's (NIO) belief that the solution to the problem of prevalence of neurological disease and the public health burden it presents lies in creating new market exclusivity for sponsors of novel disease-modifying therapeutics that are targeted to neurodegenerative disease, especially AD. The rationale of the NIO initiative follows that of the 1983 Orphan Drug Act, which has since spurred development of new medicines for hundreds of orphan diseases that, otherwise, would not have been addressable given the small market size. A guaranteed market exclusivity period of ten years would be sufficient to tilt the cost-benefit consideration toward continuing drug development for neurodegenerative diseases."

About Intellect Neurosciences

Intellect Neurosciences, Inc., develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please visit www.intellectns.com.

The Intellect Neurosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14741

Safe Harbor Statement Regarding Forward-Looking Statements:

The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those discussed in Intellect's Quarterly Report on Form 10-Q (file no. 333-128226), filed on November 20, 2012 and the risk factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 15, 2012.

Jules Abraham
JQA Partners, LLC
917-885-7378
Retrieved from "http://globenewswire.com/news-release/2013/01/02/514241/1001…"

[montamero]

Infusion gegen Demenz / Hoch dosierte Immunglobuline können Alzheimer stoppen

Baierbrunn (ots) - Kein Durchbruch, aber ein Hoffnungsschimmer: Infusionen mit hoch dosierten Immunglobulinen können Alzheimer bremsen, berichtet die "Apotheken-Umschau". Mediziner des Weill Cornell Medical College in New York City (USA) konnten das Fortschreiten der Erkrankung so bei elf Alzheimer-Patienten drei Jahre lang aufhalten. Die Immunglobuline, die Entzündungen dämpfen können, werden aus Blutspenden gewonnen. Um den Erfolg zu überprüfen, müssen wegen der geringen Patientenzahl weitere Studienergebnisse abgewartet werden.

Dieser Text ist nur mit Quellenangabe zur Veröffentlichung frei.

Das Gesundheitsmagazin "Apotheken Umschau" 12/2012 B liegt in den meisten Apotheken aus und wird ohne Zuzahlung zur Gesundheitsberatung an Kunden abgegeben.

Originaltext: Wort und Bild - Apotheken Umschau Digitale Pressemappe: http://www.presseportal.de/pm/52678 Pressemappe via RSS : http://www.presseportal.de/rss/pm_52678.rss2

Pressekontakt: Ruth Pirhalla Tel. 089 / 744 33 123 Fax 089 / 744 33 459 E-Mail: [e-mail] www.wortundbildverlag.de www.apotheken-umschau.de


http://www.finanznachrichten.de/nachrichten-2012-12/25474550…

[montamero]

Schwedische Wissenschaftler testen aktiven Alzheimer-Impfstoff

Schwedische Forscher am Stockholmer Karolinska Institut haben den aktiven Alzheimer-Impfstoff CAD106 über drei Jahre an schwedischen Alzheimer-Patienten getestet. Die Ergebnisse wurden am 6. Juni 2012 im Fachmagazin „The Lancet Neurology“ veröffentlicht.

In der aktuellen Studie konnten die Wissenschaftler um Professor Bengt Winblad zeigen, dass der Wirkstoff CAD106 bei 58 Patienten mit leichter bis mittelschwerer Alzheimer-Erkrankung eine Antikörperreaktion gegen Beta-Amyloid auslöste. Nicht bekannt ist bisher, ob der Anstieg der Antikörper tatsächlich einen Rückgang der Alzheimer-typischen Beta-Amyloid-Plaques im Gehirn nach sich zieht.

Vor zehn Jahren hatten Wissenschaftler bei Versuchen mit einem anderen aktiven Impfstoff, AN1792, einen Rückschlag erlitten, als während der Phase II-Studie bei einigen Versuchsteilnehmern Entzündungen des Gehirns und der Hirnhäute (Meningoenzephalitis) auftraten. Dr. Maï Panchal, Leiterin der Fördermittelvergabe der Alzheimer Forschung Initiative e.V. (AFI): „Die neuesten Ergebnisse sind viel versprechend. Das bedeutendste Resultat der aktuellen schwedischen Impfstudie ist, dass bei einer aktiven Immunisierung mit CAD106 keine Hirnhautentzündung bei den Versuchsteilnehmern festgestellt werden konnte. Im nächsten Schritt muss in Studien an größeren, internationalen Patientengruppen geprüft werden, ob CAD106 tatsächlich keine schweren Nebenwirkungen mit sich bringt.“

„In den Phasen II und III der Studie, also wenn die medizinische Wirksamkeit des Impfstoffes getestet wird, muss anhand von neuropathologischen Untersuchungen erarbeitet werden, ob CAD106 tatsächlich für einen Rückgang der Beta-Amyloid-Plaques sorgen kann“, so Panchal weiter. „Derzeit laufen übrigens schon vier internationale Phase II-Studien in Europa, Kanada und den Vereinigten Staaten. Wir sind gespannt auf die Ergebnisse.“

Originalartikel:
Bengt Winblad, Niels Andreasen, Lennart Minthon, Annette Floesser, Georges Imbert, Thomas Dumortier, R Paul Maguire, Kaj Blennow, Joens Lundmark, Matthias Staufenbiel, Jean-Marc Orgogozo & Ana Graf . Safety, tolerability, and antibody response of active A²immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurology, online first 6 June 2012, doi:10.1016/S1474-4422(12)70140-0

Zusammenfassung des Originalartikels:
Webseite von „The Lancet Neurology“:
http://www.thelancet.com/journals/laneur/article/PIIS1474-44…


Über die Alzheimer Forschung Initiative e.V.
Die Alzheimer Forschung Initiative (AFI) ist ein eingetragener gemeinnütziger Verein. Seit 1995 fördert die AFI mit Spendengeldern Forschungsprojekte engagierter Alzheimer-Forscher. Bis heute hat die Alzheimer Forschung Initiative 102 Projekte mit rund 5,4 Mio. € fördern können. Die AFI stellt außerdem kostenloses Informationsmaterial für die Öffentlichkeit bereit. Interessierte und Betroffene können sich auf www.alzheimer-forschung.de fundiert über die Alzheimer-Krankheit informieren und Ratgeber bestellen. Ebenso finden sich auf der Webseite Informationen zur Arbeit des Vereins und allen Möglichkeiten zu Spenden.

http://www.alzheimer-forschung.de/presse/pressemitteilungen.…

[montamero]

CAD106

October 15, 2012

In another step away from cancer therapeutic vaccines, CAD106, a vaccine co-developed by Novartis ($NVS) and Cytos that targets the amyloid β peptide, has shown early hints of immune responses in a clinical trial in people with Alzheimer' s disease.

This vaccine could have potential to slow the development of the disease and fill a major unmet medical need. The World Health Organization says dementia is the fastest-growing global health epidemic and there is no treatment available that alters the course of the disease.

CAD106 targets a fragment of the harmful form of the beta amyloid peptide, the main component of the plaques found in the brains of people with Alzheimer's disease. In the Karolinska Institutet study, people with mild-to-moderate Alzheimer's developed protective antibodies against beta amyloid without any side effects, and the researchers want to carry out larger trials.

According to the company and the Karolinska Institutet, these are the first results to show a positive effect of an active vaccine against Alzheimer's. Development of the first vaccine against beta amyloid, Elan's AN1792, had to be discontinued as it triggered meningoencephalitis (inflammation of the brain and the membranes around the brain), but there were no signs of that in the CAD106 trial.

The agreement between Novartis and Cytos goes back to 2001, and covers a collaboration to develop therapeutic vaccines for the treatment of allergies, rheumatoid arthritis, and chronic nervous system disorders.



Read more: CAD106 - FierceVaccines http://www.fiercevaccines.com/special-reports/cad106#ixzz2Gu…
Subscribe: http://www.fiercevaccines.com/signup?sourceform=Viral-Tynt-F…

http://www.fiercevaccines.com/special-reports/cad106

Early steps toward an Alzheimer’s vaccine

POSTED JUNE 12, 2012, 12:24 PM
Heidi Godman, Executive Editor, Harvard Health Letter

Some encouraging Alzheimer’s news from Sweden: a vaccine called CAD106 appears to be safe and ramps up the body’s immune system against a protein likely involved in Alzheimer’s. The hope is that this vaccine will slow the progression of Alzheimer’s disease, and possibly even stop it.

The vaccine is designed to activate the body’s immune system against beta amyloid, a protein fragment that forms deposits called amyloid plaques between nerve cells in the brain. While it’s unclear if beta amyloid plaques cause Alzheimer’s or are a result of it, scientists do know that the plaques are an important biomarker of the disease. Some researchers believe that beta amyloid plaques interfere with communication between nerve cells or somehow inhibit processes needed to keep brain cells alive.

“Twenty-five years ago,” says Dr. Anthony L. Komaroff, professor of medicine at Harvard Medical School, “we knew very little about what caused Alzheimer’s disease and therefore how it might be prevented and treated. A lot of people were hopeless. We knew that we could see certain microscopic abnormalities in the brains of people with Alzheimer’s disease, called plaques and tangles. And we knew some of the chemicals inside the plaques and tangles. But we didn’t know if they caused the disease, and whether targeting them would help people with the disease.”

This vaccine work may help answer those questions.

Safety first

In the vaccine study, published online in Lancet Neurology, researchers from the Karolinska Institute gave 58 men and women with mild-to-moderate Alzheimer’s disease injections of CAD106 or a placebo and followed them for three years. Three-quarters of those who received CAD106 developed antibodies against beta amyloid protein. Virtually all of them—including those getting the placebo—reported one or more side effects, ranging from inflammation of the nose and throat to headache, muscle pain, and fatigue.

None, though, developed meningoencephalitis, an inflammation of brain tissue. That’s important because a trial of an earlier vaccine called AN1792 was abruptly stopped when 6% of those getting the vaccine developed meningoencephalitis. That vaccine apparently triggered a response among certain white blood cells that wound up attacking healthy brain tissue. CAD106, in comparison, targets only the beta amyloid proteins.

The next step in the development of CAD106 is a larger clinical trial to confirm the vaccine’s safety and to see if it is effective at slowing the relentless progression of Alzheimer’s disease.

“It’s much too early to say whether this particular vaccine will prove to be a valuable treatment in Alzheimer’s disease,” Dr. Komaroff says. “Nevertheless, in contrast to 25 years ago, today there is a lot of evidence that beta amyloid is one important cause of Alzheimer’s disease, and that targeting beta amyloid with drugs and vaccines may bring benefits. Because of biomedical research, today we have real reason for hope.”

Several other Alzheimer’s vaccines that target the beta amyloid protein are also being tested in clinical trials. Another effort moving forward includes an insulin-based nasal spray, which has shown promise in repairing damaged brain tissue involved in memory and cognition. The Obama administration’s National Alzheimer’s Plan, which was released last month, calls for $7.9 million in funding for this spray.

http://www.health.harvard.edu/blog/early-steps-toward-an-alz…


Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A.

Source
Karolinska Institutet Alzheimer Disease Research Centre and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden. [e-mail]

Abstract

BACKGROUND:
Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to slow the progression of Alzheimer's disease. We aimed to assess the safety and tolerability of CAD106, a novel active Aβ immunotherapy for patients with Alzheimer's disease, designed to induce N-terminal Aβ-specific antibodies without an Aβ-specific T-cell response.

METHODS:
We did a phase 1, double-blind, placebo-controlled, 52-week study in two centres in Sweden. Participants, aged 50-80 years, with mild-to-moderate Alzheimer's disease were entered into one of two cohorts according to time of study entry and then randomly allocated (by use of a computer-generated randomisation sequence) to receive either CAD106 or placebo (4:1; cohort one received CAD106 50 μg or placebo, cohort two received CAD106 150 μg or placebo). Each patient received three subcutaneous injections. All patients, caregivers, and investigators were masked to treatment allocation throughout the study. Primary objectives were to assess the safety and tolerability of CAD106 and to identify the Aβ-specific antibody response. Safety assessment was done by recording of all adverse events, assessment of MRI scans, physical and neurological examinations, vital signs, electrocardiography, electroencephalography, and laboratory analysis of blood and CSF. Patients with Aβ-IgG serum titres higher than 16 units at least once during the study were classified as responders. This study is registered with ClinicalTrials.gov, number NCT00411580.

FINDINGS:
Between August, 2005, and March, 2007, we randomly allocated 31 patients into cohort one (24 patients to CAD106 treatment and seven to placebo) and 27 patients into cohort two (22 patients to CAD106 treatment and five to placebo). 56 of 58 patients reported adverse events. In cohort one, nasopharyngitis was the most commonly reported adverse event (10 of 24 CAD106-treated patients). In cohort two, injection site erythema was the most commonly reported adverse event (14 of 22 CAD106-treated patients). Overall, nine patients reported serious adverse events--none was thought to be related to the study drug. We recorded no clinical or subclinical cases of meningoencephalitis. 16 of 24 (67%) CAD106-treated patients in cohort one and 18 of 22 (82%) in cohort two developed Aβ antibody response meeting pre-specified responder threshold. One of 12 placebo-treated patients (8%) had Aβ-IgG concentrations that qualified them as a responder.

INTERPRETATION:
Our findings suggest that CAD106 has a favourable safety profile and acceptable antibody response in patients with Alzheimer's disease. Larger trials with additional dose investigations are needed to confirm the safety and establish the efficacy of CAD106.
FUNDING:
Novartis Pharma AG.

http://www.ncbi.nlm.nih.gov/pubmed/22677258

[dottore]

zusammengefasst kann man also sagen, dass Novartis an einem Impfstoff arbeitet CAD016(in Zusammenarbeit mit Cytos, die wiederum haben es derzeit hinten an gestellt)um einen Impfstoff mit diphetriegift-Teil Immunverstärkt ,
Janssen in Zusammenarbeit mit Pfizer spielt mit ACC001 einem Impfstoffverstärker aus einem Viruspartikel,
Affiris und GSK mit AD02,
INLS versucht es nun mit einem Anhängsel aus Tetanusgift, dass den Vorteil hat, dass bereits (wie bei Diphterie) durch vorherige Impfungen eine entsprechende sensibilisierung besteht und entsprechend bessere Wirkung.

Somit wäre INLS Patent der dritte Mitbewerber und die anderen beiden brauchen nicht Lizenzen bezahlen.
Ich habe jedenfalls nichts gefunden, aus dem hervorgeht, dass Novartis an Intellect zahlen müßte.

Damit will ich INLS nicht schmälern, sondern einordnen. Da schom 3 Mitbewerber in Zusammenarbeit mit Weltfirmen fortgeschrittene Studien betreiben, stellt sich die Frage, ob ILNS nicht zu recht so klein ist, frei nach dem Motto: Wer zu spät kommt bestraft das Leben.

Es steht in den Berichten oben nirgends, dass die Studie in Schweden in Zusammenhang mit ILNS wäre, vielmehr lese ich, dass Dr. Daniel Chain referiert hat über die Studie und einen Appell an die Regierung stellte, mehr Förderung für die Forschung bereit zu stellen.

[montamero]

Was ist vom vierten Quartal (Zahlen, Fakten) ausständig bzw. noch nicht veröffentlicht worden?
Wie viel Zeit bleibt noch bis zum 10-Q Filing (letztes Jahr am 02.02.)...


Rückblick:

Lonza: Aussicht auf Auftrag von Intellect Neurosciences

Donnerstag 27.09.2012, 10:02 Uhr

New York/Basel (Godmode-Trader.ch) – Lonza hat einen Auftrag von Intellect Neurosciences in Aussicht. Wie der Lifesciencekonzern am Donnerstag bekannt gab, hat das in der Forschung und Entwicklung von krankheitsmodifizierenden Therapeutika zur Behandlung von Proteinopathien tätige biopharmazeutische Unternehmen vor, die zukünftige Entwicklung und Produktion des Antikörper-Wirkstoff-Konjugates CONJUMAB-A an Lonza zu vergeben.
Lonza werde, vorbehaltlich einer endgültigen Entwicklungs- und Produktionsvereinbarung, das präklinische Studienmaterial, zunächst fokussiert auf die altersbedingte Makuladegeneration (AMD) mit Anwendungspotenzial für Alzheimer Erkrankungen, für die Optimierung und Auswahl von Intellects Antikörper-Wirkstoff-Konjugates CONJUMAB-A liefern, hieß es.

http://www.godmode-trader.de/nachricht/Lonza-Aussicht-auf-Au…




Lonza to make antibody conjugates for preclinical trials


By Gareth MacDonald+
01-Oct-2012

Lonza to make preclinical trial supplies of an antibody-drug conjugate (ADC) at its facility in Visp, Switzerland

Lonza will use its facility in Visp, Switzerland to make preclinical trial supplies of an antibody-drug conjugate (ADC) being developed by Intellect Neurosciences.
The candidate drug in question - IN-NO1-OX2 or Conjumab-A - combines one of Intellect’s beta amyloid protein targeting Antisenilin antibodies with a small molecule neuroprotective compound.

Under the contract, Switzerland-based Lonza will combine the core antibody with various neuroprotective compounds from its own library for further assessment by Intellect and several unnamed ‘specialised' contract research organisations (CROs).

Work on the project has already begun according to Stefan Stoffel, Lonza head of chemical manufacturing operations, who said: "We have already generated a detailed road map for the optimisation and manufacture of Conjumab-A, and are excited to be associated with this entirely novel and promising application for antibody-drug conjugates."

ADC development

The decision to develop and produce the candidate ADCs in Visp fits with plans Lonza outlined in August when it said making more high-tech, high-value pharmaceutical products and ingredients at the plant was key to increasing its competitiveness.

At the time recently appointed COO Beat In-Albon – who was called in to handle the ‘Visp Challenge ’ – said: “The focus will be on process production, process optimisation as well as the introduction of higher margin, new technology products.”

While it is hard to say how significant the Intellect contract is for Lonza – no financial terms were disclosed – the deal does underline the interest top tier contract manufacturing organisations (CMOs) have in ADC development and manufacture.

In recent years Lonza, SAFC, Goodwin Biotechnology and Piramal have invested in this type of manufacturing , while – in July – French firm Novasep invested €3m to add ADC production capacity at its plant in Le Mans.


http://www.in-pharmatechnologist.com/Processing/Lonza-to-mak…


Pipeline activities:

Our antibody-drug conjugate platform, CONJUMAB, provides potential development of two independent antibody-based products from the same starting material, our compound, IN-N01. Our recent agreement with Lonza, with whom we signed a letter of intent, was an important step in the development of our first ADC, CONJUMAB-A. We are excited to have reached a point at which Lonza is now manufacturing the preclinical materials for the drug optimization and drug selection program, and look forward to testing these compounds in the near future. With sufficient financial resources, we could reasonably expect to file two INDs within two years, one for CONJUMAB-A initially focused on age-related macular degeneration and a second for IN-N01 for a second indication such as familial Alzheimer's disease or traumatic brain injury, both of which could qualify as orphan diseases.

Patent news:

We remain determined to secure our ANTISENILIN patents still under review by the USPTO and hopeful that this can be accomplished over the next few months. The demonstration using biomarkers that bapineuzumab reduces amyloid plaque and neurodegeneration in the brain of Alzheimer's patients provides compelling new evidence in support of the ANTISENILIN platform technology. Similarly, we plan to continue with the appeal process that we initiated in February to overcome the challenge to our patents in Europe.
We were disappointed by the failure of one of our global pharmaceutical licensees to pay the $2 million milestone payment triggered by the issuance of our patent by the USPTO on May 8, 2012 eventually leaving us no option except to pursue our claim in the courts. The action of our licensee in this regard is unconscionable and, in my opinion at least, an affront to the pharmaceutical industry that desperately needs to foster rather than thwart innovation at a time that global pharmaceutical companies are substantially reducing their internal R&D and relying more and more on companies such as Intellect Neurosciences to provide the next generations of high value therapeutics. The community at large should be aghast that a small company such as ours needs to divert attention and limited resources from its critically important mission of developing disease modifying therapies for Alzheimer's and other serious neurological diseases.

http://finance.yahoo.com/news/intellect-neurosciences-issues…


Intellect Neurosciences Announces New Findings Supporting Its Tau Oligomer Selective TOC-1 Monoclonal Antibody for the Treatment of Alzheimer's Disease
By GlobeNewswire, November 06, 2012, 09:35:00 AM EDT
Vote up



NEW YORK, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, announced today scientists at Northwestern University have published new findings on its tau oligomer selective TOC-1 monoclonal antibody. These new data explain a phenomenon concerning the role of aggregated oligomeric tau as an inhibitor of fast axonal transport (FAT). FAT is the mechanism by which newly synthesized membrane and other proteins made in the nerve cell body essential for neuronal membrane function and maintenance are provided to the synapse.

The paper, titled, "Tau oligomers and tau toxicity in neurodegenerative disease," was written by Lester Binder, Ph.D., the Abbott Laboratories, Duane and Susan Burnham Research Professor of Genetic and Molecular Medicine, at Northwestern University. It appeared in the recent edition of Biochemistry Society Transactions.

"The inhibition of FAT requires a small stretch of amino acids termed phosphatase-activation domain, or PAD. Using a PAD-specific antibody, TNT1 and Tau oligomer selective antibody TOC-1, Dr. Binder's research group was able to demonstrate the PAD is more exposed in oligomeric tau leading to dissociation of the microtubules in diseased neurons. This leads to an increase in FAT inhibition and represents an early event in AD pathogenesis. These findings support our belief, shared by several global pharmaceutical companies with whom we are in discussions, that TOC-1 has important therapeutic potential," stated Daniel Chain, PhD, chairman and CEO of Intellect.

Intellect previously obtained development and commercialization rights to TOC-1 under an exclusive license agreement with Northwestern University and plans to develop it for the treatment of Alzheimer's disease (AD) and other tauopathies.

Dr. Chain will speak about Intellect's TOC-1 program at the International Drug Discovery Science and Technology (IDDST) conference November 8-10 in Nanjing, China.

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases especially focused on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please visit www.intellectns.com.

The Intellect Neurosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14741

Safe Harbor Statement Regarding Forward-Looking Statements:

The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward‐looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-‐128226), filed on October 15, 2012.

CONTACT: Jules AbrahamJQA Partners, [e-mail]

http://www.nasdaq.com/article/intellect-neurosciences-announ…


Daniel Chain Sues Pfizer for $2M

Posted in: Articles, biotechnology, neurological | October 17, 2012 at 6:32 am
Intellect Neurosciences has filed a breach of contract suit against Pfizer Inc. for failing to make a $2 million milestone payment for rights to its Alzheimer’s disease technology.
Intellect Neurosciences was founded by CEO Daniel Chain, who laid the groundwork for the technology in dispute with Pfizer during his tenure at Mindset, a Jerusalem-based startup.
Intellect contends that the licensing fee was triggered when the U.S. Patent and Trademark Office issued the company a patent on May 8 that covers its Antisenilin monoclonal antibody platform technology for the treatment and prevention of Alzheimer’s disease.
“It’s a distressing situation for us, a small company, to go head-to-head with a major company,” Intellect Neurosciences Chairman and CEO Daniel Chain said in a report to The Pink Sheet. The milestone payment “was clear, black and white in the agreement.”
Intellect Neurosciences’ patent discloses therapeutic antibodies to treat or delay onset of Alzheimer’s disease. The antibodies bind to both ends of the beta amyloid protein without binding to the amyloid precursor protein.
Following the recent American Neurology Association annual meeting, Chain posted an Oct. 9 personal perspective on the conference on the company’s homepage. “As the dust settles after the initial disappointing results from four major Alzheimer’s Phase III trials,” he concludes, the ANA “offered glimmers of light that renewed hope. The presenters and expert panelists conveyed a strong sense that Intellect is correct in its belief beta amyloid (Aβ) plays a central and causative role in the pathogenesis of Alzheimer’s disease and that immunotherapy represents a realistic path forward. The next-generation drugs will have an improved probability of success because of the lessons we have learned.”


http://www.bioisrael.com/daniel-chain-sues-pfizer-for-2m

[dottore]

heute 15 Tausend Umsatz. Endlich mal eine Hausnummer. Bin gespannt wie es hier weiter geht.
Aus den weiter oben genannten Gründen schau ich aber nur zu. Bin sowieso voll investiert und umschichten mag ich derzeit nicht, nicht für so was hier. Obwohl so 500 $ - Zock könnte man ja mal versuchen

[montamero]

ViroPharma: Strengthening Financial Profile & Pipeline Indicate Long-Term Upside
Ivan DeryuginDecember 27, 2012

Shares of ViroPharma (NASDAQ:VPHM) have been pressured in 2012 (falling over 17% as of December 26), as generic competition for one of its drugs has eaten into sales and profits. And while generic competition is never a welcome sign for pharmaceutical companies, ViroPharma is poised to overcome the issue, due to a strengthening balance sheet, and a promising pipeline. Unless otherwise noted, financial statistics and management commentary used in this article is obtained from one of 3 sources: ViroPharma’s Q3 2012 earnings release, its latest 10-Q filing, or its Q3 2012 earnings call.

Overview & Q3 2012 Results

ViroPharma, based in Exton, Pennsylvania, markets a number of drugs: Cinryze for the treatment of hereditary angioedema (HAE); Vancocin for clostridium difficile; and Buccolam, which is sold in Europe for the treatment of seizures. ViroPharma is also preparing to launch Plenadren in Europe for the treatment of adrenal insufficiency.

In its latest quarter, ViroPhrama posted revenues of $91.004 million, a steep drop from the $142.956 million in sales posted during the third quarter of 2011. The decline was due to generic versions of Vancocin entering the market in 2012. Vancocin sales dropped 95% year-over-year, highlighting the power that generics have in the marketplace. And sales of Cinryze have not yet risen fast enough to overcome the decline in Vancocin sales. During this latest quarter, Cinryze sales rose from $65.4 million in Q3 2012 to $85.3 million. The company posted a GAAP loss of 7 cents per share, but a non-GAAP profit of 10 cents per share, which removes non-cash expenses from the earnings calculation. ViroPharma burned $7,800 in operating cash flow during this quarter, but the company has $143.989 million in net cash & investments on its balance sheet, and I am confident in the company’s ability to quickly return to GAAP profitability and operating cash flow. Continued growth in Cinryze sales and a strong pipeline are setting the stage for a strong 2013.

Cinryze: Expanding the Patient Pool

Cinryze treats hereditary angioedema (HAE), a rare inherited blood disorder that affects between 1 in 10,000 and 1 in 50,000 people in the United States. ViroPharma is forecasting that it will end 2012 with 900 patients in the United States, and the company is working to expand its patient pool even further, says CEO Vincent Milano:

The data points that we provided you in the past continue to remain consistent with roughly 50% of our new patients coming on after having previously tried anabolic steroids and roughly half of the new patients this year have been diagnosed in the last 3 years. Another important data point is that around 30% of our new patients coming on to Cinryze therapy have done so after trying one of the available acute HAE therapies. So in contrast to the theories that the acute HAE therapies would be drawing patients away from prophylaxis, the totality of the data actually suggests that prevention of attack is a preference for many people with HAE.

As the US Hereditary Angioedema Association states on its website, Cinryze is designed to prevent HAE attacks from occurring in the first place, whereas existing treatment options merely serve to treat attacks that have already taken place. That is what sets Cinryze apart in the market among HAE medicines, and recent clinical data has further strengthened Cinryze’s competitive advantage. ViroPharma presented new safety data regarding Cinryze at the American College of Allergy, Asthma, and Immunology’s meeting that showed that increased doses of Cinryze were well-tolerated in patients that were unable to adequately control their HAE with the standard dose of 1000 units every 3 to 4 days (Cinryze is created from human blood, and is therefore dosed in units). ViroPharma studied 20 patients over the course of 3 years, and escalated their Cinryze doses in a step-function, from 1000 units to 2500 units, in increments of 500 if patients continued to have more than 1 angioedema attack each month. A 3-month safety follow-up was conducted after each dosage increase. The safety study concluded that doses of up to 2500 units present no safety issues relative to existing clinical data, and that there were no discontinuations due to adverse events. There were 2 adverse events detected during the study that were determined to be related to Cinryze: a localized blood clot and a muscle spasm, but neither event was deemed serious enough by the investigators to warrant discontinuation of Cinryze. This study will allow ViroPharma to eventually expand its addressable market, as patients that do not respond to the standard dosage of Cinryze will be able to stay on the drug.

While Cinryze sales are growing in the United States, ViroPharma is not standing still in its efforts to grow international sales. European sales of Cinryze were around $1 million in Q3 2012, and CEO Vincent Milano admitted on the company’s call that the European market is a “tough” one to break into:

We launched Cinryze in Europe in the U.K. and in Germany in the beginning of the year, and it’s been a pretty tough but steady add of patients here from the beginning. There’s been a significant change in physician and patient attitude over the last 2 years and I think that’s probably due to the success that we’ve had in the United States. If you went 2 or 3 years ago back to Europe, you’d have learned that there wasn’t a whole lot of interest in prophylaxis [Cinryze is a prophylaxis, or preventative, therapy]. But I think the benefits that the patients have realized in the U.S, and I think the thought leaders from the U.S. being at the same meetings as the Europeans, has started to change that attitude. And also, please remember that we had intended to launch Cinryze in France, Spain and Italy in September. And in those 3 countries, launch has been put back due to the overall economic situation and our ability to gain reimbursement. We do plan to be able to launch in France and in Spain before the end of the year, and it’s likely that Italy will get launched some time in the beginning of 2013.

ViroPharma is working to expand awareness of the benefits of Cinryze relative to existing treatment options for HAE in Europe, and 2012 is not representative of Cinryze’s full potential in Europe. The company’s launch in France, Spain, and Italy has been delayed due to the macroeconomic situation in Europe, which has slowed down the setting of reimbursement rates, hence patients are reluctant to spend the money for this costly treatment. But, sales should be seen in France and Spain from the fourth quarter, and Italian sales should start in Q1 2013, as the company likely expects to gain some reimbursement traction in those markets. ViroPharma is also looking to expand the use of Cinryze here in the United States, and it is attempting to do so via a far more convenient dosing mechanism.

Cinryze is currently administered intravenously, and while it is approved for home infusion, intravenous dosing is inconvenient and cumbersome. ViroPharma, in partnership with Halozyme Therapeutics (NASDAQ:HALO) is studying the safety and efficacy of Cinryze when administered subcutaneously using Halozyme’s Enhanze technology [a proprietary deliver system using recombinant human hyaluronidase enzyme (rHuPH20)], which was licensed to ViroPharma in May 2011. ViroPharma and Halozyme began a Phase IIb trial of subcutaneous Cinryze on December 19. The companies will monitor 40 patients over the course of either one or two 8-week treatment sequences. The trial will have 2 dosing options: 1,000 units of Cinryze with 24,000 units of rHuPH20, or 2,000 units of Cinryze with 48,000 units of rHuPH20. In earlier Phase II trials, patients who took Cinryze subcutaneously had no HAE attacks during the trial, and mild to moderate reactions at injection sites were the most common adverse events reported. According to ViroPharma, the addition of rHuPH20 “resulted in mean C1 INH functional concentrations greater than or equal to 0.4U/mL for 92 percent of the 72 hour post dosing period as compared to 73 percent for 1000U IV.” NO C1 INH antibodies were detected in a 30-day post-treatment follow-up after the last doses of Cinryze were administered. Earlier in 2012, there were some safety concerns with this trial, as the FDA ordered ViroPharma and Halozyme to stop clinical trials while it investigated safety signals related to rHuPH20 antibodies in another company’s clinical trial program. But the FDA lifted its clinical hold in September when it was determined that these safety issues applied only to that other clinical program, and were not “transferrable” to the clinical trials being conducted by ViroPharma and Halozyme. ViroPharma and Halozyme signed their license agreement in May 2011, in which Halozyme granted ViroPharma an exclusive, worldwide license to use Enhanze in combination with Cinryze. ViroPharma paid Halozyme $9 million for the license in May 2011, and paid another $3 million in Q4 2011 when their Phase II program was initiated. Total milestone payments to Halzoyme could reach $41 million for Cinryze ($30 million for 3 other indications), and Halozyme will receive a 10% royalty on any future sales of subcutaneous Cinryze. In its 10-Q filing, ViroPharma also stated: “Additionally, we will pay an annual maintenance fee of $1 million to Halozyme until specified events have occurred.” I view these terms as acceptable, given that subcutaneous dosing of Cinryze will further strengthen the drug’s position in the market.

Other Drugs and the Pipeline: Expanding ViroPharma’s Addressable Market

ViroPharma recently launched Plenadren in Europe, and the drug is now available in Germany, Denmark, Norway, and the United Kingdom, and ViroPharma is making progress on launching in Spain and Italy. On the company’s Q3 call, CEO Vincent Milano said that physicians in Europe have started to prescribe the drug to patients. The company is engaged in discussions with the FDA regarding commercializing Plenadren in the United States and expects to provide an update in early 2013 regarding its plans. Buccolam was also launched in Europe during Q3 2012, and sales totaled $1.2 million in the quarter. ViroPharma is working to expand the market for Buccolam as well. I expect that the company will provide much more detail regarding its progress in Europe when it reports Q4 2012 results in early 2013.

ViroPharma focuses on rare diseases, such as HAE, and while such a focus can be highly profitable, it is also dependent on securing FDA (or EMA) approval for new indications for existing drugs, as well as developing new therapies altogether. ViroPharma is making progress on both fronts.

The company has seven different pipeline programs (inclusive of the subcutaneous dosing of Cinryze discussed earlier). VP20621, which ViroPharma acquired in 2006, is the company’s drug for the treatment of recurrent C. difficile. A Phase II trial was begun in May 2011, and the company projects that full Phase II data will be available in 2013. VP20629 is licensed from Intellect Neurosciences for the treatment of Friedreich’s Ataxia (FA), a rare neurodegenerative disease that affects about 1 in 50,000 people. Symptoms of FA include heart disease, speech problems, and gait disturbance. It is estimated that there are 6,000 FA patients here in the United States. Phase I data for VP20629 showed that the drug was well-tolerated at all dose levels, and ViroPharma is set to initiate a Phase II trial in the second half of 2013, and the company plans to file for orphan drug status once Phase II data is available. ViroPharma will pay Intellect Neurosciences up to $120 million in milestones, as well as a tiered royalty rate (with a cap in the “mid-teens”), if VP20629 is approved and commercialized. ViroPharma is also working to expand the use of Cinryze into transplant medicine. The company is studying Cinryze’s effects on treating Antibody Mediated Rejection (AMR) and Delayed Graft Function (DGF). Some transplant patients have antibodies that, when combined with donor specific antibodies, destroy the transplanted organ via AMR. DGF occurs during the organ preservation process. CEO Vincent Milano expects further data on these organ transplant indications in 2013.

ViroPharma’s last pipeline asset is oral budesonide, which it has rights to via an options agreement with Meritage Pharmaceuticals. In December 2011, the two companies signed an agreement under which ViroPharma can acquire Meritage for $69.9 million once final Phase II data for oral budesonide is available. In its latest 10-Q filing, ViroPharma states that it made a $5 million milestone payment (there will be up to $175 million in milestone payments) and that Meritage is continuing the development of oral budesonide, and that it continues to hold the option to acquire Meritage for $69.9 million.

Guidance, Financials, and Capital Structure

ViroPharma ended Q3 2012 with $143.989 million in net cash & investments, and although it swung to a GAAP loss, as well as a slight operating cash burn in this quarter, I believe that Q3 2012 will be the low-point for ViroPharma in terms of earnings. Vancocin sales fell 95% in the quarter, and ViroPharma’s total sales fell by 36.34%, even as its expenses rose by 2.93%. But, ViroPharma was able to keep its operating loss to $4.173 million. Cinryze sales have ample room to grow, whereas it is difficult for Vancocin sales to fall much further. ViroPharma guided for full-year revenues to come in between $425-$435 million, and with sales for the first 9 months of 2012 coming in at $321.444 million, that implies that Q4 sales will be $108.556 million, based on the midpoint of ViroPharma’s guidance. Assuming that ViroPharma can keep its expenses under control, the company should return to GAAP profitability in Q4, as well as positive operating cash flow.

ViroPharma stands out in the biotechnology industry because it is actively buying back stock, a rarity for most companies in the sector. While it is normal for companies such as Amgen or Celgene to be buying back stock, companies of ViroPharma’s size are not usually active repurchasers. In the first 9 months of 2012, ViroPharma spent $151.985 million on share buybacks, which retired 5.8 million shares of stock (the company currently has 65,208,904 shares outstanding). On the company’s earnings call, analysts pressed ViroPharma’s executives about why the company is buying back stock when those funds can be used to acquire new pipeline assets. CEO Vincent Milano responded:

The strategy [regarding capital deployment] remains consistent, we constantly evaluate business development opportunities, versus internal opportunities, versus the opportunity to further improve our capital structure with buyback. So I would say that today, our strategy remains the same as it has been. We’ll continue to consider all of those things and deploy the capital at the times we see fit, that way we see fit. So nothing’s changed. Maybe more specifically on the business development question, we have a very robust pipeline. As I think we had a chance to at least share a reasonable portion of that with the investment community on the 21st of September. So we’re not necessarily thinking only about filling the pipeline, we’re still interested in other commercial products, specifically in the United States would be good. As you know, our team in Europe is extremely busy launching 3 products. But we’re not exclusively looking one way or the other. We’re actually continuing to look at it all.

ViroPharma is looking at all options when it comes to capital deployment, and once the company’s operating cash flow rebounds as Cinryze and its other drugs continue to grow, the company will have increased flexibility to deploy capital. And it seems that ViroPharma’s buybacks have not impacted its ability to invest in the pipeline, which is moving forward through clinical development. That, however, failed to impress analysts. Cowen & Company analyst Phil Nadeau asked CEO Vincent Milano why the company is buying back stock if, “It doesn’t seem like for the next couple of years your stock’s going to be valued on an EPS basis; It’s more on top line growth.” Nadeau sees little reason to spend money to buy back stock if the market does not care about EPS, but rather how quickly ViroPharma can grow its sales and completely mitigate the effects of generic Vancocin, and he believes that more cash on the balance sheet allows for even greater “flexibility” in acquiring promising clinical programs. In my view, however, ViroPharma’s buyback program is neither positive nor negative, at least at this point in its corporate life cycle. While ViroPharma may be temporarily unprofitable as it transitions through its commercialized drugs (and invests millions into launching them), the company has reduced its share count by 6.57% since the end of the third quarter of 2011, and that will position the company well in terms of EPS when it returns to profitability. And these buybacks have not imperiled the company’s balance sheet. ViroPharma ended the quarter with $303.622 million in cash & investments, and its $159.633 million in debt (consisting of convertible notes) is due in March 2017, giving the company ample time to fortify its balance sheet. It is true that ViroPharma’s profitability has declined on a year-over-year basis. For the first 9 months of 2011, the company posted pro forma EPS of $1.49, and just $0.57 in pro forma EPS for the first 9 months of 2012. 2012 has clearly been a transition year for the company as it invests in launching multiple new products across the world and absorbs the fallout from the launch of generic Vancocin. 2013 and the years beyond are what matter.

Conclusions

For ViroPharma, 2012 has been a transitional period, but the company is well-positioned for 2013 and beyond. It has a solid cash position, and it has the ability to invest in its existing pipeline programs, as well as acquire new assets. The company has a clear pathway to return to profitability, and investors who add to or initiate positions in ViroPharma are likely to be rewarded for their conviction in the years to come. The company is set to release a good deal of clinical trial data in 2013, which, combined with growth in the sales of Cinryze, as well as other drugs, is likely to cause its stock price to rise. The average analyst price target for shares of ViroPharma is currently $34.98, which implies upside of 54.3% based on the company’s closing share price of $22.67 on December 26, 2012. Investors stand to see a solid return even if shares rally to just $30. ViroPharma’s best days are ahead of it, something that is not reflected in its current share price.


http://propthink.com/viropharma-strengthening-financial-prof…

[montamero]

The Company’s product pipeline includes OX1(Phase II trial in the second half of 2013,up to $120 million in milestones, as well as a tiered royalty rate (with a cap in the “mid-teens”)), OX2, IN-N01, NO1-OX2 (ADC development by Lonza), TOC-1, tauC3, and the vaccines RV01, RV02, RV03.

Lonza to Expand Antibody Drug Conjugate (ADC) Manufacturing Capacity to Meet Growing Customer Demand

Basel, Switzerland, 8 January 2013 – Lonza today announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland. Oncology therapeutics including ADCs represent one of the fastest growing segments of the pharma and biotech industry and the deployment of ADC targeted therapies has intensified in recent years.

Because cGMP manufacturing of ADCs presents unique challenges, facilities must be designed to handle both biological species and highly potent cytotoxic small molecule drugs. Lonza has been a pioneer in the manufacturing of ADCs since its initial investment in 2006 which established manufacturing suites for both small and large scale projects, dedicated Research & Development labs, and Quality Control facilities specifically for ADCs. Since 2010, Lonza has validated large scale manufacturing of platform technologies primarily utilized by ADC drug developers.

The expansion of the ADC facility will double the existing large-scale manufacturing capacity in Visp while allowing current operations to continue without interruption. It is the next step in bringing challenging new technologies to one of Lonza’s main sites. The capacity expansion, expected to be complete in the second quarter of 2014, has the potential to bring new job opportunities across all functions in Visp.

“We have witnessed significant growth in the ADC market in the past 24 months and this investment is necessary to continue to support the growing product demands from our customers” said Stefan Stoffel, Head of Lonza’s Chemical Manufacturing business unit. “Lonza Visp will continue to offer a fully integrated end-to-end development and manufacturing solution for ADCs, including the cytotoxic small molecules used in these products and all associated analytics. In addition, Lonza can support protein development and manufacturing via our global biologics development and manufacturing sites.”

Lonza’s continued investment to increase ADC capacity and highly trained personnel allows its customers to capitalize on the unique infrastructure of the Visp site and limit their own investment in the expertise, assets, and infrastructure required to work with these highly potent biological products in a highly regulated environment.

http://www.lonza.com/about-lonza/media-center/news/2013/1301…

[dottore]

trotz der großen Kursgewinne in den letzten Wochen ist der übergeordnete Abwärtstrend nicht nur intakt, sondern der Kurs prallte in den letzten Monaten immer wieder von dessen Oberkante ab, und zwar sehr präzise.
Das alles trotz der scheinbar so guten Nachrichten (die kein Fake sind)

[montamero]

Form 8-K for INTELLECT NEUROSCIENCES, INC.

18-Jan-2013

Unregistered Sale of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities.
During the period beginning on January 3, 2013 and ending on January 15, 2013, Intellect Neurosciences, Inc. (the "Issuer") sold $105,000 aggregate principal amount of its three-year 14% convertible promissory notes (the "Notes") together with five-year warrants (the "Warrants") to purchase 15,750,000 shares of common stock of the Issuer, par value $.001 per share (the "Common Stock") for aggregate cash consideration of $105,000. The Notes have an initial conversion price and the Warrants have an initial exercise price of $.01 per share. The sale of the Notes and Warrants has resulted in an adjustment to $.01 per share to the conversion or exercise price of all other convertible or exercisable securities of the Issuer containing a ratchet adjustment provision. These private sales of securities were exempt from registration pursuant to the provisions of Section 4(2) of the Securities Act of 1933, as amended.

http://biz.yahoo.com/e/130118/ilns8-k.html

[montamero]

LONZA Full Year Results 2012
Date: 24 January 2013
Location:
City: Basel
Country: Switzerland
http://www.lonza.com/about-lonza/knowledge-center/events/cor…

[montamero]

Novel Alzheimer's Therapeutics Developer Says Investors Should Remain Undeterred Despite Disappointing Results From Major Phase 3 Trials


LOS ANGELES, CA--(Marketwire - Jan 30, 2013) - During his distinguished career, Dr. Daniel G. Chain, Ph.D. discovered various novel therapeutics to treat Alzheimer's disease which were licensed to multiple Big Pharma giants.
Dr. Chain trained as a Post-doctoral Research Fellow at the Center for Neurobiology and Behavior at Columbia University in New York. Dr. Chain obtained his B.Sc. in Biochemistry from the Institute of Biology in London and obtained his Ph.D. in Biochemistry from the Weizmann Institute of Science in Israel.
He currently serves as Chairman of Intellect Neurosciences, Inc. ( OTCQB : ILNS ), where he has also been Chief Executive Officer since October 2005.
In an exclusive interview with BioMedReports, Chain says that biotech investors should remain undeterred by the challenges currently being faced by those trying to find a cure for Alzheimer's disease and other age-related cognitive impairments.
BioMedReports: How would you characterize the mood among Alzheimer's researchers after the phase 3 results for Bapineuzumab and Solanezumab?

Dr. Daniel G. Chain, Ph.D.: Obviously, people were very disappointed by the results from the two sets of major Alzheimer's Phase 3 trials, but there were also glimmers of light that renewed hope and even strengthened the prevailing belief that beta amyloid (Aβ) plays a central and causative role in the pathogenesis of Alzheimer's disease. Few now doubt that immunotherapy represents a realistic path forward pending improvements in drug design and the way we conduct clinical trials. Ely Lilly's drug solanezumab showed modest improvement in clinical outcomes when data was pooled from two clinical trials. The drug is to be further tested in a third phase 3 trial by the company and two independent trials conducted by leading academic groups. While bapineuzumab failed to show clinical benefit, the use of biomarkers clearly demonstrated the drug had engaged the target, reduced the amount of plaque and slowed neurodegeneration based upon the decrease in the amount of tau protein measured in the cerebral spinal fluid (CSF). Unfortunately, the drug also caused a significant incidence of vasogenic edema and microhemorrhages, especially in patients that carried the APOE4 gene. A Phase 2 trial is ongoing using a subcutaneous formulation that may avoid these side effects. There is a feeling of optimism among researchers that next generation drugs will have an improved probability of success because of the lessons we have learned from these results and other important recent developments in the field. I experienced this first-hand when I was invited as a Distinguished Speaker to the 6th Annual Alzheimer's Drug Discovery Summit in December and had the opportunity to listen to foremost leaders in the field including academic researchers and industry experts.
Among the themes that have become prevalent is that there is a compelling case for early intervention in the treatment of the disease in which relevant biochemical and neuropathological changes in the brain start many years -- in some case two decades or more -- before symptoms occur! Moreover, the rate of change is far greater before the appearance of symptoms such that the stage we commonly refer to as "Mild," is in fact relatively far advanced, reflecting significant damage to the brain, which is probably beyond repair.

Q: What are the main areas of progress in Alzheimer's research?

Dr. Daniel G. Chain: The development of sensitive brain imaging techniques such as structural MRI to measure brain atrophy, FDG-PET to measure glucose metabolism, and PET amyloid imaging agents represent some of the most important recent advances in the field laying the foundation for studies such as by the Alzheimer's Disease Neuroimaging Initiative (ADNI) and Dominantly Inherited Alzheimer's Network (DIAN) that provided extremely valuable information regarding the sequence of changes preceding and leading to AD. In fact, these studies led to a new way to think about the disease in which presymptomatic AD is just as much a disease state as symptomatic disease.

Q: Describe the main programs at Intellect Neurosciences.

Dr. Daniel G. Chain: Intellect has four main programs underway at the moment: CONJUMAB-A, TAUC3, TOC-1 and RVO3.
We are pioneering the use of antibody-drug conjugates and bi-specific vaccines for the treatment and prevention of multifactorial neurodegenerative conditions such as Alzheimer's disease, Huntington's disease and age-related macular degeneration. Increasingly we hear researchers emphasizing the need to target more than one disease component where, for example, Aβ, tau protein and oxidative stress act in concert and synergistically causing irreversible damage to nerve cells. The use of combination therapies may even allow intervention after symptoms have begun in contrast to monotherapies, targeting only Aβ, for example. However, regulators are averse to the idea of combining two independent investigational drugs before testing each one singly in human clinical trials and demonstrating clinical benefit. That issue is circumvented by the use of antibody drug conjugates in which two different molecules are combined chemically into a single entity as is the case with our CONJUMAB platform.

I am excited about the therapeutic potential of CONJUMAB-A, our lead preclinical program which I believe offers important advantages to other Aβ antibodies currently in clinical development. All the other antibodies e.g. solanezumab, bapineuzumab, gantenerumab and crenzeumab are designed for a single purpose, namely to clear Aβ from the brain. None of these antibodies act on secondary neurotoxic mechanisms such as oxidative stress which causes most of the damage from Aβ. By contrast, CONJUMAB-A, an antibody drug conjugate, is empowered with additional neuroprotective properties to alleviate the damage while also potentially enhancing the clearance of Aβ. In principle our approach could be applied to improve many different types of antibodies including those that previously disappointed in clinical trials. However, we are currently focused on optimizing CONJUMAB-A using our own antibody IN-N01 which targets the N-terminus of Aβ. We believe IN-N01 to be superior to bapineuzumab because of its reduced potential to cause inflammation which results from our reengineering of the originally produced IG1 class antibody into an IgG4 class antibody. We believe this safety feature is particularly important for antibodies that bind Aβ aggregates and not just soluble single monomeric Aβ. Among several potential indications, we have decided to focus on age related macular degeneration (AMD) for proof of concept studies since AMD and AD share several similarities while the eye offers less challenge for delivering the drug.

Over the past two years, Intellect has established its position as a leader in tau immunotherapy using funds from our deal with ViroPharma to support new patent filings by the company, in-license new technologies and initiate an important collaboration with leading Alzheimer's research groups led by Dr. Frank LaFerla and Dr. Kim Green at the University of California, Irvine. Tau immunotherapy is rapidly gaining traction in the Alzheimer's field and has potential applications for many orphan indications as well, such as frontotemporal dementia. However, in contrast to other approaches that have targeted tangles, Intellect is targeting the earliest steps in tau pathology focused on two different pathogenic forms, a truncated form known as delta tau and an aggregated from known as oligomeric tau -- each of which occurs before filaments leading to tangle formation. Over the next several months we expect to generate important in vivo data in relation to the two monoclonal antibodies, TauC3 and TOC-1, that we acquired from Northwestern University under an exclusive license agreement.

Finally, we continue our development of our RECALL-VAX platform focusing on a bi-specific chimeric peptide vaccine approach that targets both Aβ and delta tau in a flu-shot like vaccine approach. Vaccines against multiple antigens have precedent so this is another approach for combination therapies. Disease-modification itself is becoming less attractive as an approach for treating Alzheimer's disease for two main reasons. First, as evidenced by the Phase 3 clinical trials results, patients who are symptomatic probably have disease that is too far advanced to benefit significantly from treatments that slow the degenerative process. Second, treating very early stage or presymptomatic patients will be extremely expensive and prove too costly a burden for healthcare systems. An article by scientists from the Karolinska Institute in Sweden, published in the October issue of Current Alzheimer's Research, indicated the economic cost of treatment with a chronically and frequently administered disease-modifying drug would outweigh the cost of palliative care, including full-time nursing care of patients with advanced disease. This economic model leads one to conclude that a vaccination given on an annual or semi-annual basis may be the only economically feasible approach to prevent and manage Alzheimer's disease. Therefore, a vaccine such as RV03 being developed by Intellect Neurosciences offers a promising prophylactic approach that could potentially be administered to tens of millions of people around the world. Although still at an early stage, we are confident about our ability to produce a high value asset.

Q: Do you feel confident regarding Intellect's pipeline?

Dr. Daniel G. Chain: We are very confident in the science behind our pipeline, and are encouraged by the interest shown in our programs by several global pharmaceutical companies some of which have already signed confidentiality agreements. In addition, many independent papers have been published recently that support many of our hypotheses for the development of these assets. Further, we are beginning to see encouraging early stage results that we hope to share soon regarding each of our pipeline programs.
Q: What challenges do you face?
Dr. Daniel G. Chain: The biggest challenge is the funding needed to support our R&D activities and also to grow and maintain our substantial global patent portfolio, which is the heart of Intellect's business model. We need to dispel the skepticism that pervades among many stakeholders in the pharmaceutical industry resulting from previous disappointments in the AD field, or at least separate ourselves from it.
One of Intellect's strengths is its diversified portfolio, which provides us "multiple shots on goal." We are extremely cost-efficient as the result of effective outsourcing R&D to highly specialized contract research organizations. Even so, as a small company, maintaining adequate funding to continue all of our programs concurrently is quite challenging. We are currently in talks with potential licensing and co-marketing partners to help maintain the pace of our research, but in this environment, we are facing the same challenges as all other companies of our relative size. We, therefore, have to choose which programs to push forward at any given moment, which often disrupts the momentum of other programs, all based upon the funding we receive and the goals of potential partners who continue nevertheless to show considerable interest and have expressed an eagerness to see validation in preclinical models.

Q: Do you have anything you wish to add?

Dr. Daniel G. Chain: It is imperative that the company and its investors remain undeterred by the challenges currently being faced both by the industry and within Intellect itself. Intellect has continued to grow and develop new strategies to continue on regardless of what the market has done. We wish to communicate to our current and potential investors that significant advances have been made in the Alzheimer's area and express our confidence in our ability to prevail where others have failed. While one set of compounds for which we hold licenses has met with challenges, that is not the entirety of Intellect Neurosciences. Intellect has never relied solely on one program to sustain it, and we have continuously executed on our plans to license our programs, and anticipate being able to do so again as we generate new data and advance our earlier-stage programs through proof of concept.

The full version of this report can be found here:
http://www.biomedreports.com/20130130120929/novel-therapeuti…

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html
Follow Us
News developments and live healthcare sector updates are available constantly via Twitter at: http://twitter.com/BioMedReports
About BioMedReports.Com
BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com
Contact:
Media Contacts Only:
M. Davila
Assistant Editor
BioMedReports.Com
e-mail: Email Contact

[montamero]

Intellect Neurosciences Initiates in vivo Proof of Concept Studies in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody

NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced it has initiated in vivo proof of concept studies for its monoclonal antibody, TauC3, in a preclinical model of Alzheimer's disease. The studies are being conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team.

"Intellect recently completed additional in vitro characterization of the TauC3 antibody, which was demonstrated to have a high affinity for delta tau," said Dr. Daniel. G. Chain, Intellect's Chairman and CEO. "We also optimized production and produced sufficient quantities to initiate in vivo studies that will include thorough examination of the antibody's effect on neuropathology and behavioral changes in this preclinical model. We look forward to publishing the data later this year."

TauC3 specifically targets the neoepitope that is formed following cleavage of intact tau protein by proteolytic enzymes known as "executioner" caspases. This pathological process is stimulated by an accumulation of amyloid beta in the brain of Alzheimer's patients. It is believed that the smaller cleaved tau, referred to as delta tau, is especially toxic and prone to form tangles inside nerve cells and occurs early in the pathogenesis of the disease so antibody-mediated removal of delta tau would be expected to prevent the irreversible damage to nerve cells.

About Intellect Neurosciences

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please visit www.intellectns.com.

The Intellect Neurosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14741

Safe Harbor Statement Regarding Forward-Looking Statements:

The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those discussed in Intellect's Quarterly Report on Form 10-Q (file no. 333-128226), filed on November 20, 2012 and the risk factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 15, 2012.

Jules Abraham
JQA Partners, LLC
917-885-7378

http://www.globenewswire.com/news-release/2013/02/07/521841/…

[montamero]

FDA May Relax Guidlines on Early-Stage Alzheimer’s Trials

By Michelle Fay Cortez - Feb 7, 2013 5:09 PM GMT+0100

The lack of definitive biological markers for the earliest stages of Alzheimer’s disease has made it impossible to enroll patients in drug-research trials, U.S. regulators said, slowing development of new treatments.
The methods for trials were established in 1984 and cover patients with full-blown dementia who suffer both cognitive and functional limitations, the Food and Drug Administration said in a statement today. The agency is proposing to relax guidelines for early-stage Alzheimer’s drug trials by letting researchers show that a medication slows the cognitive decline, rather than improvement in both cognitive and functional deterioration.
People in the earliest stages of Alzheimer’s don’t always have functional limitations such as problems getting dressed, bathing and taking care of their own daily needs. For this group of people, showing that a medication slows the cognitive decline may be enough to win regulatory approval, the FDA said.
After an approval, companies would have to conduct larger, longer studies to show the improvement in mental function translates into improved health, the FDA said.

The draft document is subject to a 60-day comment period and could change based upon the input the FDA receives.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at [e-mail]

http://www.bloomberg.com/news/2013-02-07/fda-may-relax-guidl…

[montamero]

Antwort auf Beitrag Nr.: 44.118.173 von montamero am 08.02.13 11:20:08

BioMedReports: How would you characterize the mood among Alzheimer's researchers after the phase 3 results for Bapineuzumab and Solanezumab?

Dr. Daniel G. Chain, Ph.D.: Obviously, people were very disappointed by the results from the two sets of major Alzheimer's Phase 3 trials, but there were also glimmers of light that renewed hope and even strengthened the prevailing belief that beta amyloid (Aß) plays a central and causative role in the pathogenesis of Alzheimer's disease. Few now doubt that immunotherapy represents a realistic path forward pending improvements in drug design and the way we conduct clinical trials. Ely Lilly's drug solanezumab showed modest improvement in clinical outcomes when data was pooled from two clinical trials. The drug is to be further tested in a third phase 3 trial by the company and two independent trials conducted by leading academic groups. While bapineuzumab failed to show clinical benefit, the use of biomarkers clearly demonstrated the drug had engaged the target, reduced the amount of plaque and slowed neurodegeneration based upon the decrease in the amount of tau protein measured in the cerebral spinal fluid (CSF). Unfortunately, the drug also caused a significant incidence of vasogenic edema and microhemorrhages, especially in patients that carried the APOE4 gene. A Phase 2 trial is ongoing using a subcutaneous formulation that may avoid these side effects. There is a feeling of optimism among researchers that next generation drugs will have an improved probability of success because of the lessons we have learned from these results and other important recent developments in the field. I experienced this first-hand when I was invited as a Distinguished Speaker to the 6th Annual Alzheimer's Drug Discovery Summit in December and had the opportunity to listen to foremost leaders in the field including academic researchers and industry experts.
Among the themes that have become prevalent is that there is a compelling case for early intervention in the treatment of the disease in which relevant biochemical and neuropathological changes in the brain start many years -- in some case two decades or more -- before symptoms occur! Moreover, the rate of change is far greater before the appearance of symptoms such that the stage we commonly refer to as "Mild," is in fact relatively far advanced, reflecting significant damage to the brain, which is probably beyond repair.

http://finance.yahoo.com/news/novel-alzheimers-therapeutics-…

[dottore]

da ist sie wieder, die Verunsicherung. Ist das hier nun die Chance meines Lebens? Soll heißen von Anfang an dabei gewesen zu sein. Ausgerechnet ich soll schneller gewesen sein, als die "Insider"? So ähnlich habe ich hier schon vor 1 Monat geschrieben. Die Meldungen sind nachprüfbar. Scheint was dran zu sein, aber irgendwie finde ich weder Vertrauen noch Mut hier einzusteigen. Und nun das. 800 % Kurssteigerung an einem Tag, wahrscheinlich mit kleinen Umsätzen hochgezogen.
Mein Instinkt sagt mir, dass ich die Finger davon lassen soll, aber wie oft habe ich mich schon geirrt. Klar überkommt mich das Gefühl, hätte ich doch blos 500 oder 1000 € riskiert. Heute füge ich hinzu, mit dem Betrag wäre es allemal einen Zock wert gewesen.
Aber umgekehrt habe ich mich 1-2 Monate gefreut, nicht eingestiegen zu sein, weil scheinbar ja nichts passierte.

Wer den Mut hat und ein gutes Timing kann hier bestimmt mitzocken, aber bitte zocken, investieren bezweifel ich.

Ich finde das hier ausgesprochen spannend und werde es beobachten, auch wenn ich nicht einsteige. Wer es etwas sicherer mag, schaut sich Advaxis an. Auch hoch spekulativ

[dottore]

wie gewonnen, so zerronnen. Mit dem Unterschied, dass die Zocker 4,6 Mio Aktien platzieren konnten. Zum Kurs zwischen 1 und 2 Cent. Das sind immerhin zwischen 50 und 70Tausend $

Ich würde sagen, eine schöne Entschädigung für die monatelange Vorbereitung. Und ein paar Wellen kommen da noch, weil ja jetzt einige auf Verlusten sitzen und mitpushen werden.

So etwas wie heute bestärkt mich in meiner Skepsis. Nein, das ist nicht die Chance des Lebens ...

[montamero]

Für weitere Informationen verweise ich auf das Investorshub
http://investorshub.advfn.com/Intellect-Neurosciences-Inc-IL…

[montamero]

ILNS MANIPULATION

Sell Vol. 50,39%; Short Vol. 51,62%

Buy: 283.200
49,61%
Sell: 287.700
50,39%
RegularVol: 570.900
100%
http://ih.advfn.com/p.php?pid=trades&symbol=NO%5EILNS

Short Volume 294.700
51,62%
RegularVol: 570.900
100%
http://otcshortreport.com/index.php?index=ilns&action=view

Short Volume Ratio 0,516
http://shortvolume.com/

Short Interest: What It Tells Us
April 23 2011| Filed Under » New York Stock Exchange, Short Selling

As some of you may already know, short selling allows a person to profit from a falling stock. The existence of this ability to short sell a stock should not come as a surprise as stock prices are constantly rising and falling. Thus, there are brokerage departments and firms whose sole purpose is to research deteriorating companies that are prime short-selling candidates. These firms pore over financial statements looking for weaknesses that the market may not have discounted yet or a company that is simply overvalued. One factor they look at is called short interest, which serves as a market-sentiment indicator. We'll cover it in detail in this article.

Tutorial: How To Use Short Selling

A Review of Short Selling
Essentially, short selling is the opposite of buying stocks - it's the selling of a security that the seller does not own, done in the hope that the price will fall. If you feel a particular security's price, let's say the stock of a struggling company, will fall, you can borrow the stock from your broker-dealer, sell it and get the proceeds from the sale. If, after a period of time, the stock price declines, you can "close out" the position by buying the stock on the open market at the lower price, return the stock to your dealer-broker and realize a gain.
The catch is, if the stock price rises, you lose money because you have to buy the stock back at a higher price. In addition, your broker-dealer can demand that the position be closed out at any time, regardless of the stock price. However, this demand typically occurs only if the dealer-broker feels that the creditworthiness of the borrower is too risky for the firm.


Short Interest
Short interest is the total number of shares of a particular stock that have been sold short by investors but have not yet been covered or closed out. This can be expressed as a number or as a percentage.

When expressed as a percentage, short interest is the number of shorted shares divided by the number of shares outstanding. For example, a stock with 1.5 million shares sold short and 10 million shares outstanding has a short interest of 15% (1.5 million/10 million = 15%).

Most stock exchanges track the short interest in each stock and issue reports at month's end. These reports are great for traders because by showing what short sellers are doing, they allow investors to gauge overall market sentiment surrounding a particular stock. Alternatively, most exchanges provide an online tool to calculate short interest for a particular security.

Reading Short Interest
A large increase or decrease in a stock's short interest from the previous month can be a very telling indicator of investor sentiment. Let's say that Microsoft's short interest increased by 10% in one month. This means that there was a 10% increase in the number of people who believe the stock price will decrease. Such a significant shift provides good reason for investors to find out more. We would need to check the current research and any recent news reports to see what is happening with the company and why more investors are selling its stock.

A high short-interest stock should be approached with extreme caution but not necessarily avoided at all cost. Short sellers (like all investors) aren't perfect and have been known to be wrong from time to time.

In fact, many contrarian investors use short interest as a tool to determine the direction of the market. The rationale is that if everyone is selling, then the stock is already at its low and can only move up. Thus, contrarians feel that a high short-interest ratio (which we will discuss below) is bullish - because eventually there will be significant upward pressure on the stock's price as short sellers cover their short positions (i.e. buy back the stocks they borrowed to return to the lender). (Learn more in Can Perpetual Contrarians Profit As Traders?)

Short-Interest Ratio
The short-interest ratio is the number of shares sold short (short interest) divided by average daily volume. This is often called the "days-to-cover ratio" because it determines, based on the stock's average trading volume, how many days it will take short sellers to cover their positions if positive news about the company lifts the price.

Try Currency Trading Risk-Free at FOREX.com
Again, let's assume Microsoft has a short interest of 75 million shares, while the average daily volume of shares traded is 70 million. Doing a quick and easy calculation (75,000,000/70,000,000), we find that it would take 1.07 days for all of the short sellers to cover their positions. The higher the ratio, the longer it will take to buy back the borrowed shares - an important factor upon which traders or investors decide whether to take a short position. Typically, if the days to cover stretch past eight or more days, covering a short position could prove difficult.

The NYSE Short Interest Ratio
The New York Stock Exchange short-interest ratio is another great metric that can be used to determine the sentiment of the overall market. The NYSE short-interest ratio is the same as short interest except it is calculated as monthly short interest on the entire exchange divided by the average daily volume of the NYSE for the last month.

For example, suppose there are five billion shares sold short in August and the average daily volume on the NYSE for the same period is one billion shares per day. This gives us a NYSE short-interest ratio of five (five billion /one billion). This means that, on average, it will take five days to cover the entire short position on the NYSE. In theory a higher NYSE short interest ratio indicates a more bearish sentiment towards the exchange.

Short Squeeze
Some bullish investors see high short interest as an opportunity. This outlook is based on the short interest theory. The rationale is, if you are short selling a stock and the stock keeps rising rather than falling, you'll most likely want to get out before you lose your shirt. A short squeeze occurs when short sellers are scrambling to replace their borrowed stock, thereby increasing demand and decreasing supply, forcing prices up. Short squeezes tend to occur more often in smaller cap stocks, which have a very small float (supply), but large caps are certainly not immune to this situation.

If a stock has a high short interest, short positions may be forced to liquidate and cover their position by purchasing the stock. If a short squeeze occurs and enough short sellers buy back the stock, the price could go even higher. Unfortunately, however, this is a very difficult phenomenon to predict. (Find out how this strategy is used in Short Squeeze The Last Drop Of Profit From Market Moves.)

The Bottom Line
Although it can be a telling indicator, an investment decision should not be based entirely on a stock's short interest; however, investors often overlook this ratio despite its widespread availability. Unlike the fundamentals of a company, the short interest requires little or no calculations. Half a minute of time to look up short interest can help provide valuable insight into what sentiment investors have toward a particular company or exchange.

http://www.investopedia.com/articles/01/082201.asp#axzz2MT35…

[montamero]

SHORT SELLING, DEATH SPIRAL CONVERTIBLES, AND
THE PROFITABILITY OF STOCK MANIPULATION
http://www.sec.gov/comments/s7-08-08/s70808-318.pdf

When Does Short Selling Become Manipulation?
http://www.klgates.com/files/tempFiles/901e34d6-b3ee-4ac4-bd…


Intellect Neurosciences, USOTC:ILNS, ISIN: US45822W2098
March 1, 2013
Short Sell Volume 51,62%; Sell Volume 50,39%;

Buy: 283.200
49,61%
Sell: 287.700
50,39%
RegularVol: 570.900
100%
http://ih.advfn.com/p.php?pid=trades&symbol=NO%5EILNS

Short Volume 294.700
51,62%
RegularVol: 570.900
100%
http://otcshortreport.com/index.php?index=ilns&action=view

Short Volume Ratio 0,516
http://shortvolume.com/

[montamero]

Trading Volume March 8, 2013
Intellect Neurosciences (ILNS:OTC US), ISIN: US45822W2098
Regular Volume 677.800 (100%)
Buy 423.700 (15 trades; 62,51%)
Sell 254.100 (5 trades; 37,49%)
Short 293.700 (43,33%)

http://ih.advfn.com/p.php?pid=trades&symbol=NO%5EILNS
http://otcshortreport.com/index.php?index=ilns&action=view
http://shortvolume.com/

[montamero]

Intellect Neurosciences vs. Pfizer - $2m + Damage
Plaintiff summary motion
http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

[montamero]

http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

[montamero]

Alla scoperte dei titoli speculativi del mercato OTC: Oggi tocca a Intellect Neurosciences (ILNS.PK)
Scritto il 20 marzo 2013

Raccolgo sempre molto volentieri le segnalazione dei vari titoli biotech, sopratutto di aziende che non conosco. L’amico Franco mi segnala due company quotate nel mercato OTC. Raccogliere informazioni in questo mercato diventa a volte complicato, sopratutto avere aggiornamenti e opinioni magari da chi ne capisce più di noi.
Iniziamo con la prima segnalazione ovvero Intellect Neurosciences, Inc. (ILNS.PK) (OTCBB:ILNS). Come segnalava non ricordo più chi sul blog che fine fanno le scoperte che spesso sentiamo ai telegiornali di vaccini, molecole o meccanismi innovativi?. Spesso si rivelano dei buchi nell’acqua altre invece danno l’inizio a studi clinici o interessamento da parte di qualche grossa biotech che fiuta “l’affare”.
Potremmo dire che forse questo potrebbe essere il caso dell’azienda oggetto dell’articolo di oggi. Partiamo non dall’inizio ma dalla fine. Proprio nel mese di Marzo il ceo dell’azienda è stato impegnato in alcune conference a Barcelona al Centre Convencions Internacional e a Firenze all’ 11th Annual Conference on Alzheimer’s disease and Parkinson’s disease.
Vediamo cosa ci dice il ceo “”Abbiamo scoperto un nuovo modo per attaccare alcuni tipi di malattie complesse mediante l’uso di anticorpi coniugati in cui due molecole diverse – un anticorpo rivolto ad un polipeptide amiloidogenica e una piccola molecola neuroprotettiva – sono combinati chimicamente in un’unica entità,” ha detto il dottor Daniel Chain, l’inventore del CONJUMAB. “L’anticorpo ha un chaperone-like (esiste non è una parolaccia) ruolo nel tenere la amiloide mentre la piccola molecola riduce la neurotossicità causata dal peptide. Il nostro farmaco CONJUMAB-A, capitalizza recenti intuizioni che collegano i meccanismi che contribuiscono alla patogenesi di AMD e malattia di Alzheimer , in particolare il ruolo di stress ossidativo e beta amiloide (a ²) che si ritiene essere un mediatore fondamentale nella progressione della AMD secca a AMD umida (con AMD parliamo di maculopatie degenerative).
L’amico Franco che è stato davvero professionale mi ha mandato diversi link. Il primo riguarda la pipeline davvero interessante con tre farmaci e con diversi partner ma solo uno può portare $, al momento, ovvero l’accordo con Viropharma. Il farmaco in questione è il VP 20629 (OX1 or indole-3-propionic acid (IPA) per la malattia friedreich’s ataxia. Per chi non conoscesse Viropharma (VPHM) vi posso dire che è un ottima azienda che si muove bene nel mondo biotech e che ha alcuni farmaci già approvati (che vendono) e altri promettenti in sviluppo.
ViroPharma is conducting Phase 2-enabling toxicology studies with VP 20629; the company expects to initiate Phase 2 clinical testing in late 2012/early 2013. Questo è il farmaco che ci interessa.
Intellect could receive in excess of $100 million in milestone payments from ViroPharma and, if approved, royalties from sales over many years. Viropharma ha già pagato 6,5 M di $. E’ vero il mercato per questa malattia non è grosso, è una malattia ereditaria che a oggi non ha una cura però i 100 M di $ che l’azienda potrebbe ottenere sono a vari raggiungimenti di obbiettivi e poi vi è una parte legata alle vendite del farmaco. Mi pare un ottimo accordo.
L’azienda ha inoltre un accordo con Lonza azienda quotata nel mercato svizzero per il farmaco CONJUMAB-A che abbiamo visto all’inizio dell’articolo. In base a questo accordo Lonza ha un opzione per il futuro sviluppo e la produzione del farmaco anticorpo coniugato CONJUMAB-A.
Per il momento direi di fermarmi qui. Ho altro materiale da analizzare, ma si possono già tirare delle conclusioni. L’azienda non è in grado di portare avanti sviluppi clinici con i propri mezzi e quindi cerca di vendere le proprie molecole ad altri. L’accordo con Viropharma è un ottimo accordo che potrebbe portare nelle casse dell’azienda diversi dollari.
Per concludere tenendo conto della quotazione di ieri 0.0093$, e della capitalizzazione bassa ( circa 1M di $) ogni buona notizia che arriva da Viropharma può far esplodere la quotazione di Intellect Neurosciences . Il farmaco ha da poco iniziato la phase 2. Non sappiamo quando arriveranno altri soldi alla piccola azienda, di solito il grosso arriva alla fine della phase 3 e alla commercializzazione ma ci vorranno anni. Quindi per chi ha una piccola somma da poter puntare e dimenticandosela per anni potrebbe essere una buona giocata speculativa. A voi.

http://finanzanostop.finanza.com/2013/03/20/alla-scoperte-de…

[montamero]

http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

[montamero]

Informiert euch im IHUB!
Best Regards
montanus

[montamero]

Former ‘King of Biotech’ settles with SEC

By Bernard Vaughan | NEWS.GNOM.ES –

By Bernard Vaughan

NEW YORK (NEWS.GNOM.ES) – An investor formerly known as the “King of Biotech” has reached a settlement with the U.S. Securities and Exchange Commission over a market manipulation scheme, according to court documents filed on Thursday.

David Blech, who earned the nickname as a founder of companies and a major investor in the biotechnology sector, agreed to pay $1.03 million in disgorgement and interest for the scheme.

In 2012 the SEC had accused Blech of buying and selling significant amounts of stock in two biopharmaceutical companies, Pluristem Therapeutics Inc and Intellect Neurosciences Inc through more than 50 brokerage accounts he established in the names of family and friends in order to create an artificial appearance of activity in the stocks.



The SEC complaint further accused Blech, who had already been convicted of securities fraud in 1998, of selling investments for biopharmaceutical companies despite being barred from acting as a broker-dealer. It also accused him and his wife, Margaret Chassman, of violating federal securities laws by making unregistered sales of securities and failing to disclose their transactions in brokerage accounts.

Chassman agreed to pay close to $550,000 in disgorgement, interest and a civil penalty, according to the settlement.

The settlement was approved by Magistrate Judge Sarah Netburn in Manhattan federal court.

“He’s pleased to be putting this episode behind him,” Roland Riopelle, a lawyer for Blech, said on Thursday.

A lawyer for Chassman declined to comment.

In May, Blech was sentenced to four years in prison after pleading guilty in a related criminal case to stock manipulation stemming from his trades in Pluristem and Intellect.

The case is USA v David Blech, U.S. District Court, Southern District of New York, No. 12-cr-00372.

(Reporting by Bernard Vaughan; Editing by Chris Gallagher)

http://news.gnom.es/business/former-king-of-biotech-settles-…

ILNS

[montamero]

Hallo Leute,
ich suche nach einem neuen Broker/Dealer welcher u.a. auch Pennystocks handelt. Vielleicht kann mir jemand behilflich sein. Danke

[montamero]

ILNS VS. PFE
-außergerichtliche Einigung od. Übernahme
Danach:
-Tauc3 Results
-another 2 million milestone (EPO)
-Evli Investment
-CONJUMAB & Lonza
-ponezumab Results
-OX1 Ph1 Results
-License Tauc3
-License Conjumab
etc.
All IMO

[montamero]

Nett, oder?

[KaOsiris]

Oh ja, das ist sehr nett und hat noch Potential, viel viel netter zu werden.

[KaOsiris]

Antwort auf Beitrag Nr.: 46.846.366 von KaOsiris am 18.04.14 12:51:28

Northwestern University, Intellect Neurosciences Assigned Patent



http://www.4-traders.com/INTELLECT-261941/news/Intellect-Neu…




Neurosciences : Northwestern University, Intellect Neurosciences Assigned Patent
04/18/2014 | 07:14am US/Eastern

By Targeted News Service

ALEXANDRIA, Va., April 18 -- Northwestern University, Evanston, Ill., and Intellect Neurosciences, New York, have been assigned a patent (8,697,076) developed by four co-inventors for "antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies." The co-inventors are Lester I. Binder, Chicago, Daniel G. Chain, New York, Yifan Fu, Clarendon Hills, Ill., and Kristina Patterson, Chicago.

The patent application was filed on April 27, 2012 (13/458,609). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=H…

Written by Sudarshan Harpal; edited by Jaya Anand.

SH0418JA0418-1001610

(c) 2014 Targeted News Service

[KaOsiris]

Antwort auf Beitrag Nr.: 46.846.582 von KaOsiris am 18.04.14 14:14:14

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=H…" target="_blank" rel="nofollow ugc noopener">http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=H…

[montamero]

Ein langfristiger Aufwertstrend zeichnet sich ab
http://www.investopedia.com/terms/g/goldencross.asp